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Abstract 
Background 
In our aging population the burden of dementia is increasing, necessitating the urgent identification 
of treatable risk factors. Small cross-sectional studies demonstrate associations between non- 
valvular atrial fibrillation (NVAF), silent cerebral infarction and decreased cognitive function, but 
there are few longitudinal studies in this area. This thesis reports the results of a prospective 
longitudinal cohort study of cognitive decline in people with recent-onset NVAF compared to 
controls. 
To inform the thesis, an extensive literature review was undertaken . This included searches on 
NVAF and cognitive decline, NVAF and silent infarction, epidemiology of NVAF, other risk 
factors for cognitive decline, epidemiology of cognitive decline and the neuropsychological tests 
included in the CAFE battery. 
Methods 
362 people over 60, screened in primary care, underwent baseline assessment including a battery of 
neuropsychological tests, repeated at 12 months (n=304). Cases (n=175) with recent-onset NVAF, 
were matched for age, sex and GP practice with controls in sinus rhythm. Data were compared 
using SPSS software (version 11) with both parametric and non-parametric analysis. 
Results 
Baseline characteristics, including cognitive function, were similar for cases and controls. There 
was wide variation between individuals in change in performance on the neuropsychological tests 
11 
over 12 months, with some improving and some deteriorating for each sub-test. Cases (NVAF) 
significantly (p<0.05) deteriorated in four subtests measuring attention/ non-verbal memory, and 
significantly (p<0.05) improved in two subtests measuring verbal memory. Controls significantly 
(p<0.05) deteriorated and improved in the same sub-tests as cases, but significantly (p<0.05) 
deteriorated in another three subtests measuring attention/non-verbal memory, and significantly 
(p<0.05) improved in another six subtests. Treatment with warfarin or aspirin did not appear to be 
associated with change in cognitive status. 
Conclusions 
At baseline there was no significant difference in cognitive function between cases in NVAF and 
controls in sinus rhythm. At follow-up there was no consistent relationship between NVAF and 
cognitive decline over 12 months, nor any apparent effect of antithrombotic therapy. Explanations 
include true independence of NVAF and cognitive decline, or too short a follow-up period. An 
additional follow-up at 36 months is underway to explore this further. 
111 
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Chapterl- Introduction 
1.1 
More than half a million people in England and Wales currently fulfil diagnostic criteria for 
dementia. ' As the population ages, progressive cognitive decline leading to dementia will 
become even more prevalent, placing an additional burden on patients, their carers, and the 
NHS. It is therefore imperative that risk factors for dementia are identified and treated in 
order to prevent dementia or slow cognitive decline wherever possible. 
Published work has demonstrated that cardiovascular risk factors may predispose not only to 
vascular dementia, but may also contribute to a dementing process similar to Alzheimer's 
disease. 2 This may be explained by pathological mechanisms, 3'4 clinical effects and/or 
common risk factors5 for both vascular and Alzheimer-type dementia. Consequently, there is 
potential for prevention; for example it has been suggested that anti-platelet therapy in 
hypertension may be associated with reduced risk of dementia. 6 
Mild cognitive impairment has been shown to precede more than half of cases of vascular 
dementia, 7 and half of those with vascular cognitive impairment (i. e. cognitive impairment of 
vascular origin) without dementia have been shown to develop dementia within 5 years. 8 
Identification of such `at-risk' groups, for example those with NVAF, offers potential for 
preventive measures. 
Non-valvular atrial fibrillation (NVAF), present in 5% of the over 65's, 9 is an established 
independent risk factor for stroke and a potential contributor to cognitive decline and vascular 
dementia through silent cerebral infarction. 10-13 NVAF could therefore be a modifiable risk 
factor for dementia and cognitive decline of both Alzheimer's and vascular aetiologies. To 
date research addressing an association between atrial fibrillation and cognitive status has 
been primarily restricted to small cross-sectional studies of selective populations with neither 
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careful consideration of potential confounders nor of the effect of antiplatelet or anticoagulant 
therapy. Because cross-sectional studies measure exposure and disease outcome 
simultaneously, they cannot establish aetiology or causation. 14 However, they are useful in 
generating aetiological hypotheses and a number of cross-sectional studies addressing NVAF 
and cognitive decline, including our pilot study in the North of England, 15 have demonstrated 
that those with atrial fibrillation have significantly lower scores on neuropsychological testing 
than those in sinus rhythm. 16-2° Only one study in this area has demonstrated lack of 
association between NVAF and atrial fibrillation. 21 
Primary and secondary stroke prevention studies in NVAF have demonstrated reduction of 
stroke risk through use of antithrombotic therapy. However, literature in the last five years 
suggests that the uptake of such treatment into clinical practice has been variable. This may be 
in part because of the difficulties in weighing up the risks and benefits of therapy. 22.23 
Clarification of the potential role of antithrombotic agents in reducing the risk of cognitive 
decline in patients with NVAF in addition to stroke risk reduction would help to inform the 
clinical decision making process when faced with a patient for whom such therapy is being 
considered. 
This prospective cohort study aimed to explore whether or not older people with NVAF have 
an increased risk of cognitive decline over time when compared with controls in sinus rhythm. 
This builds upon a pilot study and the limited existing work in this field. The ideal study 
design to assess the effect of antithrombotic therapy on cognitive status would be a 
randomised controlled trial. However, this would be unethical since the protective effect of 
warfarin and aspirin against stroke is well proven. 24 This therefore suggests that a more 
appropriate study design to explore such an association would be a prospective inception 
cohort study of a representative population, with repeated assessment of cognitive function 
1.3 
and analysis of the potential impact of treatment with antithrombotic therapy. 25 The 
Cognition and Atrial Fibrillation Evaluation (CAFE study) is such a study, with a cohort as 
close to inception as was feasible (recruiting only those with a diagnosis of NVAF in the last 
5 years). In this thesis, CAFE's findings are reported. 
Aims and objectives: The aim of the CAFE study was to determine whether NVAF confers 
additional risk for the subsequent development of cognitive impairment or cognitive decline. 
The objectives were to determine: 1) whether NVAF in the community is associated with 
poorer performance on detailed neuropsychological testing than matched controls in sinus 
rhythm; and 2) whether cognitive function declines more over time in NVAF cases than in 
matched controls. 
Hypotheses: The null hypotheses tested in this study were as follows: 1) the cognitive 
function of people with NVAF is no different to that of age and sex-matched controls in sinus 
rhythm, when assessed by detailed neuropsychological testing; and 2) the decline in cognitive 
function over time in people with NVAF is no different to that of controls. Secondary null 
hypotheses included: 1) the cognitive function of cases with greater risk of stroke is no 
different to that of cases with lesser risk of stroke; and 2) the decline in cognitive function 
over time in cases with greater risk of stroke is no different to that of cases with lesser risk of 
stroke. 
CAFE was a community-based, prospective, longitudinal cohort study (N= 362), with follow- 
up at one year. The study compared the performance on detailed neuropsychological testing 
of participants with atrial fibrillation with that of matched controls in sinus rhythm. In 
addition, cases were stratified according to treatment with aspirin or warfarin. Results were 
1.4 
also stratified according to stroke risk (due to cerebrovascular risk factors) for cases only. 
CAFE's baseline results represent the largest cross-sectional analysis comparing cognitive 
function in older people with NVAF or sinus rhythm, adding considerably to previous cross- 
sectional data. The results of CAFE's 12-month follow-up represent the only substantial 
longitudinal study of cognitive function in those with NVAF reported to date. As such the 
findings are of considerable interest and have implications for future research into a 
potentially preventable cause of dementia. 
1.5 
Definitions of terms used in the thesis 
Atrial fibrillation: A common cardiac arrhythmia resulting in a continuous, rapid activation 
of the atria, with electrical response of the atria but conduction of only a proportion of the 
electrical activity and very little mechanical response of the atria. Non-valvular atrial 
fibrillation (NVAF) is atrial fibrillation in the absence of valvular heart disease. 
Cognitive impairment: When calculating the sample size for this study, cognitive 
impairment was defined as a (negative) difference in score of 10% on a basket of tests. When 
interpreting the results of the study, all differences (even those below 10%) were reported. 
This was to enable to reader to understand all changes present in the sample. Any difference 
in scores of 10% or greater would have been highlighted had they occurred. 
Types of cognitive impairment: different methods exist for grouping different types of 
cognitive impairment, but commonly used definitions are: - 
Cognitive impairment, no dementia (CIND) describes those who have demonstrable cognitive 
impairment, with low MMSE score, which does not fulfil criteria for dementia. 
Age-associated memory impairment (AAMI) is defined as memory test performance of at least 
one SD below the mean observed for young adults. In Age-associated cognitive impairment 
(AACI) performance is at least 1.5 SD below the mean observed on any test of cognitive 
function. 
Mild cognitive impairment (MCI) is defined as a transitional stage between normal ageing and 
dementia, with demonstrable cognitive impairment where criteria for dementia are unmet. 
Types of dementia: Dementia is defined as a global impairment of memory, thinking, 
intellect and personality, without impairment of consciousness. Vascular dementia includes 
1.6 
all dementias due to vascular causes (discussed further in Chapter 3), for example multi- 
infarct dementia, strategic-infarct dementia, subcortical ischaemic vascular dementia, 
hypoperfusion dementia, haemorrhagic dementia and dementias caused by specific 
arteriopathies. Other types of dementia are less relevant to this thesis, but include Alzheimer's 
disease (AD), dementia with Lewy bodies and mixed AD and vascular dementia. 
Biological plausibility of the hypothesis: 
The pathophysiological explanation underlying this study's hypothesis is that NVAF leads to 
uncoordinated and inadequate contraction of the atria such that there is incomplete ventricular 
filling, pulmonary venous congestion and decreased cardiac output. The uncoordinated 
contraction of the atria increases the risk of formation of micro-emboli, which in turn can 
obstruct cerebral arterioles leading to multiple silent cerebral infarctions. Over time the 
accumulation of many small, silent cerebral infarctions in areas of the brain involved in 
cognition may lead to gradual onset of cognitive decline. An alternative explanation is that the 
decreased cardiac output resulting from NVAF leads to cerebral hypoperfusion, which in turn 
causes ischaemic damage to critical areas of the brain, resulting in cognitive decline. 
Pilot study 
A pilot study was undertaken in Gateshead, England in 1998, prior to the work reported in 
this thesis 15. This involved comparison of 27 participants with NVAF with 54 age and sex 
matched controls in sinus rhythm. The cohort underwent the same battery of 
neuropsychological tests as used in the main study reported in this thesis, and NVAF was 
associated with poorer performance on all subtests of the neuropsychological test battery. The 
differences were significant for the delayed logical memory Subtest (score of 38.7 for cases, 
1.7 
49.4 for controls, p=0.02), PASAT 4 (score of 41.9 for cases, 53.8 for controls, p=0.02) and 
PASAT-2 (score of 25.6 for cases, 34.7 for controls, p=0.08). 
1.8 
Chapter 2- Risk factors for cognitive decline 
" Part 1: Literature search methodology 
o Purpose of searches 
o Search strategy 
o Sources other than electronic database searches 
o Selection of abstracts and full texts 
o Study quality 
" Part 2: Findings from the literature 
o a) Findings from the literature on atrial fibrillation as a risk factor for cognitive 
decline 
o b) Findings from the literature on the epidemiology of atrial fibrillation 
o c) Findings from the literature on other risk factors for cognitive decline 
" Chapter 2 Summary 
2.1 
Part 1: Literature search methods 
Purpose of Searches 
Literature searches were undertaken prior to commencement of the study and at intervals 
throughout the project. The search on atrial fibrillation, silent cerebral infarction and cognitive 
decline (search one) informed study design and quality, reduced the likelihood of duplication and 
provided understanding of the issues specific to the study of atrial fibrillation and cognitive 
impairment and decline. The search on epidemiology of NVAF (search two) helped to ascertain 
the importance of addressing the research question and will also aid future incorporation of 
findings into practice through policy and strategic dissemination. The search on other risk factors 
for cognitive decline (search three) enabled identification of potential confounders. These could 
then be addressed in the study methods and analysis of results. A search for risk factors for stroke 
in atrial fibrillation was undertaken since this was consistent with the pathological mechanism in 
the study hypothesis, such that risk factors for stroke in atrial fibrillation may also be risk factors 
for silent cerebral infarction in atrial fibrillation. 
Although background knowledge of studies of risk factors for stroke alone, with no focus on 
cognitive function was necessary, these studies were not systematically searched for. This was 
because although silent infarcts are part of the hypothetical pathway to cognitive decline in this 
study, I decided that for the purposes of this thesis it was more appropriate to concentrate on 
studies of cognitive function. 
2.2 
Search strategy (detailed strategies are in Appendix 1) 
Choice of electronic database 
Medline (searches 1,2 and 3), Embase (searches 1,2 and 3) and PsycINFO (searches 1 and 3) were 
the most appropriate databases for all of the searches outlined in this chapter since they are most 
likely to include journals publishing relevant articles. Medline was searched from 1966 to January 
2001 and repeated on 2 "d March 2004. Embase was searched in January 2001 and repeated on 2nd 
March 2004. PsycINFO (previously Psychlit) was searched from 1984 to January 2001. 
Use of methodological filters and existing search strategies 
i) For searches on studies of atrial fibrillation, silent cerebral infarction and cognitive decline 
(search 1) 
The most appropriate study design to explore this topic would be longitudinal cohort studies with 
prospective follow-up of a representative community-based population. 
The McMaster strategies 
26,27 
for identification of articles on prognosis and on aetiology, causation 
and harm 
26,27 
were appropriate for searching for longitudinal studies, our main area of interest. 
28 
The Cochrane Dementia and Cognitive Impairment Group (CDCIG) is a working group of 
experts who regularly undertake and organise systematic reviews of trials on dementia and 
cognitive impairment. Although they are primarily concerned with randomised controlled trials, 
their search strategies are comprehensive, sensitive and up to date, and focus on cognitive decline 
and dementia. Their search strategy for detecting studies on cognitive impairment and dementia 
was modified for this study. 
No published strategies exist for identification of articles on NVAF. Therefore, with permission, I 
used a validated strategy devised by another researcher 
29,30 
2.3 
The two McMaster strategies described above were combined with the core section on cognitive 
decline and dementia from the CDCIG and the NVAF strategy to create a detailed search strategy 
which could be applied to Medline, Embase and PsycINFO (see appendix). 
The above search was suitable for retrieving longitudinal studies. However, much of the work in 
this field is cross-sectional in design, therefore in addition a more basic search was undertaken 
combining the NVAF search described above with the CDCIG strategy but without combination 
with the McMaster strategies. 
ii) For searches on epidemiology of NVAF (search 2) 
The aforementioned McMaster strategies for identification of articles on prognosis and on 
aetiology, causation and harm 26.27 were combined with the validated NVAF strategy, with the 
addition of search terms to include articles focusing on stroke risk for searches on risk factors for 
stroke in atrial fibrillation. 
iii) For searches on other risk factors for cognitive decline (search 3) 
The McMaster strategies described above were combined with the adapted CDCIG strategy. The 
ideal study design to explore risk factors for cognitive decline would be a community-based, 
prospective cohort design with sufficient follow-up. The search strategy was devised to include 
such studies. There were no further explicit inclusion criteria (for screening abstracts) for this 
search, other than that the studies addressed risk factors for cognitive decline. This differs from the 
more detailed and specific inclusion criteria for the search on epidemiology of cognitive decline 
(Chapter 3), which used the same search strategy. 
2.4 
iv) Specificity and sensitivity 
Search 1 was designed to be highly sensitive, therefore with less specificity, to maximise the 
number of articles identified. For this search the priority was to ensure all pertinent articles were 
retrieved, since these studies were of immediate relevance to the CAFE study. 
For searches 2 and 3, the aim was to broaden the knowledge base on the broader subject areas of 
relevance to CAFE. Since these searches covered wider topic areas the potential number of articles 
retrieved was huge; therefore the search strategies were designed to be specific rather than sensitive. 
Sources other than electronic database search: 
In addition to formal literature searches, other sources of information were used to inform this 
study. These sources included: - 
Websites: 
31 
The evidence-based mental health website ,a 
joint venture between the BPS (British 
Psychological Society), the BMA and the Royal College of Psychiatrists was searched, including 
an individual search of the journal " Evidence based mental health" via the website. 
The Cochrane library provided useful information, as described earlier, and the Medical Research 
Council website32 provided a list of papers and conferences, published and in press, with abstracts. 
Searches of other websites were unproductive. 
Grey literature: 
Contact with relevant experts in the field led to contact with further experts, who provided 
information on specific ongoing studies and also pointed out potential papers that may have been 
missed by the literature search. Such information was also provided by supervisors, colleagues and 
2.5 
contacts from conferences. In addition a number of papers were encountered through other 
opportunistic methods such as generally keeping up to date with the literature and attending 
conferences. The web-sites above and bibliographies of studies also provided a potential source of 
grey literature. In addition, the National Research Register33 and Centrewatch34 were used to 
search for ongoing studies. 
Selection of abstracts and frill texts 
A protocol was developed to identify articles for which full text should be obtained. This was 
designed to include desired characteristics of relevant papers and was used when screening 
abstracts from the electronic database searches, in order to identify studies which could address the 
research question. The identification of abstracts from electronic databases was designed such that 
it would initially be maximally sensitive in order to minimise the possibility of overlooking 
relevant articles. The search strategies were then modified according to the number and relevance 
of abstracts retrieved, for example searches 2 and 3 were modified to become more specific, due to 
the huge number of research papers obtained in the initial searches. 
Study quality 
Variation in study quality may result in biased conclusions, since studies of differing quality will 
produce results of varying reliability. In addition the appropriateness of the study sample, design, 
and data collection characteristics may influence results 35'36 Assessing quality of studies in this 
way made interpretation of their findings more accurate and also helped to inform the design and 
conduct of CAFE. Literature on the appraisal of epidemiological research suggests consideration of 
the following issues when appraising validity of epidemiological research: - 
2.6 
" The study sample should be well defined at the level of both invitation to participate and 
agreement to participate, and should be representative of the entire population from which they 
were recruited. Potential biases which need to be considered at this stage include selection bias, 
for example did those invited to participate differ from those not invited in important 
characteristics which may impact upon cognitive decline? In addition, what was the baseline 
risk of cognitive decline - at what point in the progression of cognitive decline were patients 
when they entered the study? 
" The period of follow-up needs to be sufficiently long to allow outcomes to occur, and 
sufficiently complete to permit follow up of an adequate proportion of the cohort. The literature 
searches (searches 1 and 3) intended to explore the length of follow-up required to show 
significant cognitive decline and the likelihood of the outcome event (i. e. cognitive decline in 
those aged 60 years and over) in a specified time period (i. e. the follow-up period). 
" Loss to follow-up would jeopardise a study's validity since we are looking at relatively low- 
risk conditions (AF and cognitive decline). In addition, this could lead to bias if occurrence of 
important characteristics differed between those who were and were not followed up. 
" Outcome criteria need to be objective and unbiased Since there is no internationally 
recognised neuropsychological test battery in use, the outcome criteria for searches one and 
three vary. It is likely that studies which report the rate of cognitive decline using a recognised 
scoring system that has been validated and published elsewhere will be more valid. Another 
source of potential bias, observer bias, would be prevented if the observer measuring cognitive 
function is blinded to known likely risk factors for dementia, particularly the risk factor which 
is the focus of the study (e. g. for this study this would be NVAF). 
2.7 
Part 2: Findings from the literature 
a) Findings from the literature on atrial fibrillation as a risk factor for cognitive decline 
1. Evidence for an association between silent cerebral infarction and atrial fibrillation 
One study of a cohort of patients with atrial fibrillation demonstrated that 23 of 72 asymptomatic 
patients with AF had MRI features of cortical infarcts. 37 Another prospective study noted 
evidence of cerebral infarction on MRI investigation of 14 out of 15 asymptomatic patients with 
AF. 38 This study also found that those patients on warfarin treatment developed fewer additional 
periventricular hyperintensities at 12-month follow-up than those not treated with warfarin. In both 
of these studies however, the numbers were very small and there was no control group. Another, 
larger cross-sectional study demonstrated a significantly increased risk (relative risk 2.2) of 
periventricular white matter lesions in those with atrial fibrillation compared to sinus rhythm 
controls, but no increased risk of subcortical white matter lesions. 39 
These findings for chronic NVAF contrast with other work describing no increased risk of silent 
cerebral infarcts in those with paroxysmal AF. 12 
Larger studies of those with AF who have already suffered clinical stroke include the following: 
Kempster et a113 found that those with AF had three times the incidence of silent infarcts when 
compared to controls in sinus rhythm; and a small longitudinal study37 described an increased 
likelihood of development of symptomatic brain infarction in patients with AF who had pre- 
existing silent cortical strokes when compared to those with AF who had no previous silent cortical 
strokes on MRI, suggesting that silent infarcts may predict symptomatic infarcts. 
2.8 
Studies of primary and secondary stroke prevention with warfarin and aspirin also address this 
issue. For example the SPAF primary prevention study included detection of silent, predominantly 
lacunar, infarcts in 37 of 141 patients with AF. 40 In the SPINAF study, 41 a primary prevention 
study of 516 patients with AF, 76 had evidence of silent infarct at entry into the study, associated 
with a history of hypertension, elevated mean systolic blood pressure or angina. A study of 985 
AF patients with recent TIA or non-disabling stroke found that 139 had evidence of silent infarct 
on CT scan, with or without co-existing evidence of symptomatic infarcts. 42 
An autopsy study of 966 patients confirmed that those with a history of AF or hypertension had a 
greater number of silent cerebral infarcts than those without these conditions. 1 t 
2. Evidence for an association between atrial fibrillation and cognitive decline 
A number of cross-sectional studies demonstrate that those with atrial fibrillation have significantly 
lower scores on neuropsychological testing than those in sinus rhythm: - 
" Kilander et al found that men with NVAF had significantly (p<0.01) lower scores on MMSE 
and Trail-Making Tests than those in sinus rhythm, independent of history of stroke, diabetes, 
hypertension and poor left ventricular function. 20 
9 Sabatini et al demonstrated significantly lower MMSE scores in those with NVAF compared 
to those in sinus rhythm. 17.19,20 
A cross-sectional analysis of the longitudinal Rotterdam study demonstrated a statistically 
significant positive association between atrial fibrillation and both cognitive impairment (odds 
ratio 1.7) and incidence of dementia (odds ratio 2.3) of both vascular and Alzheimer-type 
aetiologies. This study used an extensive neuropsychological assessment for diagnosis of 
dementia, but only used the MMSE (<26) to diagnose cognitive impairment. 18 
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Only one study in this field demonstrated lack of association between NVAF and cognitive 
impairment: - 
The InCHIANTI study reported that atrial fibrillation was statistically significantly (p=0.04) 
more prevalent in those with low cognitive performance with subcortical features than those 
with high cognitive performance or without subcortical features. However, this became non- 
significant (p=O. 11) after adjustment for age, suggesting no significant association between 
NVAF and poor cognitive function. 21 
The only longitudinal study retrieved was a study of 411 patients undergoing coronary artery 
bypass grafting. This work reported more cognitive decline 6 weeks after surgery in those who 
developed post-operative atrial fibrillation (p=0.036). This study used the Randt Memory Test, 
Digit Span and Symbol subtests of WAIS, Wechsler Memory Scale Figural Memory test, Trail 
Making Test, and Rey Auditory-Verbal learning test. 16 
Though not focused solely on NVAF, a recent cross-sectional analysis of the Framingham Study 
cohort demonstrated that those with higher 10-year risk of stroke had poorer performance on 
neuropsychological testing. Although the study was not designed to look specifically at NVAF and 
the number of participants with NVAF was small (n= approximately 65), the presence of NVAF 
was found to be associated with poorer performance on tests of abstract reasoning and visual- 
spatial memory. The presence or absence of NVAF is a variable in the Framingham stroke risk 
calculation. 43 
Published work has demonstrated that vascular risk factors including NVAF may lead not only to 
vascular dementia, through silent cerebral infarcts, but also to a dementing process similar to 
Alzheimer's disease, in addition to `mixed' aetiology dementias. 44 Post-mortem studies4 have 
demonstrated that a high proportion of dementias have both vascular and Alzheimer-type 
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pathological changes. Suggested pathological mechanisms for this include a direct effect of 
vascular disease on the pathological process, for example cerebral ischaemia may lead to 
deposition of amyloid and may disturb the blood-brain barrier, and inflammation may also play a 
role. 44 Finally, there may be common risk factors for both vascular and Alzheimer-type 
dementia, 44 with potential for prevention; for example the Syst-Eur trial demonstrated less 
dementia in those who received anti-platelet therapy. 6,44 
3. Pilot study 
Prior to commencement of the work outlined in this thesis, a pilot study had been carried out. 15 
This local, community-based cross-sectional study demonstrated that older people with NVAF and 
no history of stroke performed more poorly on detailed neuropsychological testing than did 
matched controls in sinus rhythm. The difference was most marked in the memory and new 
learning parts of the test. However, observation of change over time was not performed in the pilot, 
therefore it was not possible to determine whether cognition changed over time. This study 
generated the hypothesis for the work described in this thesis. 
4. Evidence for the relationship between the duration of atrial fibrillation and the 
presence of silent infarcts or cognitive decline 
Limited evidence is available on this subject. The work done by the EAFT study group42 found no 
significant association between the duration of AF and the presence of silent infarcts. However, the 
study may not have accurately measured the exact time of onset of AF, a problem exacerbated by 
the often asymptomatic nature of AF. 
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b) Findings from literature on the epidemiology of atrial fibrillation 
1. Prevalence and nature of AF, risk of stroke and the role of anticoagulants in prevention 
Many studies in the UK and internationally have demonstrated that non-valvular atrial fibrillation 
(NVAF) is a common condition which increases with age. Estimates of prevalence range from 1- 
3% in those under 60 years to 9% in those over the age of 80 years, 45-49 although these studies are 
from different countries, and some are small, using selected populations. The incidence 
approximately doubles with each decade of adult life. Between 55 and 64 years the incidence is 2 
to 3 new cases per 1000 population, rising to an incidence of 35 per 1000 population between the 
ages of 85 and 94 years. 50 A large, community-based prevalence study in the UK described an 
overall prevalence of 4.7% in the over 65's rising to 10% in men over 75 years. 9 
Most NVAF occurs in those with cardiovascular disease. 51 Cardiac failure, left ventricular 
hypertrophy and diabetes have been shown to be associated with NVAF. 
Chronic AF is associated with doubling of overall mortality even when adjustments are made for 
pre-existing cardiovascular conditions with which AF is associated. 51,52 With ageing populations 
in the developed world, AF has become the most common arrhythmia diagnosed in hospital. 53 
AF results in haemodynamic effects due to irregular ventricular filling, and increased risk of atrial 
thrombus formation. Symptoms range from palpitations to pulmonary oedema, with thrombus 
formation leading to cerebral infarcts and clinical stroke. 
Management options to reduce these complications of NVAF include restoration of sinus rhythm, 
but this is often unsuccessful, short-lived or inappropriate. Management of established NVAF 
includes rate control (commonly digoxin) and anticoagulation or treatment with antiplatelet agents 
to prevent thrombus formation. A study comparing the two management options found that those 
assigned to rhythm control had no survival advantage over those assigned to rate-control. 54 
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Randomised controlled trials have demonstrated the efficacy of anticoagulants in preventing the 
risk of stroke in patients with NVAF, 24,55-61 being more effective than aspirin; and the benefits of 
antiplatelet therapy have been further confirmed by recent meta-analyses. 24,62-64 
A large proportion of patients in the community would be likely to benefit from the use of 
antithrombotic therapy. 9'65 Appropriate use of anticoagulants is now well-known and widely 
accepted66 and the importance of anticoagulation is reflected in the NHS National Service 
Framework for Older People, which includes a milestone for the identification and treatment of 
patients by 2004 at risk of stroke because of atrial fibrillation. 67 Nonetheless, many studies have 
revealed apparent under-use of warfarin. 9,68 The work described in this thesis may help to 
highlight the importance of appropriate identification and management of people with NVAF. 
2. Findings from the literature on risk factors for cerebral infarction/ stroke in atrial 
fibrillation 
Data from longitudinal analyses of study cohorts (control groups and/or aspirin treated trial 
participants with atrial fibrillation) has been used to identify potential risk factors for stroke. 69 Four 
such risk stratification schemes, specifically for those in atrial fibrillation, are the Stroke Prevention 
in Atrial Fibrillation (SPAF) scheme, the Atrial Fibrillation Investigators (AFI) schemes, the 
American College of Chest Physicians Consensus (AACP), and the Scottish Intercollegiate 
Network Guidelines (SIGN, based on SPAF). 69 56,70,71 The risk factors described in these schemes 
are shown in table 2.1. 
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Table 2.1: Statistically Significant Risk factors for stroke in atrial fibrillation 
Risk Classification Scheme 
Level of risk 
American 
SPAF AF1 College of SIGN Chest 
Physicians 
Previous stroke/ Previous stroke/ Previous stroke/ Previous stroke/ 
TIA TIA TIA TIA* 
Women >75 Agez65 years Age>75 years Age>65 years 
years History of History of plus one other 
High Systolic BP > hypertension hypertension risk 
factor: - 
160 mmHg Diabetes Left ventricular Hypertension 
Left Ventricular mellitus dysfunction Diabetes 
Dysfunction >1 moderate Heart failure 
risk factor Left ventricular 
dysfunction 
History of Age 65-75 Age> 65 years 
hypertension years with no other 
with no other Diabetes risk factors 
Moderate risk factors mellitus Age<65 years 
Coronary with other risk 
disease factors 
Thyrotoxicosis 
No history of Age <65 years Age<65 years Age <65 years 
Low hypertension with no other with no other with no other 
with no other risk factors risk factors risk factors 
risk factors 
* SIGN classified previous stroke/ TIA as a separate `very high' risk group 
In addition to the schemes described above, the CHADS2 scheme (Congestive heart failure, 
Hypertension, Age>75 years, Diabetes Mellitus and prior Stroke), an amalgamation of SPAF and 
AFI, also quantifies risk of stroke for those in AF according to the following risk criteria: prior 
cerebral ischaemia, history of hypertension, diabetes mellitus, recent congestive heart failure 
exacerbation and agez75 years. 72 
Furthermore, data from the Framingham Heart Study has been analysed to produce a method of 
obtaining risk of stroke for people with AF. 73 Statistically significant (p<0.1) risk factors for stroke 
suggested by this work are advancing age (hazard ratio 1.34 per 10 year increment), female sex 
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(hazard ratio 1.73), increasing systolic blood pressure (hazard ratio 1.10 per 10mm Hg increment), 
prior stroke or transient ischaemic attack (hazard ratio 1.69) and diabetes (hazard ratio 1.69). 
In summary, most studies of people with AF report the following as risk factors for stroke in AF: 
previous stroke/ TIA, age>75 years, history of hypertension, left ventricular dysfunction and 
diabetes. 
c) Findings from literature on other risk factors for cognitive decline 
Our search strategy was designed to look specifically for studies addressing cognitive decline. This 
search highlighted the following as major potential risk factors for cognitive decline: - 
1. Hypertension 
A large amount of work addresses the effect of hypertension on cognition and dementia: The 
following studies suggested an association between hypertension and cognition: - 
9 Data from the Framingham study 74-77 demonstrated that hypertension may be associated 
with reduced cognitive function, but only in subjects followed for a long period with no 
anti-hypertensive therapy. 
" The Rotterdam study 78 found that silent cerebral infarcts were associated with 
hypertension, but not with diabetes and smoking or excessive alcohol consumption. 
Reports from this longitudinal study also describe an increased stroke risk in those with 
silent brain infarcts and white matter lesions, independent of major stroke risk factors. 79 
"A cross-sectional study 80 in the UK showed an association between hypertension and 
impaired cognitive function, with older patients with hypertension having impaired 
attention, short-term and long-term memory. Cognitive assessment scores were 
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significantly lower in hypertensive than normotensive groups. These groups were matched 
for age, educational level, depressive disorder and psychotropic medication. 
" Further cross-sectional work found that higher diastolic blood pressure was associated with 
poorer performance on neuropsychological testing, and that this association was greater for 
younger than older subjects. 81 
" The Syst-Eur trial 6 demonstrated that in elderly people with isolated systolic hypertension, 
antihypertensive treatment was associated with a lower incidence of dementia. If 1000 
hypertensive patients were treated with anti-hypertensive drugs for 5 years, 19 cases of 
dementia might be prevented. This study found that a reduction of 7mm Hg (systolic) and 
3.2mmHg(diastolic) over four years halved the incidence of dementia. 82,83 
" The PROGRESS study found that cognitive decline reduced from 11% to 9% over 4 years 
in those taking perindopril and indapamine, due to prevention of stroke. M 
" The Kungsholmen project, a longitudinal study of ageing and dementia 85 and other studies 
86-88; found that hypotension was associated with lower cognitive function and that systolic 
BP of at least 130 mmHg is important to the maintenance of cognitive functioning in the 
very old (>85 years). However, it also showed an association between severe hypertension 
that is not well controlled (systolic pressure >180 mmHg / diastolic >95mmHg) and poor 
cognitive function in this age group. 
" The Honolulu-Asia Aging Study 86 showed that midlife systolic blood pressure predicts 
low cognitive function in later life. After adjustment for confounders (age, CHD, stroke, 
atherosclerosis), every 10mmHg increase in systolic blood pressure in mid-life led to a 5% 
increased risk of poor cognitive function in later life (mean age 78years). These findings 
are supported by data from the National Heart, Lung and Blood Institute Twin Study. 89 
"A prospective population-based study 90 showed that raised systolic blood pressure and 
high serum cholesterol concentration , and particularly a combination of these risks in 
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midlife, increases the risk of Alzheimer's disease in later life. This is further evidence for a 
role of vascular risk factors in the pathogenesis of Alzheimer's disease, not just `vascular' 
dementia. 
" Another prospective study demonstrated higher risk of cognitive decline in those with high 
systolic BPs. 91 
9 Studies of the effect of antihypertensive therapy have demonstrated that it is safe and that 
treating hypertension is not hazardous to cognitive function 92,93 
The following studies suggested no association between hypertension and cognition: - 
" Analysis of the Established Populations for Epidemiologic Studies of the Elderly (EPESE) 
94 cohort demonstrated no relationship between blood pressure and cognitive function over 
a 6-year period of observation (after adjusting for age, sex and education). 
" The Study on Cognition and Prognosis in the Elderly (SCOPE)95 reported no significant 
difference in cognitive decline or dementia between those who did and did not receive an 
angiotensin receptor blocking anti-hypertensive treatment (candesartan), despite a slightly 
more effective blood pressure reduction in those who took candesartan. 
Summary for hypertension as a risk factor for cognitive decline: - 
There are conflicting results from different studies. There is more evidence for than against the 
hypothesis that hypertension is associated with cognitive decline, although the extent of this 
association is modest. In addition, it appears that any cognitive declinelimpairment is related 
directly to hypertension, rather than antihypertensive drug therapy. 
2.17 
2. Age 
A very large number of longitudinal studies demonstrated that older age is associated with 
cognitive decline. 77,96-99 
Of all the studies identified that have addressed the issue of age and cognitive decline, the majority 
have demonstrated an inverse association between age and cognitive performance. Only one study 
described lack of such an association between advancing age and cognitive decline in the majority 
of its cohort, finding this relationship only in women of below median intelligence. 77 
For most studies, analyses were primarily of changes in the cognitive function of the cohort over 
time. However, several of the studies also demonstrated that within the cohort, a small number of 
individuals did not deteriorate over time. 
Summary for age as a risk factor for cognitive decline: - 
Overall, the age of a cohort appears to be associated with a modest cognitive decline in the 
majority of people, though within study populations some individuals show no decline with age. 
3. Cardiovascular disease 
The Rotterdam studyl00 demonstrated that atherosclerotic disease accounts for considerable 
cognitive impairment in the general population. Previous vascular events, presence of plaques in 
the carotid arteries and presence of peripheral arterial atherosclerotic disease were associated with 
worse cognitive performance (MMSE), independent of the effects of age and education. The 
Whitehall II studylol, a longitudinal study of British civil servants, found that angina, coronary 
heart disease and intermittent claudication were all associated with poor cognitive function. 
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Cross-sectional work102 has demonstrated an association between congestive heart failure (CHF) 
of all NYHA classification grades and cognitive impairment (MMSE<24), showing a 1.96 times 
increased risk of cognitive impairment for those with CHF (odds ratio 1.96; 95% Cl: 1.07-3.58, 
p<0.028). Another study 103 confirmed that CHF was significantly associated with an increased 
likelihood of impaired cognition. 
Another cross-sectional study 104 demonstrated that those with a left ventricular ejection fraction 
of less than 30% (i. e. systolic dysfunction) performed significantly worse on MMSE. 
Hypercholesterolaemia has been shown to be associated with poor performance on memory tests. 
90,105 Despite this, the MRC/ BHF Heart Protection Study of individuals at high risk of vascular 
disease demonstrated no significant differences in proportion with cognitive impairment, or mean 
neuropsychological test score, between groups who did and did not take simvastatin. In addition, 
similar numbers in each group went on to develop dementia. This fording was despite the fact that 
the simvastatin group showed a 25% reduction in deaths from vascular causes. 106 Similarly, the 
PROSPER (pravastatin in elderly individuals at risk of vascular disease) study found no effect of 
pravastatin on cognition, 107 and the Sydney Older Persons Study, a prospective study of those aged 
over 75 years, demonstrated a protective effect of hypercholesterolaemia for the development of 
dementia and cognitive decline. 108 
Summary for cardiovascular disease as a risk factor for cognitive decline: - 
There is some evidence for associations between cognitive decline and previous cerebrovascular 
events, carotid artery plaques, peripheral atherosclerotic disease, vascular disease, CHF (all NYHA 
grades), left ventricular dysfunction and hypercholesterolaemia. However, these findings are 
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contradicted by the results of recent studies which found no effect on cognition of cholesterol- 
lowering therapy, and in one study a protective effect of hypercholesterolaemia. 
4. Diabetes 
A longitudinal study 98 demonstrated that cardiovascular disease and diabetes are associated with 
cognitive decline. Another prospective study also showed that diabetes in women was associated 
with cognitive impairment and decline. 109 Diabetes was shown to be associated with reduced 
performance on tests of abstract reasoning and visuospatial ability. 105 
Summary for diabetes as a risk factor for cognitive decline: - 
There is some evidence suggesting an association between diabetes and cognitive decline and 
impairment. 
5. Educational Level 
Intelligence level as a young person may affect the extent and rate of cognitive decline with age, 
for example one longitudinal study 77 demonstrated that advanced age was only associated with 
cognitive decline in women of below median intelligence. 
A cross-sectional sub-analysis of the Rotterdam studylOO demonstrated that lower (past) 
educational level was associated with poorer cognitive function. 
The IOWA 65+ Rural Health Study, 110 a longitudinal study, demonstrated that educational level 
was associated cross-sectionally with cognitive test performance but did not predict cognitive 
decline. Another longitudinal study 98 demonstrated that a shorter duration of education was 
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associated with greater cognitive decline. Other prospective cohort studies reported that formal 
education had a protective effect against age-related cognitive decline, t1t with higher NART- 
predicted IQs being associated with less cognitive decline. 91 
A further prospective study reported that low educational level may also be a genuine risk factor 
for dementia (in addition to leading to increased detection on screening tests). 112 
The Nun Study, a longitudinal study of Catholic Sisters, found that cognitive function decreased 
with age at baseline, particularly in nuns without Bachelors degrees; whilst cognitive function 
declined over the follow-up period (1.6 years) to a greater extent in those nuns with Bachelor's 
degrees. A possible explanation provided was a healthy survivor effect in those without degrees, 
although it is not clear why this may be. 99 
Summaryfor educational level as a risk factor for cognitive decline: - 
Most studies agree that a lower level of education is associated with poorer performance on 
neuropsychological tests. There is some conflict over the association with education and cognitive 
decline over time, with some studies showing less decline in those with more education; some 
studies finding no association; and others noting greater decline in those with more education. 
6. Depression 
Most work on depression and cognition has not been examined with longitudinal studies. However, 
one longitudinal, community-based studyt 13 explored this area and demonstrated that men and 
women with depressive symptoms were at increased risk of cognitive decline independent of 
insomnia. Another longitudinal study of factors predicting cognitive decline 77 demonstrated that 
depression was only associated with cognitive decline in women of below median intelligence and 
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men of above median intelligence. Possible explanations for this suggested vulnerability of women 
of below median intelligence to the negative influence of depression on cognition include 
biological explanations and deficiencies in metamemory skills (worldly knowledge reserves and 
ability to make pragmatic use of cognition) in this group. 
Other prospective studies found an association between depressive symptoms and both cognitive 
impairment and cognitive decline. 114,115 Further work suggests a positive relationship between 
depression and subsequent cognitive decline, 116,117 but only in those with mild cognitive 
impairment at baseline. This study suggests that depression may occur early in the dementing 
process but may not itself be a risk factor for dementia. 
Case-control studies 118-120 demonstrated an association between cognition and depression scores, 
but this study design makes it difficult to establish cause and effect. In contrast, another cross- 
sectional study 121 demonstrated no association between depression and cognition. 
Sumvnary for depression as a risk factor for cognitive decline: - 
All identified longitudinal studies exploring this area found an association between depression and 
cognitive decline, although two of these studies found this association was only present in specific 
groups (according to intelligence or baseline cognitive function). Findings from cross-sectional 
studies were conflicting, with some showing an association between depression and cognitive 
impairment, and one study showing no association. 
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7. Use of medication 
A small longitudinal study 122 demonstrated a significant decline in cognitive function associated 
with administration of some antihypertensive medication, although the SCOPE study95 
demonstrated no association between use of antihypertensive treatment with candesartan and 
cognitive decline or dementia. 
Another study 123 demonstrates minor beneficial effects of the drug dihydroergocristine (an 
adrenergic alpha-antagonist and dopamine agonist) in reducing the risk of cognitive decline. 
A longitudinal studyl24 described how aspirin users, especially intermittent users, benefit slightly 
in having a reduced risk of cognitive decline. 
Further prospective work has demonstrated an association between decline in memory and use of 
high dose non-steroidal anti-inflammatory drugs. 125 
A prospective cohort study found that those who used benzodiazepines at recommended or higher 
doses had significantly worse memory scores than non-users. 126 
Summaryfor medication use as a risk factor for cognitive decline: - 
Studies demonstrate that some antihypertensives and benzodiazepines may increase the risk of 
cognitive decline or impairment, whilst dihydroergocristine and aspirin may reduce the risk of 
cognitive decline or impairment. 
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8. Lifestyle factors (Alkohol smoking, exercise and diet) 
A longitudinal study exploring predictors of cognitive decline 77 reported that neither alcohol nor 
smoking appear to be reliable predictors of change in cognitive function. This work also 
demonstrated that the number of cigarettes smoked daily was only associated with cognitive 
decline in women of below median intelligence. 
Another longitudinal study98 demonstrated that those who smoke and have cardiovascular disease 
(CVD) or diabetes may have a higher risk of cognitive decline, whereas those (with CVD/ 
diabetes) who drink moderate alcohol compared to abstainers may have a reduced or no alteration 
in risk of cognitive decline. 
More longitudinal work undertaken as part of a larger study127, the Canadian Study of Health and 
Aging (CSHA) demonstrated an association between alcohol abuse (using DSM criteria) and 
cognitive impairment. However, the Cardiovascular Health Study 128 found that consumption of up 
to six units weekly was associated with a lower risk of dementia compared to abstention. 
The British Doctors Study129, another longitudinal study, demonstrated that persistent smoking has 
little effect on the age-specific rate of Alzheimer's disease. An Australian study found no 
association between Alzheimer's disease or cognitive function and `health habits' (exercise, 
smoking, alcohol use). 130 
An American longitudinal study found no significant relationship between smoking and the 
incidence of cognitive impairment, once data had been adjusted for age. 131 This conflicts with 
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work in Japan demonstrating a significantly higher risk of cognitive impairment in continuous 
smokers compared to never smokers. 132 
In addition, the Rotterdam study demonstrated no association between high dietary fat (total, 
saturated, cholesterol and trans fat) intake and increased risk of dementia, 133 and further work 
demonstrated no increased risk of dementia in those with a low body mass index (BMI). 134 
Summary for lifestyle factors as risk factors for cognitive decline: - 
The evidence on lifestyle factors as risk factors for cognitive decline and impairment is conflicting. 
Of the smoking studies identified, only two demonstrated an association between smoking status 
and cognitive decline or impairment, whilst four demonstrated no association. Of the alcohol 
studies, one demonstrated an association between alcohol abuse and cognitive impairment, but two 
studies demonstrated no association and two studies showed a reduced risk of cognitive decline in 
those consuming moderate amounts of alcohol. The only study addressing exercise found this had 
no effect on the risk of Alzheimer's disease, and fat intake or BMI do not appear to affect risk of 
dementia. 
9. Other risk factors for cognitive decline 
9 Insomnia: a longitudinal community-based studyt 13 observed that chronic insomnia 
predicts incident cognitive decline in older men. 
" Ethnicity: a cross-sectional study (n=2,581)135 observed that African Americans scored 
lower than Japanese Americans on the Cognitive Abilities Screening Instrument (CAST), 
this gap decreasing when only those within the high education groups were compared. 
9A population-based cross-sectional study demonstrated that neighbourhood type (in this 
case suburban, transitional or barrio) has been shown to predict cognitive impairment. 136 
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" Social disengagement (failure to maintain many social connections and participate in social 
activities) has been shown to be associated with risk of cognitive impairment. 137 
"A pooled analysis of four community-based prospective cohort studies demonstrated that 
women had a significantly higher risk of developing Alzheimer's disease (AD) after the 
age of 85 years than men, with no such increased risk of vascular dementia. 138 In contrast 
with this, the Cardiovascular Health Study found little effect of sex (or race) on incidence 
of dementia. 139 
9 Genetic influences: a longitudinal study 140 observed a 45% pairwise concordance for 
decline on the Wechsler Adult Intelligence Scale (a test used to measure cognition) for 
monzygotic twins, and 8% for dizygotic twins. 
" APOE Genotype: a prospective cohort study. '4' demonstrated that APOE 4 was 
significantly and uniquely related to lower score at baseline and significantly increased the 
odds of cognitive decline by 59%. Further work also demonstrated an association between 
APOE 4 status and cognitive decline, 142-145 and showed the use of oestrogen to provide 
some protection over cognitive decline in those with the APOE4 allele, 146 with a protective 
effect of hormone-replacement therapy in post-menopausal women. 147 Evidence also 
suggests that the combination of the APOE 4 allele and history of cerebrovascular disease, 
148 and the combination of APOE 4 allele and midlife hyperglycaemia 149 may have a 
synergistic effect on cognitive decline. 
" Evidence for an association between endogenous oestrogen levels and cognitive decline is 
unclear, with some studies demonstrating no association, 150 and others showing less risk 
of cognitive impairment in those with high oestrogen and low testosterone levels. 151 Other 
work describes no protective effect of oestrogen replacement therapy on age-related 
cognitive decline. 111,152 
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"A small, prospective study has shown an association between cortisol levels and cognitive 
decline, with a non-significant inverse association between dehydroepiandosterone sulfate 
(DHEAS) levels and cognitive decline. 153 
" Studies of serum levels of the amino-acid homocysteine have shown no association 
between this and cognitive decline. This is despite the demonstrated association between 
homocysteine and increased risk of cerebrovascular and cardiovascular disease. 154 
" Residence: a longitudinal study 77 of factors predicting cognitive decline demonstrated that 
rural residence was only associated with cognitive decline in women of below median 
intelligence. 
" High-grade stenosis of the left internal carotid artery, without history of stroke or TIA, has 
been shown to be associated with cognitive impairment and decline, even after adjustment 
for right carotid artery stenosis (thus reducing the likelihood that this fording is due to other 
vascular risk factors and atherosclerosis). -. 155 
" Participation in leisure activities has been shown to be associated with reduced risk of 
dementia in one prospective'study. 156 
" Seropositive status for herpes simplex virus and cytomegalovirus has been demonstrated as 
being associated with cognitive impairment in those with cardiovascular disease. 157 
" Studies have demonstrated an association between low birth weight and poor cognitive 
function, although to date this has only been demonstrated up to early adulthood. 158,159 
2.27 
Chapter 2 Summary 
" To inform the work reported in this thesis, an extensive review of relevant literature was 
undertaken. 
"1 carried out three separate searches addressing; 1) studies of atrial fibrillation (AF), silent 
cerebral infarction and cognitive decline; 2) studies of the epidemiology of AF and 3) 
studies of other risk factors for cognitive decline. 
" Strategies for searching electronic databases and grey literature were designed using 
recognised methodological filters. Selection of studies was done systematically. Study 
quality was considered when searching for literature, although a formal assessment of 
study quality is not reported here. 
" There is evidence for associations between AF, silent cerebral infarction and cognition, but 
to date this has been largely from cross-sectional studies, including the pilot study 15 
carried out prior to the work reported in this thesis. In order to adequately explore the 
aetiology of cognitive decline, longitudinal studies measuring cognitive function in 
representative populations over an appropriate period of time are needed. The work 
reported in this thesis is such a study. 
" AF is a common condition, the prevalence of which increases as the population ages. 
Studies of people with AF report previous stroke/ TIA, age>75 years, history of 
hypertension, left ventricular dysfunction and diabetes as risk factors for stroke in AF. It is 
plausible that these may also be risk factors for silent stroke leading to cognitive decline in 
those with AF. 
" Despite the proven efficacy of anticoagulant and antiplatelet therapy in preventing stroke in 
people with AF, there is significant underprescribing of these treatments. The work 
reported in this thesis addresses the role of anticoagulant and antiplatelet therapy in 
preventing cognitive decline in addition to stroke. 
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9 There are many studies of risk factors for cognitive decline other than AF. The most widely 
studied risk factor is hypertension, for which evidence suggests there may be a modest 
association with cognitive decline. There is also strong evidence supporting the association 
between age and cognitive decline. 
9 There is more scanty literature supporting an association of cardiovascular disease, diabetes, 
depression, education, medication and lifestyle with cognitive impairment. 
" Knowledge of the existing work on risk factors for cognitive decline, obtained through the 
literature searches described here, provided a sound base on which to design the method for 
the study (the Cognition in Atrial Fibrillation Evaluation) described in this thesis. 
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Chapter 3- The Epidemiology of Cognitive Decline 
" Part 1: Literature search method 
o Purpose of the search 
o Objectives 
o Search strategy 
o Criteria for inclusion 
o Data extraction 
o Assessment of study quality 
o Data synthesis 
" Part 2: Findings from the literature 
o Cognitive function research methodology 
o Pathogenesis of cognitive decline 
o Incidence and prevalence of cognitive decline 
" Part 3: Results of the formal systematic review 
o Key findings 
o Issues arising from the formal systematic review, including critical appraisal 
" Chapter 3 summary 
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Part 1: Literature search methodology 
Purpose of Search 
In order to study the role of atrial fibrillation in the aetiology of cognitive decline, it was vital to 
have a thorough understanding of the nature of cognitive decline in the general elderly population, 
i. e. to what extent would we expect cognitive decline in the general population? To explore this 
further I undertook a formal systematic review of the rate and nature of cognitive decline in the 
general elderly population. 160 Part of this search formed a component of an MSc in Health 
Sciences. 161 In addition to the formal systematic review, other literature of relevance was identified 
to complete the understanding of the epidemiology of cognitive decline. 
Objectives 
The objectives of the systematic review were: 
(i) To systematically obtain and appraise all of the relevant literature on cognitive decline in the 
general elderly population; (ii) to collate the main findings following appraisal of the literature; (iii) 
to present a systematic description of the current literature, with comment on the quality of studies 
included; and (iv) to identify issues of relevance to the work reported in the main body of this 
thesis, that is the Cognition and Atrial Fibrillation Evaluation (CAFE). 
The objectives of the less formal search on epidemiology of cognitive decline were to summarise 
the natural history of cognitive decline and to identify issues in the study of cognitive decline that 
would be relevant to CAFE. 
Search strategy (Appendix 1): 
Before the review, literature searches on methods of systematic review and cognitive function 
research were conducted in order to inform study design. This highlighted issues such as the 
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association of cognitive decline with increased mortality, the numerous different tools used to 
assess cognitive function and the reliability of estimates of change. In addition, it was clear that 
there was limited literature on the clinical significance of declining scores on neuropsychological 
tests. 
As for the searches described in Chapter 2, the McMaster strategies for aetiology, causation and 
harm26'27 were combined with the core section on cognitive decline and dementia from the 
Cochrane Dementia and Cognitive Impairment Group (CDCI)28. This detailed, combined, 
electronic search strategy was then applied to Medline (1966-2000), Embase (1990-2000) and 
PsycINFO (1984-2000). This search strategy was effectively the same as that undertaken for 
search 3 in chapter 2, although the inclusion criteria for screening abstracts were different (see 
below). The identification of abstracts from electronic databases was designed to be maximally 
sensitive in order to minimise the possibility of overlooking relevant articles. In addition a search 
of web resources and grey literature was undertaken. 
Criteria for inclusion: 
Based on the literature review, it was decided that participants of included studies should be 
predominantly aged 60 years and over and should be a representative community sample. They 
should not be subgroups of the population selected on the basis of existing specific illness. 
Included studies should be designed as community-based, prospective cohort studies, with high 
rates of follow-up. These criteria were incorporated into a protocol for screening of the abstracts 
generated by the search of electronic databases, which was modified slightly after piloting by two 
reviewers (myself and Dr Janice O'Connell, who acted as second observer for several stages of the 
review). 
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I then used the protocol to select those abstracts for which full text paper retrieval was appropriate. 
This included studies for which the abstract was not sufficiently detailed to allow evaluation of 
inclusion criteria. To increase the objectivity and consistency of the decision to include or exclude 
a paper based on reading the full text, an `In/Out' form (Appendix 2, Box 1) was developed and 
piloted (HP, JO'C, RT). Where there was uncertainty, the abstracts were discussed with a second 
and third observer (JO'C, RT) and a medical statistician (AH). In five cases it was necessary to 
correspond with the original author. The review was not blinded to author / journal / title, since this 
would have been logistically difficult 162,163 given time and resource constraints. 
Data extraction 
The data extraction sheet (Appendix 2, Box 2) was derived from the Centre for Reviews and 
Dissemination's example data extraction sheets for reviews of effectiveness, 16 but in addition we 
incorporated quality measures and recommendations from the literature on critical appraisal of 
cohort studies. 26 35,70,165 The sheet was piloted, modified and implemented. Although the rate of 
cognitive decline was the primary outcome measure, I also extracted data which could form the 
basis of quality appraisal of the research, and also information to enable meaningful comparisons 
between cohorts. 
Assessment of study quality 
When an estimate of methodological quality of reviewed studies is incorporated into a review, the 
interpretation of the findings can alter. 166 There is no consensus on the appropriate method of 
grading the quality of studies used in systematic reviews. 
Based on a search of the literature on quality appraisal and cognitive decline study methods 
described above26.35,70,167-169 key criteria were selected relevant to cohort studies of cognitive 
decline: i) that the study sample was well defined and representative; ii) that the period of follow- 
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up was sufficiently long to allow cognitive decline to occur; iii) that loss to follow-up was minimal; 
and iv) that outcome criteria were objective and unbiased. Providing that a study met these criteria 
or addressed them satisfactorily, the study was included in the review. An appraisal checklist and 
quality assessment form, again based on the literature search, were designed and piloted, 
incorporating three main headings (participants and setting, methods and analysis, and results - 
Appendix 2, Box 3). The appraisal checklist addressed the quality criteria as described, with the 
selection of `good', `fair', or `poor/not reported' for each of the three headings. This checklist and 
quality assessment form was then applied to all studies included in the review, to further evaluate 
each study. 
Data synthesis 
A data-extraction spreadsheet was developed, using information from the data-extraction form. 
The final decision on how best to combine the results was made after summarising the results of 
the different studies. The predefined options for combining results included meta-analysis of 
published results, pooled analysis of primary data or narrative review 170. The former two options 
are more objective, since they use explicit criteria and can be reproduced scientifically to provide a 
quantifiable result. 35 However, as with much research, 171 the studies were heterogeneous in terms 
of participant's populations, countries of origin, and neuropsychological tests employed. Thus it 
proved impossible to pool or combine the data by meta-analysis. In addition the length and number 
of follow-ups between studies were different, with varying proportions lost to follow-up. Hence 
narrative review was the most appropriate method for presenting summary information. Reviewing 
the differences between studies in this manner helped to distinguish between the important effects 
of true diversity and variations due to confounding and bias. 171 
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Part 2: Findings f rom the literature 
The principal outcome of interest to CAFE is reduced cognitive function in people with NVAF, but 
because one of the proposed underlying pathophysiological mechanisms is silent cerebral 
infarction, the discussion here also includes a commentary on the literature on silent infarction. 
Although the search strategy included literature on Alzheimer's disease, this chapter focuses on the 
findings of the literature on vascular dementia, vascular cognitive impairment and cognitive 
impairment/dementia due to mixed aetiologies, since these areas are of most relevance to this thesis. 
Cognitive function research methodology 
Outcomes from cross-sectional versus longitudinal studies: 
Williams 172 suggests that the association between cognitive decline and age was more strongly 
demonstrated when the cohort was analysed at a cross-sectional level than when the same 
participants were analysed over time (after repeated long term follow-up). Hence cross-sectional 
studies of associations between age and cognition may over-estimate the true association. Cross- 
sectional studies are not able to adequately assess aetiology and causation. The ideal 
epidemiological study to explore these areas would be an inception cohort study of a representative 
population. 14 
Different tools used to assess cognitive decline: 
It is apparent that even in the diagnosis and assessment of cognitive decline and dementia, there is 
no single mental status test or battery of tests which is recommended by all guidelines, neither 
nationally nor internationally. 173 
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The effect of cognitive impairment on mortality: 
Moderate and even mild cognitive impairment (defined as a score of 24 to 27 on the MMSE) has 
been shown to be associated with increased mortality. 174,175 In addition, vascular factors have 
been shown to predict drop-out rates in some cohort studies, therefore individuals who may be at 
greatest risk of cognitive deterioration are more likely to be lost to follow up. 176 
The effect of cognitive impairment on general activities: 
Further work based on the Canadian Study of Health and Ageing 177 reinforces the association 
between cognitive decline and age-related functional deficits, demonstrating that people with 
cognitive decline are `functionally older' (e. g. in terms of gait, mobility problems, activities of 
daily living and cardiovascular problems) than those without cognitive decline. 
Institutionalization of those with cognitive impairment: 
Cognitive impairment and dementia are important causes of institutionalisation in the elderly, 
178,179 therefore studies which exclude those living in such institutions at baseline or follow-up are 
likely to have a selection bias resulting in misleading estimates of the rate of cognitive decline in 
the general elderly population. In addition, studies which include only institutionalised groups may 
inadvertently (or deliberately) select patients according to factors such as severity of impairment 
and the interests of the institution. 180 
Age associated memory impairment (AAMI): 
Several studies used subjects with AAMI as their target population. AAMI is a term proposed by 
the National Institute of Mental Health (NIMH) in the USA. The criteria for AAMI are: 1) memory 
test performance of at least one SD below the mean observed for young adults; and 2) intact 
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general cognitive function as measured by instruments such as the MMSE. Up to one third of 
healthy 60 to 78 year old subjects meet the NIMH criteria for AAMI. 181 
Length of follow-up and reliability of estimates of change in test scores: 
Several studies have demonstrated improvement in cognitive function in early follow-up 
assessments, 333 for example at one year, followed by subsequent decline or stability. Possible 
explanations for such findings include learning effects in the follow-up assessment and higher 
anxiety in the first assessment, and it is also likely that regression to the mean has taken place. In 
addition, Van Belle's work 182 demonstrates that the reliability of estimates of change with certain 
neuropsychological tests (for example the MMSE) is likely to increase with a longer duration 
between assessments. He also demonstrates that estimates from a single instrument over a short 
time period are less reliable than if such results were combined with the results of other tests. 
Pathogenesis of vascular cognitive impairment and decline 
Published work demonstrates that a degree of cognitive decline is almost universal in those aged 
over 60 years. However, there is always some individual variation, and those with better cognitive 
functioning at baseline tend to have less decline. 183 
Normal ageing results in degenerative changes (senile plaques, neurofibrillary tangles in the 
hipppocampus), an increasing number of small, silent vascular infarcts and loss of up to 50% of 
cortical synapses. This may lead to a reduction in brain reserve capacity, following which only 
minor lesions could result in dementia. 
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The Rotterdam study 78 demonstrated that 24% of non-demented participants had one or more 
cerebral infarcts on MRI, of which 83.8% were silent rather than clinical. Skoog found that 
vascular factors (stroke and stroke risk factors) are present in more than 50% of dementias. 184 In 
addition, vascular dementia related to stroke is the second most common cause of dementia after 
Alzheimer's disease. A recent study demonstrated an association between silent cerebral infarcts 
and history of atherosclerotic vascular disease (without history of stroke or TIA). 185 
There is a range of pathological definitions, from `multi-infarct dementia' - due to large and small 
strokes, to the broader `vascular dementia' which includes other types of cerebrovascular disease 
associated with dementia, to `vascular cognitive impairment' that includes the milder end of the 
spectrum. 186 In addition, dementia can be due to many small infarcts ('multi-infarct') or a single/ 
several larger infarcts in specific areas of the brain controlling cognitive function (strategic-infarct 
dementia). Furthermore, a recent study has demonstrated an association between cognitive status 
and cortical microinfarcts and demyelination. 187 Costs of carrying out detailed brain imaging (e. g. 
MRis) mean that most research has focused on multi-infarct dementia, ignoring ischaemic white 
matter lesions. 
Often mixed pathologies result in dementia. Approximately half of vascular dementias may be 
pure (i. e. no evidence of Alzheimer's type pathology). 
Cognitive impairment due to vascular pathology covers a range of disease severity from dementia 
(including VaD, AD and mixed AD186. '88 to cognitive impairment with no dementia (CIND). 
Approximately 46% of those with CIND develop dementia within 5 years8. It is suggested that 
whether or not CIND progresses to dementia can partly be predicted by sex (women are at greater 
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risk of dementia) and possibly by performance on neuropsychological testing (poor performance 
on tests of memory and category fluency being associated with incident dementia) .8 
Classification of vascular dementia may be as follows 186,189; _ i) large vessel dementia affecting the 
carotid artery, circle of Willis and larger meningeal branches; ii) multi-infarct dementia / strategic 
infarct dementia affecting the anterior circulating artery and middle circulating artery territories, the 
thalamus, basal ganglia, basal forebrain, and the angular gyrus (AF may predispose to this type); iii) 
small vessel dementia affecting intra-cerebral arterioles, of cortical and / or subcortical sub-types 
(both are associated with hypertension and arteriosclerosis); and iv) hypoxic-ischaemic 
hypoperfusive dementia, where a temporary reduction in blood supply results in tissue damage - 
although the brain has autoregulatory mechanisms, interruption to blood supply is likely to be 
general, resulting in a global encephalopathy, with focal lesions in vulnerable areas. AF may 
predispose to both small vessel dementia and hypoxic-hypoperfusive dementia. Classification 
schemes for vascular cognitive impairment (other than according to primary vascular aetiology as 
described above) include categorising the dementia according to type of ischaemic brain lesion (e. g. 
lacunar infarct); according to anatomical location of brain lesions (e. g. cortical); and according to 
primary clinical syndrome (e. g. defined brain areas). 
Evidence suggests that mild cognitive impairment often precedes both vascular dementia 
(particularly where the pathology is predominantly small vessel disease rather than multi-infarct or 
strategic-infarct dementia) and Alzheimer's disease. 190 
The pathogenesis of decline in cognitive function with age may be related to a variation between 
individuals in the presence, severity of and rate of change in white matter hyperintensities. The 
presence of periventricular and deep white-matter hyperintensities has been shown to be associated 
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with a decline in performance IQ in the 70 to 80 years age group. 186 However, this only explains a 
small proportion of the wide variation in cognitive decline related to age. 
Incidence and prevalence of vascular cognitive decline 
There is a lack of consensus on what the diagnostic criteria should be and how they should be used 
in research, making it difficult to compare figures for incidence and prevalence described here: 186 
Prevalence 
Geography: The proportion of people with vascular dementia among those with any dementia 
varies from 11% (Spain) to 45% (Sweden) in Western European studies, and is thought to be 
generally higher in Asia, former Soviet Union and Eastern European countries. However, this may 
be due to different diagnostic criteria, and possibly age differences in those recorded. In addition, 
the previously high proportion of vascular dementia in Japan may be reversing to the European and 
North American trend, due to societal changes +/- diagnostic changes. Urban versus rural living 
also plays a role, for example there are higher rates of vascular dementia in Beijing, where there is 
higher salt intake and higher hypertension prevalence, than in the more rural Shanghai, where 
Alzheimer's predominates. 
Sex: Vascular dementia has a higher reported prevalence in men than women (contrasting with AD, 
especially after 80years), especially in those under the age of 75 years. 184,191,192 
Effect of better stroke management: there is no indication that the prevalence of vascular 
dementia is decreasing, despite better treatment of hypertension and a decline in stroke incidence. 
This may be partly explained by the ageing population, but also an increase in stroke survivors. 
Thus paradoxically, better treatment of stroke may have led to higher prevalence of vascular 
dementia. 
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Vascular dementia prevalence rises with increasing age, although less steeply than for Alzheimer's 
disease. Therefore we can conclude that the ageing population will lead to an increase in the 
number of vascular dementia cases. 
Incidence 
Vascular dementia and AD differ in duration of disease and survival, for example reported 
mortality in vascular dementia is higher than Alzheimer's. Because of this, vascular dementia may 
make a bigger contribution to dementia incidence than prevalence. Therefore incidence studies are 
preferable to prevalence studies. 
However, there are few incidence studies in general, possibly due to decreased resources and short- 
term research funding policies, and particularly few studies of incidence of vascular dementia. 
The incidence of vascular dementia rises steeply with age up to 90 years or more, but less steeply 
than Alzheimer's disease; therefore survival differences are not likely to be responsible for this 
effect. The Rotterdam study demonstrated a levelling off of incidence in vascular dementia in the 
oldest age categories, compared to a steep increase with age for Alzheimer's disease incidence. 78 
This could be due to the `healthy survivor' effect. 
Sex: as for prevalence, men have a higher incidence of vascular dementia at younger ages (and 
higher than women at all ages), and women have a higher incidence of Alzheimer's at older ages. 
192 
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Part 3: Results of the formal systematic review 
Many studies were identified which addressed cognitive decline in the general elderly population, 
but only 19 met the inclusion criteria for this review. Studies addressing cognitive decline in the 
general elderly population were clinically and methodologically heterogeneous. In particular, the 
lack of an international gold-standard battery of neuropsychological tests prevented quantitative 
combination of study results. Therefore the review was unable to establish the precise rate of 
cognitive decline in the general population, as originally intended. When studies using the same 
neuropsychological tests were grouped together, the rate of decline varied greatly between studies. 
This variation in performance cannot be explained by differences in age. The study cohort with the 
greatest annual decline in Mini Mental State Examination (MMSE) score was also the oldest 
group. 193 However, for the remaining studies using this test there was no relation between age of 
the cohort and MMSE rank. Furthermore, age of the cohort had no obvious effect on Cambridge 
Cognitive Examination (CAMCOG) rank in studies employing that test. Quantitative comparison 
of these particular studies was not possible due to heterogeneity of the participants. 
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Key findings: 
Although it was not possible to combine the results, the extraction and summary of data from each 
study was performed. This led to the following key findings: 
Cognitive decline is almost universal: most of the studies which did not exclude those with 
dementia demonstrated significant decline for the whole sample over the study intervals, 
although two studies described very small changes194,195 in the whole sample. Studies 
excluding people with dementia showed smaller rates of decline, although in most cases these 
were still statistically significant. All of the studies which addressed the effect of age on 
cognition noted that the rate of cognitive decline increased as age at baseline increased. In 
addition, those which analysed the effect of baseline cognitive function found an inverse 
association between this and the rate of cognitive decline. Despite these group observations 
however, intra-individual variation in the rate of decline was also described, regardless of 
predictions based on factors such as age or initial cognitive function. Even where there was a 
statistically significant trend towards an association between increasing age and increased 
cognitive decline, a proportion of individuals demonstrated no such change in cognition. 
Although the majority of studies reported only mean declines in subgroups, some studies 
described the proportion of participants whose cognition was unchanged; 15% of the 
participants in the Cambridge Project for Later Life (CPLL)196 had unaltered cognitive 
function, and a further 28% improved over the mean 28 months follow-up. 32% of the 
participants in Epidemiologic Catchment Area (ECA) study 197 demonstrated no change or 
improvement in cognitive function during the mean 11.6 years follow-up. 
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Quality: Following appraisal of the included studies, whilst all met core inclusion criteria the 
quality otherwise varied between studies. The quality criteria with highest overall scores were 
the effectiveness of the studies' analyses to account for the passage of time, where 18 out of 
19 scored `good'; and the adjustment of the analyses for prognostic factors/confounders, 
where 12 out of 19 scored `good'. Quality criteria for which studies scored poorly were the 
reporting of a power calculation, where 16 out of 19 scored `poor/not reported'; and whether 
or not an appropriate, trained professional carried out the neuropsychological testing, where 9 
out of 19 scored `poor/ not reported'. 
Overall, one of the most important limitations in the studies included in this review was 
high loss to follow up, varying from 16.9% at best and 93.3% at worst, with obvious potential 
for non-response bias. Since cognitive impairment has been shown to be associated with 
increased mortality 174,175 individuals who are declining are more likely to be lost to follow- 
up176, such that high attrition rates in longitudinal studies may lead to considerable under- 
estimate of the true rate of cognitive decline in the very old. 174,175,198 Although difficult in 
this age group, such bias could be minimised by future studies through maximising the 
completeness of follow-up. Interestingly, for studies included in this review, the proportion of 
participants lost to follow-up does not correlate with the annual rate of cognitive decline when 
studies using MMSE are compared. In the same way, loss to follow-up does not strongly 
correlate with annual rate of decline in studies using CAMCOG. Adjustments for the effect of 
attrition need to be made in studies of elderly cohorts, before true decline can be estimated. 
One way in which this has been done is by assuming a linear decline in scores over time, then 
extrapolating the rate of decline at interim assessments for participants who have been lost to 
later follow-ups198. In this way missing data can be incorporated into the main analysis or 
sensitivity analyses. 
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In addition, the type of neuropsychological test used in some cases was likely to be insensitive 
to minor changes in cognition, and in others was not widely used within the field, with 
minimal literature to support validity. 
Issues arising from the formal systematic review, including critical appraisal 
The initial aim of the review was to focus only on studies which included a representative sample 
of the community, incorporating those who suffer from dementia. It became clear that some studies 
excluded those with dementia at baseline, but met every other criterion for inclusion in the review, 
and were therefore included. By including both types of study in the review and appraising them 
separately, more useful information has been gathered. 
Literature is scanty on what constitutes a clinically significant decline for most of the 
neuropsychological tests used. The studies included in this review commented only vaguely on the 
significance of their findings in relation to the general population, making interpretation of results 
very difficult. Better understanding of clinically significant cognitive decline is crucial to the 
design, conduct and interpretation of the results of research studies and the implementation of their 
findings into clinical practice. 
A number of potential biases within the review methodology were possible. 35,199-203 The decision 
taken to only include articles written in English, and `file-drawer phenomenon', 199 where 
researchers are less likely to submit non-significant research for publication, may have contributed 
towards publication bias in this review. An attempt was made to reduce such bias by including 
grey literature searches. The possibility of inclusion and information bias was tackled by setting 
specific, explicit criteria for inclusion at the onset; contact with lead researchers in the field; and the 
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use of second observers, checklists and protocols to ensure implementation of specific and explicit 
criteria was intended to reduce selector, observer and interpretation biases. However, I was the 
only observer who extracted data from included studies and formulated conclusions, thus there is 
potential for interpretation bias. Quality scoring bias may occur if methods and criteria for 
assessing quality are not established from the outset, such that the study quality appraisal may be 
influenced by the studies retrieved. This review tackled such bias by establishing an appraisal 
checklist prior to study selection. 
I chose to present cognitive decline and duration of follow-up as mean values for most studies, 
since these were the only available results. However, median values may have been more 
appropriate since some of the data may be skewed (i. e. non-normal). The effect of generation 
demonstrated by one of the studies 204 suggests that cognitive performance depends not only on 
ageing and but also birth-cohort generation-specific factors. This suggests that test reference values 
may soon become outdated and should be regularly reassessed. In addition, test norms should be 
used with caution if examiner factors are likely to influence test results. 
It was apparent from the included studies that there was almost universal cognitive decline in the 
elderly, though this was small in those with good functioning at baseline. This suggests that 
cognitive decline is an important condition and it is crucial to explore potential aetiological factors 
such as atrial fibrillation. 
The lack of a "gold standard" battery of neuropsychological tests made choosing a battery for 
CAFE difficult. Ideally a consensus should be reached among researchers in this field, aided by a 
systematic review of neuropsychological tests with reference to validity, reliability, clinical 
significance of change and relevance to appropriate cognitive domains, for which further primary 
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research may also be required. This could be made possible by the influence of grant-giving bodies, 
who may encourage collaborative research and recognise specific neuropsychological test batteries 
with demonstrated validity and reliability. In addition, international professional groups such as the 
International Psychogeriatric Association could encourage establishment of a consensus on 
appropriate design and conduct of studies in the field and standardisation of neuropsychological 
tests. 
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Chapter 3 Summary 
"A comprehensive review of the literature on the epidemiology of cognitive decline 
consisted of a formal systematic review of cognitive decline in the general elderly 
population. In addition specific searches for literature covering issues of relevance to the 
work reported in this thesis were undertaken where appropriate. 
"A number of issues in cognitive function research methodology were identified, including 
the challenge of high attrition rates in elderly populations, the need for longitudinal studies 
when looking at change over time and the effect of cognitive function on mortality leading 
to survivor bias. 
" Pathological classifications of cognitive decline include vascular dementia, Alzheimer's 
disease and mixed dementia. Prevalence and incidence of dementia varies according to 
sub-type and geography. 
" Key findings from the systematic review were that cognitive decline is almost universal, 
that quality of studies in this area varies widely, that studies in this area are vulnerable to 
bias, particularly selection and survivor bias, and that there is a need for a gold-standard 
battery of neuropsychological tests in order to make studies of cognitive decline 
comparable. 
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Chapter 4- Neuropsychological tests used in the CAFE study 
" Selection of the CAFE neuropsychological test battery 
9 Literature search on CAFE neuropsychological tests 
o Purpose of search 
o Search strategies 
o Literature search findings 
- Key characteristics of CAFE neuropsychological tests 
- Sensitivity literature 
- Clinical significance and normative data 
- Correlation with NART scores 
" Chapter 4 summary 
4.1 
Selection of the CAFE neuropsychological test battery 
Measurement of cognitive function can be approached in many different ways. This in itself can 
cause problems, since different studies therefore use varying approaches, reducing homogeneity 
and thus making it more difficult to compare results. 169 
CAFE used the same neuropsychological test battery as the pilot study described earlier 15. This 
battery had been validated, and contained nine components which measured general cognitive 
function, pre-morbid intelligence, verbal long term memory, short term memory, information 
processing and attention, selective attention, divided attention and non-verbal memory. This battery 
was selected because it was pen and paper based and therefore portable. In addition, the battery 
could be administered in one hour, was appropriate for an elderly cohort, and it was relatively easy 
to train the research doctor and nurse to administer the battery. 
The CAFE neuropsychological test battery contained widely used components including: the Rey 
Complex Figure, 205 primarily a measure of non-verbal memory and visuo-spatial ability; the Mini 
Mental State Examination (MMSE), 182-206-208 a measure of general cognitive function; the Logical 
Memory and Digit Span Subtests of the Wechsler Memory Scale (WMS) 209-211 which measure 
short and long-term verbal memory and attention; Map Search and Telephone Task subtests of 
Tests of Everyday Attention, 212,213 which measure selective and sustained / divided attention; and 
the Paced Auditory Serial Addition Test (PASAT), 291,311 principally a measure of information 
processing and attention. 
In addition, the National Adult Reading Test (HART), 214,215 a measure of premorbid intelligence, 
made it possible to determine whether or not performance on other tests was influenced by 
intelligence level. 
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The battery was developed to assess cognitive impairment due to cerebrovascular disease, by 
Professor Ian Robertson at the Medical Research Council Cognition and Brain Sciences Unit in 
Cambridge. 
Literature Search on CAFE neuropsychological tests 
Purpose of search 
This search was undertaken to fully inform the design, conduct, analysis and interpretation of 
findings of the study, since the neuropsychological tests used formed the basis of the primary 
outcome measure of the study. 
Search strategies 
An extensive literature search was undertaken to identify papers examining the subtests of this 
battery in terms of. i) clinical significance; ii) sensitivity in measuring change over time; ii) 
construct validity. Medline was searched between 1966 and (most recently) March 2004. 
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Literature search findings 
1. Key characteristics of the neuropsychological tests within the CAFE battery 
Findings from the literature search on key characteristics of the different components of the battery 
are reported here, focusing on clinical significance, reliability in measuring important differences 
and reliability and validity in measuring change over time. In addition, a table to help with 
orientation of direction of test scores, a table summarising cognitive domains of the tests, and 
documents used to carry out Rey Complex Figure, Map Search, Telephone Task and NART are 
provided in Appendices 3 and 4. 
a) Mini mental state examination (NIlVISE) 
i) Literature on clinical significance or clinical importance. 
With retest intervals of 1-2 years, normal people show about 2 points of change and retest 
correlations are lower (<0.80) than for shorter intervals 216 217 Therefore caution is needed in 
interpreting small changes in scores. Those with dementia show an annual decline of 2-3 points 216 
Modest correlations have been demonstrated between MMSE and functional capacity, such that a 
score of 26 or below may signify functional impairment (e. g. cooking etc). 216 Although 
intellectual impairment is considered if the score is 23 or less, only one third of those with this 
score were diagnosed with dementia in one community study. 218 
Change in MMSE over time has been shown correlate with decline in other cognitive function tests 
when measured in the general elderly population, with increasing decline in the oldest old 
(>80yrs) 208 
4.4 
ii) Literature on reliability, validity and sensitivity in measuring important differences and 
change over time 
MMSE has been shown to be sensitive to dementia and good at predicting AD and more severe 
cognitive decline, although is less sensitive to very mild cognitive decline. 216 In addition, there is 
evidence that MMSE is a poor predictor of conversion to dementia219. 
The test-retest reliability and interrater reliability have been shown to be inadequate in detecting 
small changes in cognitive function (such as response to new drug therapies), with a true change 
only detected reliably if it was of at least three points220. Other work demonstrates high interrater 
reliability for the Modified-MMSE, with high test-retest reliability over 3 years221, and there are 
further reports of high interrater reliability (above 0.65). 206,216 Internal consistency estimates are 
reported between 0.31 (community samples) and 0.96 (secondary care samples)? 06,216 
This test is very widely used, and is proven to be valid and reliable to assess cognitive function on a 
cross-sectional basis2O6'207, except for those with very severe dementia where discrimination is lost. 
However, although valid as a measure of general cognitive function, it does not show validity for 
accurately measuring specific cognitive domains without further neuropsychological tests 
(attention, copy and memory are sometimes suggested)222. Reliability appears to depend on length 
of observation period, with demonstrated reliability coefficients for change in MMSE at six months 
of 0.16 and at 2 years of 0.75. MMSE reliability is suggested as reasonable if the period of 
observation is greater than one year182. 
In addition, MMSE has been shown to be reasonably reliable when studied in those with 
progressing dementia 182, providing that the length of time between observations is one year or 
more. 
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iii) Other issues 
" MMSE components include orientation, registration, attention and calculation, immediate 
memory, short-term verbal memory recall and `subtracting serial sevens', a test of mental 
tracking. However, it is inappropriate to use MMSE to measure a specific domain since it is not 
adequately sensitive 223. 
" MMSE is not educationally biased (i. e. the score is not greatly influenced by level of education 
of the participant) regarding reliability and construct validity224, but is educationally biased as a 
screening test predicting dementia (eliminated by having a2 point higher scoring cut-off for 
those with more education i. e. above primary school). 
" MMSE has been shown to be related to premorbid intelligence (correlation coefficient with 
NART is 0.56 and education, and also decreases with advancing age, although race, ethnicity, 
social class, gender and depression are thought to have little effect. 216 
" Disadvantages of MMSE include ceiling effects, with the maximum score of 30 being easily 
achievable in those without cognitive impairment. 
" MMSE is often part of a test battery (e. g. CAMCOG and CERAD- Consortium to establish a 
registry for AD). 225,226 
b) National adult reading test (NART) 
i) Literature on clinical significance or clinical importance. 
Although a stated measure of premorbid intelligence, thus being deliberately insensitive to early 
dementia (Spreen), NART has been shown to deteriorate in moderate/ severe dementia, with 
degree of underestimation increasing with severity of dementia, and can underestimate IQ in those 
with mild dementia with linguistic problems. 216,225,227 In addition, some report that NART scores 
decline even in the early stages of dementia. 228,229 NART has not been standardised on an elderly 
population, and is a poor discriminator for those with very high or very low intelligence. 218 
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However, when those with and without cortical atrophy were tested, NART score was not 
significantly different between the two groups, 218,230 and other studies of dementia found that 
NART score stayed the same throughout the observation period 218,23L232 With only a few studies 
showing deterioration in NART218'233 and one study showing stability of score in those with mild 
dementia and deterioration in those with moderate/severe dementia. 234 
Overall, it appears that NART is correlated with disease severity, 228,235 declining with disease 
progression. 228,236 
ii) Literature on reliability, validity and sensitivity in measuring important differences and 
change over time 
NART has been shown to be very reliable 218,237 with demonstration of high interrater reliability 
232 and high test-retest reliability. 218,237 
NART has been shown to be strongly associated with current cognitive status (using MMSE and 
CAMCOG), supporting its acceptability as a measure of premorbid intelligence238. Further work 
demonstrates its' reliability in predicting premorbid intelligence239. NART has been shown to be 
reliable over time, with high test-retest reliability over 7 years240. Other work demonstrates 
reliability of change in NART over time for those with no dementia /minimal/mild dementia215, 
although less reliability and need for correction using MMSE score for moderate or severe 
dementia 214,215,241. 
Further studies describe no variation of change in scores with age 208, supporting the usefulness of 
NART as a measure of pre-morbid functioning. 238 
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This test has been very widely used and there is considerable evidence for its reliability on a cross- 
sectional basis. Practice effects are reported to be statistically significant but very small216,218 
NART correlates with education (r=0.51) and social class (r=0.36), 225 with no gender differences. 
225 Moderate to good correlations have been demonstrated between NART IQ and measures of 
general intellectual ability (0.4 to 0.8) 216 242 and education. 216 NART has demonstrated validity as 
a measure of intelligence, 218 with evidence for good construct validity, 237 and has been shown to 
be a predictor of some components of WAIS-R. 
iii) Other issues 
" Since measurement of change is a fundamental component of the CAFE battery, it is also 
useful to take one measurement which is relatively insensitive to change. For this study, the 
NART was selected because it is the most commonly used estimate of premorbid intelligence. 
Correlation of performance on the NART with performance on the other subtests made it 
possible to determine whether intelligence was confounding the results. The New Adult 
Reading Test (NART) is the version used for CAFE. 216 
" NART is based on the observation that the ability to read irregularly spelled words remains 
intact in mild dementia. 
". NART has been standardised against WAIS-R. PASAT score can be predicted from NART 
and age (PASAT = 215.74 - (1.85xNART) - (0.77xage), 216,218 and NART has also been 
shown to correlate with WAIS-R (0.72)216,225,243 Others report that although NART can be 
useful in estimating verbal premorbid intelligence and learning, it does not improve estimation 
of other neuropsychological domains. 
" The Cambridge Contextual Reading Test (CCRT) sets the NART in semantic and syntactic 
context and is demonstrated to show higher prediction of premorbid intelligence than NART in 
those with mild/ moderate dementia245 
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" Some use demographic information (education, sex) in conjunction with NART errors to arrive 
at IQ. 216,218,239 
" NART has been used in many other test batteries. 225 
c) Wechsler Logical Memory test sub-test of Wechlser Memory Scale - Revised (WMS-R) 
i) Literature on clinical significance or clinical importance 
The literature search found no reports on clinical significance of performance on the Logical 
Memory test, except for one report that an average gain in score of 1 point after one year in a 
young group, 225,246 and 0.7 points in one year in an older group (mean 69 years) may be expected 
due to practice effects. 225,247 
This test measures memory functions which are equally represented in both hemispheres, therefore 
damage to one side of the brain only (e. g. unilateral silent infarcts) may have no effect on the 
performance of this subtest 225 
The Logical Memory subtest has been shown to distinguish those with dementia from those 
without 248 and discriminate between those with dementia and those with an evolving dementia; 
but not to predict which elderly subjects with early memory complaints would develop 
dementia. 249 In addition, the test has been shown to be sensitive to detecting dementia of 
Alzheimer's type 216,250 
ii) Literature on reliability, validity and sensitivity in measuring important differences and 
change over time 
The Wechsler Memory Scale (WMS) has been widely used since 1945 209, and therefore there is 
much published literature reporting high test and re-test reliability 210 and construct validity 211. 
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The WMS has been shown to decline over time, with largest decline in those with shortest survival 
time at age 70 or over. 251 Another prospective study described no significant change in the score 
in a sub-group of the general elderly population who did not go on to develop dementia. However, 
it also demonstrated that the logical memory subtest declined prior to the onset of detectable 
clinical changes in the whole sample. 252. Further prospective work suggests that the Logical 
Memory and Digit Span tests are highly sensitive to early cognitive decline, and can differentiate 
between normal elderly subjects and those who later go on to develop dementia 253. 
There are some reports of practice effects in repeated administrations with the Logical Memory 
test254, and there is potential for bias due to priming patients toward correct or incorrect 
responses. 255 However, high interrater reliability has been demonstrated specifically for the 
verbatim scoring approach that was adopted for the CAFE study 256 Reported reliability 
coefficients range from 0.71 to 0.87216,257, which are reasonable and more reliable than many other 
subtests of the WMS-Revised (WMS-R). One-year test-retest reliability has been demonstrated 
with reliability coefficients of 0.54 and 0.47 225,258. In addition, the WMS-R has been extensively 
validated against the California Verbal Learning Test, showing high correlations259 216. There are 
some reports of practice effects in repeated administrations of the Logical Memory Subtest. 254, but 
test order does not affect the validity of the Logical Memory test 260 
Immediate recall of the Logical Memory subtest is reported to remain stable through middle age 
and then progressively declines. Reports on delayed recall vary, but show decline from age as early 
as 20 years, with levelling off in the sixth decade, then further decline. However, because age and 
education are highly correlated in the normative population, it can be difficult to interpret older 
people's scores as due to age alone. Gender does not appear to be related to score, although 
education may be. 225 
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iii) Other issues 
" The WMS, of which the Logical Memory test is part, is among the most commonly employed 
intelligence tests in adults261 WMS has been revised in 1987 and 1997/8, the most recent 
version being called WMS III 218,262,263 
" The Logical Memory subtest measures recognition, recall and learning (with long delayed 
recall), immediate memory and recent episodic memory, 218 and has frequently been used to 
assess memory in stroke. 
9 CAFE adopted the `items correctly repeated' or `verbatim' scoring system and used the WMS- 
R Logical Memory test (LM-R) which has delayed recall at 30mins and has been shown to 
have consistent interrater reliability. 225,264 
" Limitations of this subtest included lack of adequate scoring criteria and lack of adequate 
normative information. 261 For example, the time delay for recall varies from 20 minutes to one 
hour, which is likely to affect the score; however, the revised LMS had improved criteria with 
a set 30 minute delay. 225 
" Logical memory performance has been shown to be independent of IQ, 216,265 race and gender, 
216 although high correlations have been demonstrated between LMS and other tests of 
learning (and verbal tests, reflecting the need for verbal organisation and syntax in repeating 
the tests). 
d) Digit Span subtest of Wechiser Adult Memory Scale - Revised (WMS-R) 
i) Literature on clinical significance or clinical importance 
As for the Logical Memory test, the literature search found few reports on clinical significance of 
performance on the Digit Span test. Again, as for Logical Memory, the digits forwards component 
of the Digit Span subtest measures memory functions which are equally represented in both 
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hemispheres, therefore damage to one side of the brain only would have no effect on the 
performance of this subtest 266 
Twin studies have demonstrated that the demented twin had shown greater decline on digit forward 
than the non-demented twin 20 years earlier. 267 225 
This test has been shown to be particularly sensitive to problems with interaction between 
executive and attentional components, e. g. in HN, 228 whilst in healthy people, scores on digit span 
remain good into the 80s, although deterioration in score in this group predicted death within 
several years. 225,268 
ii) Literature on reliability validity and sensitivity in measuring important differences and 
change over time 
A negative relationship has been demonstrated between initial level of cognitive functioning and 
rate of change in digit span score. 269 Digit Span has a reported reli abili ty coefficient of 0.88, "216,270 
which is considerably higher than many other Subtests of the WMS-R. 
There are some reports of practice effects in repeated administrations with digit-span 271, although 
other work reports that these effects, though statistically significant, are negligible. 225 Test order 
does not affect the validity of Digit Span 260 
Digits forwards is one of the least sensitive tests to detection of dementia, although scores become 
noticeably reduced after the early mild stages. 225,272,273 However, prospective work suggests that 
the Digit Span test (forwards and backwards) is among the neuropsychological measures most 
sensitive to early changes in cognitive functioning, and is thus best able to delineate normal elderly 
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subjects from those who later are diagnosed as having probable dementia. Digit Span is also said to 
be relatively resistant to the effects of normal ageing in contrast to dementia 253, and another 
prospective study described no significant change in the Digit Span score in a sub-group of the 
general elderly population who did not go on to develop dementia 252. 
Digit Span is part of both the Wechsler Adult Intelligence Scale and the WMS. Both of these scales 
have been widely used since 1945 209, and therefore there is much published literature reporting 
high test and re-test reliability 210 and construct validity 211. 
iii) Other issues 
" Digit Span is the most common method for measuring span of immediate verbal recall and has 
a speed component. 225 Digit Span is part of both the WMS263 and the Wechsler Adult 
Intelligence Scale (WAIS), which has been very widely used since 1945 209. 
" Digits backwards relies on working memory in addition, and is more of a memory test 
(involving `double tracking' since both memory and reversing operations must process 
simultaneously) than digits forwards. Digit span scores are reduced if there are problems of 
immediate memory, concentration or attention. 225 
" Because digits forwards measures immediate memory, even patients in advanced stages of 
dementia could still score highly. Tests which are more unfamiliar, abstract, speed-dependent 
and need capacity for attention and learning are more likely to be lower in those with 
progressing dementia (i. e. digits backward, etc). 
" Digit span performance correlates highly with intelligence level 216,265. 
" The forwards and backwards score is usually combined, with the assumption that the two tests 
behave similarly. This appears to be the case for those up to around 80 years of age, although 
some work suggests that as age increases, forward span remains stable but backwards 
deteriorates. 225,274 
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" As recommended in textbooks of neuropsychological assessment, CAFE uses the raw score for 
digit span, rather than any of the scoring transformations available. 225 
" Education is reported to have an effect on Digit Span score. 225 Age is not reported to have an 
effect on score below 65/ 70 years. 225,275,276 Anxiety may reduce score 225,277 
e) Rey Complex Figure - copy and delayed recall (also known as the Rey-Osterrieth 
Complex figure Test) 
i) Literature on clinical significance or clinical importance 
The Rey Figure can distinguish those with probable Alzheimer's disease from normal. 216,278 
There is evidence to suggest that depression is found to be associated with subtle difficulties in 
delayed recall. 216,279 
ii) Literature on reliability, validity and sensitivity in measuring important differences and 
change over time 
The literature search revealed few studies of the reliability of change over time of this test. 
" Rey copy may not be sensitive to early dementia changes since in dementia, impairments in 
constructional tests which assess access to semantic and lexical knowledge (e. g. drawing 
something meaningful) are present early in the disease, whereas impairments in constructional 
tests that do not need this (e. g. copying Rey figure) are not apparent until later in the 
dementia. 28 Delayed recall may be more sensitive to memory deficits than immediate recall. 
For CAFE, as for many other studies, immediate recall was not used, only copy and delayed 
recall, since there is little difference between copy and immediate recall in normal patients. 
216,280,281 
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High interrater reliability (>0.90) has been demonstrated for total score (for copy and recall) using 
the standard scoring system, despite its' subjectivity282, although more variable interrater reliability 
has been reported for individual scores on the 18 items. 216,278 There are also reports of a high 
number of simple scoring errors when using this test, with errors on up to 25% of figures scored283. 
Practice effects of 10% improvement have been demonstrated when retested after one month for 
the same figure, and a study of elderly patients found the copy was not reliable with retesting at one 
year, although the delayed recall was moderately reliable at this time interval. 216,278 In addition, a 
ceiling effect may occur, particularly with copy 216,284 
Age may affect performance, especially > 70 years, 216,285 perhaps due to age-related deterioration 
in organisational capacity - the way the person divides the figure into smaller parts, 216,286 and there 
is consistent evidence of an effect of age on recall, although others find no correlation between 
score and age for copy. 225 
Only moderate correlation between Rey score and intelligence is reported. 216,280,285 There are 
conflicting reports on the effect of education on both copy and recall, where some demonstrate 
poor performance in those with low education, whereas others describe no association. In addition, 
gender and handedness do not appear to have an effect on Rey score. Rey score is considered 
sensitive to brain lesions. 216 
iii) Other issues 
9 The Rey Figure measures planning, organisational skills, problem-solving as well as perceptual, 
motor and memory factors 216,2M Rey copy measures visual-constructional ability, delayed 
recall measures amount retained over time. More precise cognitive functions needed are visual 
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perception, visuospatial organisation, motor functioning (and memory for recall)216,286 In 
addition, Rey score requires use of strategy, for example the best strategy is to deal with the 
overall figure then the details. 225 It is suggested that this Rey score also measures executive 
functions (planning/ problem solving), 216,287 and it has been described as a test of incidental 
learning, 216a test of visuographic memory and visuographic copying. 225 
" The length of delay between copy and delayed recall varies widely between studies from 3 
minutes to 45 minutes, although length of delay does not affect performance if under one hour. 
216,278 In the CAFE study, as for others, 207,216 participants were told they would need to recall 
the figure. 
" Analysis of the Rey figure can be in much more detail, for example several methods for 
observing the patients strategy in copying the figure are reported, although this level of detail in 
analysis was not performed for CAFE, nor was time taken to copy recorded. 225 
" This test has been reasonably widely used, and the literature reports that although there are 
often scoring errors with this method 283, scoring can be reliable between scorers282. For 
repeated administrations, some use the Taylor figure (a similar complex figure) for retesting 
216,225 in order to reduce possible practice effects (not used for the CAFE study). 
f) Paced auditory serial addition test (PASAT) 
i) Literature on clinical significance or clinical importance. 
The literature search yielded no reports on the clinical significance or importance of scores on the 
PASAT 
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ii) Literature on reliability, validity and sensitivity in measuring important differences and 
change over time 
There is a good evidence for reliability of the PASAT when used in cross-sectional studies, 291,311 
although no literature on reliability of change over time. Excellent objectivity through good inter- 
observer reliability has been demonstrated (r=0.99) for the PASAT288, but practice effects have 
been reported . 
216,225,289 
There is some evidence for construct validity, with moderate correlations to other measures of 
attention e. g. digit span, 216 and validity has also been well demonstrated through factor analytic 
loadings on the attention/ concentration factor. 228 
Reports are conflicting on whether or not there is a correlation with general intelligence 216,290,291 
288. Some report that there is a correlation with education, 216,292,293 whilst others find no effect of 
education 216,294 288 nor gender, although there is an association with age 216,225,294 291. However, 
the PASAT is very sensitive to problems with information processing ability. 225,290 
iii) Other issues 
" The PASAT measures information processing capacity similar to that seen on reaction-time 
and divided attention tasks228 but also requires good mental arithmetic, verbal ability and 
complex motor skills. Problems are that it relies on fast speech responses and is not suitable for 
the very anxious. 216 
" PASAT score has been shown to correlate with NART and WAIS. 216 
" This test is sometimes used to detect malingering, by looking at the pattern of responses. 225 
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g) Map search subtest of the Tests of Everyday Attention 
i) Literature on clinical significance or clinical importance. 
Poor performance indicates a difficulty in ignoring irrelevant information and picking out the 
targets in complex visual arrays. This may cause problems in reading forms, bus timetables, TV 
listings and finding items on supermarket shelves etc. 295 `Poor performance' is determined using 
comparison with normative values. 
As with all of the Tests of Everyday Attention (TEA), Map search has reported ecological validity, 
i. e. is predictive of everyday functioning. 26,228 
ii) Literature on reliability, validity and sensitivity in measuring important differences and 
change over time 
The literature search yielded no reports of reliability of change over time reliability for Map search. 
The tests of the TEA have high reported reliability and ability to discriminate between minimal 
cognitive decline and mild Alzheimer's disease. Map search test has been shown to have 
ecological validity and satisfactory reliability, 228 although validity may possibly be affected by 
visual problems212. This test has high test-retest reliability (Pearson's correlation coefficients of 
0.83,0.86,0.87,0.80), demonstrated for normative populations212,295. 
Score on Map search correlates with other measures of attention, e. g. PASAT, Trails B, and there 
is no reported correlation with NART IQ. 216 
iii) Other issues 
" This test is part of the battery known as `Tests of Everyday Attention'212,295 
" There is a sparsity of other studies/ investigators using the tests of the TEA212,213 
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h) Telephone search task and i) Telephone search dual task of the Tests of Everyday 
Attention 
i) Literature on clinical significance or clinical importance. 
Poor performance on this test indicates difficulty in doing more than one thing at a time, and may 
lead to problems in, for example, writing a phone message whilst talking to the person leaving the 
message etc. 295As with all of the Tests of Everyday Attention (T'EA), Telephone search task has 
reported ecological validity, i. e. is predictive of everyday functioning. 216,228 
ii) Literature on reliability, validity and sensitivity in measuring important differences and 
change over time 
The literature search yielded no reports of reliability of change over time reliability for the 
Telephone tasks. The Telephone search task is shown to have ecological validity and satisfactory 
reliability, but although reliability of telephone search while counting (dual task decrement) was 
satisfactory for two groups of non-brain-damaged subjects (0.51 and 0.61) it was lower in a group 
of participants with stroke (0.40) 228The tests of the TEA have high reported reliability and ability 
to discriminate between minimal cognitive decline and mild Alzheimer's disease, and the 
Telephone task has demonstrated high test-retest reliability (Pearson's correlation coefficient of 
0.61) for normative populations, but is less reliable than other Tests of Everyday Attention with 
suggested explanations of large and variable learning effects with this test 22,295. 
The validity of Telephone tasks may possibly be affected by peripheral auditory deficits212,295. 
However, the Telephone task had been validated using the most inexpensive tape recorder on the 
market, providing reassurance that high quality equipment was not required, and test validation by 
the authors had included mild hearing impairment, which did not have an effect on the results. 
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There is a sparsity of other studies/ investigators using these tests, 212,213 and no studies of 
reliability of change over time. 
iii) Other issues 
" This test is part of the battery known as `Tests of Everyday Attention' 212,295 
" There is a sparsity of other studies/ investigators using the tests of the TEA 212,213. 
Sensitivity Literature 
To improve the accuracy of detecting dementia, it is recommended that test results need to be used 
in combination with analysis of potential confounders, particularly age, sex and education, since 
insensitivity of neuropsychological tests may produce misleading results. Despite this, tests of 
episodic memory have been shown to be particularly sensitive in detecting individuals in a 
preclinical phase of dementia 296. 
Most of the literature on test reliability and validity is for assessing/ research in patients with 
dementia, rather than those with possible mild cognitive decline. 
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Clinical significance and normative data 
When the literature was searched for information on the clinical significance of changes in test 
scores, it was not possible to find specific criteria on whether or not a score of X or a change of Y 
over time constitutes a clinically significant score/ change. The literature does suggest, however, 
that if neuropsychological test scores are compared to age-adjusted norms, a score more than 1 or 
1.5 standard deviations (different authors have alternative views on which value is most 
appropriate) or more below expected level of functioning (using age adjusted means) can be 
considered as clinically significant cognitive decline such that it meets the neuropsychological 
assessment component of the criteria for cognitive impairment/ age-associated memory 
impairment. 219 
Unfortunately, most neuropsychological tests have not been formally standardised, therefore the 
normative population is usually small numbers of healthy volunteers/ controls. In addition, there 
are sometimes several sources of normative population data, which may differ, leading to very 
different results depending on which normative population is selected. Norms for people with 
limited education do not exist, and norms for very old patients are limited. Therefore it is 
recommended that raw scores are presented with or without percentile rankings based on norms 261. 
It is worth bearing in mind, however, that although neuropsychological tests may not give precise 
cut-offs for diagnosis of dementia or cognitive impairment, they do provide a reliable baseline for 
subsequent detection of change. 261 
Comparisons between normative data and the CAFE results are described in chapter 6 
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Chapter 4 Summary 
" The CAFE study neuropsychological test battery was selected because it had developed for the 
purpose of examining cognitive impairment due to cerebrovascular disease, had been used in 
the CAFE pilot study, had been validated, was portable and measured a range of cognitive 
domains (general cognitive function, pre-morbid intelligence, verbal long term memory, short 
term memory, information processing and attention, selective attention, divided attention and 
non-verbal memory). 
" The tests in the CAFE battery were the Rey Complex Figure, the Mini Mental State 
Examination, the Logical Memory and Digit Span subtests of the Wechsler Memory Scale 
(WMS) , the Map Search and Telephone Task subtests of Tests of Everyday Attention, and the 
Paced Auditory Serial Addition Test. In addition the National Adult Reading Test (NART) was 
used to measure premorbid intelligence. 
"A literature search was undertaken to examine the clinical significance, reliability, 
sensitivity and validity of performance on the Subtests of the CAFE battery. Overall, there 
was reasonable evidence of reliability and validity of the subtests for use on a cross- 
sectional basis. However, the literature search revealed very few reports on reliability, 
sensitivity or validity of the subtests in measuring change over time. In addition, the 
literature on clinical significance or clinical importance of performance on the subtests 
was extremely limited. 
" Reports on the sensitivity of the tests in detecting dementia were far more plentiful than 
reports specifically addressing mild cognitive impairment or decline. 
" In summary, the CAFE neuropsychological test battery provides an acceptable method of 
measuring cognitive function in the cohort. Although evidence for reliability and validity of 
these tests in measuring change over time is limited, this appears to be the case for the majority 
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of neuropsychological tests. Therefore choice of the tests was made on other grounds, namely 
the range of cognitive domains tested, and practical factors such as ease of administration, 
portability and time constraints. 
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Chapter 5- Methods 
" Part 1: Identification of Participants 
o Practice involvement 
o Form design 
o Notes screening 
o Letter to participants 
o Inclusion and exclusion criteria 
o Power calculation 
" Part 2: Interview and Examination 
o Overview of baseline and follow-up visits 
o Details of components included in the visits 
o Validity of interview and examination components 
o Ethical approval 
" Chapter Summary 
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Part 1- Identification of participants 
Recruitment 
Practice involvement: Practices were approached by starting with largest practices first. A letter, 
co-signed by members of the project team (Professor Richard Thomson, Dr Janice O'Connell, 
Professor Chris Gray and Dr Helen Park), was sent to the senior partner of each practice and I 
followed this up with a telephone call. At the first visit to the practice, I talked to the senior 
partner of the practice, and negotiated attendance at a practice meeting, in order to explain the 
study more fully to all partners. This was to maximise the involvement of all partners in the study, 
thus maximising the potential number of patients referred to the study. Also during the first visit, 
the GP checklist (Appendix 5) was completed with the practice manager, and the senior partner 
signed a consent form (Appendix 6). Posters with details of the CAFE study were displayed in 
surgery waiting rooms of the practices involved (Appendix 7). 
Form design: A Microsoft Access form was developed within the project team, in order to make 
note searching efficient. This led to the production of exclusion and inclusion proformas, in order 
to collect data on reasons for exclusion at this stage. This would allow identification of possible 
confounding factors and give an estimate of generalisability of the results to the general 
population. 
Notes screening: We chose to identify patients with atrial fibrillation by performing digoxin 
searches on GP's computerised patient records (Figure 5.1). This was appropriate and likely to be 
a representative method of screening since 96% of practices are now computerised. 
Digoxin screening was thought to be an efficient way of detecting those with AF297 since 91% of 
GPs using software use computerised repeat prescribing systems. In addition, screening for those 
51 
with atrial fibrillation as a problem title Read code was performed wherever problem titles were 
used by practitioners, but this was less productive, since the extent to which GPs use the computer 
outwith repeat prescribing is variable. If a practice (n=45) had a computerised disease register for 
atrial fibrillation then this was run in addition to the digoxin search. 
Controls were randomly identified by selecting the adjacent patient on the general practitioner's list 
when ordered by date of birth and sex (no twins were encountered). 
Once notes had been identified in this manner, I hand searched them. At this stage the notes were 
included or excluded using objective criteria (see below). In either case, relevant details were 
recorded on the appropriate Access form on a portable computer. 
Figure 5.1: 
Flowchart for searching GP notes to identify those with atrial fibrillation 
Ctvonic AF diagnosis recorded in notes? If no - EXCLUDED 
If yes 
Do notes state patient is taking medication 
(asprin, warfarin, digo», other) to treat AF? 
If yes If no 
Is patient currently receiving prescriptions for was pulse recorded as irregiiar at last examination? 
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Letter to participants 
Following identification of potential participants through GPs, patients were invited by letter to 
participate in the study (see Appendix 7). The letter had been approved by the ethics committee, 
was signed by the senior partner within the practice, and countersigned by myself. A reply-slip was 
included for patients to return. All individuals expressing interest in participating also received a 
patient information leaflet prior to the baseline visit, with full details on precisely what would be 
involved in the study, again agreed by the ethics committee (Appendix 8). Those participants who 
did not return a reply-slip received one duplicate of the original invitation letter, in case the first 
letter had been mislaid. No further follow-up of those who did not reply took place. 
GP newsletter 
GPs were kept up to date with CAFE progress with regular newsletters (Appendix 7). 
Inclusion and exclusion criteria 
Inclusion and exclusion criteria were applied to cases and controls at both the note searching and 
interview/examination stages (see table 5.1). Precise definitions are listed in Appendix 9. A 
checklist for exclusion was designed and used to search the GP notes (Appendix 10). 
Inclusion criteria: - 
2 Any participant who fulfils the case definition and does not meet any exclusion criteria. 
  The case definition is `men and women aged 60 or over with non-valvular atrial fibrillation 
(NVAF)'. 
Reasons for the exclusion criteria are: - 
" Established dementia: Several reasons for exclusion of this group include: 
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1) further cognitive decline would be difficult to assess since the progression of dementia is 
not constant; 
2) completion of the neuropsychological test battery would be extremely difficult with such 
patients since it requires understanding of the test explanations; 
3) these patients may also have other risk factors for dementia, although such potential 
confounders could be addressed in the analysis; 
4) exploration and establishment of cause of dementia would be very difficult in this group 
since the advantages of a longitudinal study would be of no use in establishing cause of 
existing dementia at baseline; and 
5) CAFE aimed to address whether AF is a risk factor for the subsequent development of 
cognitive decline, rather than addressing whether AF affects further cognitive decline in 
established dementia. 
" Previous stroke/TIA: these patients may have had residual cognitive deficit following their 
cerebrovascular accident (CVA), making subsequent measurement of cognitive decline 
difficult. In addition, the CVA may result in problems with vision, language and motor 
skills that make completion of the neuropsychological test battery difficult. 
" Severe visual or hearing impairment: this would affect ability to comply with the test 
battery. 
" Severe congestive heart failure (NYHA class 3 and 4): this is known to increase risk of 
thromboembolism independently of AF, therefore could bias the results. 
" Those who speak English poorly: this would affect understanding of explanations of the 
test battery, which may lead to underestimate of performance. 
" Those who are very frail: this criterion was included to prevent unnecessary intrusion into 
the lives of those for whom request for help with this research project would be 
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inappropriate and disturbing, for example the terminally ill. GPs were asked to use their 
discretion in helping the CAFE team to decide who fitted into this group. 
Table 5.1: Summary of CAFE exclusion criteria 
Exclusion Criterion How is this ascertained? 
Established dementia From patient record and mini-mental state 
examination (exclude if <24) 
Previous strokelrIA (WHO criteria) From patient record + interview + examination 
History / clinical findings of rheumatic heart 
disease 
From patient record + examination 
Prosthetic valves From patient record 
Severe visual or hearing impairment From patient record + interview 
Cardiac rhythm other than AF or sinus (includes 
permanent cardiac pace-maker, paroxysmal AF) 
From patient record + examination 
Severe congestive heart failure (NYHA class 3 and 
4) 
From patient record + interview 
Those who speak English poorly From interview 
Those who are very frail (see definitions) From patient notes + interview 
Power calculation 
The sample size provides 80% power to detect a 10% difference in scores on a basket of tests 
between subgroups. We chose this sample size because a 10% difference is likely to be of clinical 
importance. Sample size estimation was based on the following calculation, specific to the MMSE: 
a sample size of 176 (n=352) in each group would have 80% power to detect a difference in means 
of 1.5 assuming a standard deviation of 5.0 using a two group t-test with a 0.05 two-sided 
significance level. This sample size would give sufficient power for the detection of clinically 
meaningful differences for other outcome measures. In addition to focusing on a single outcome 
variable, a pooled estimate was based on several of the cognitive function tests using the evidence 
available. This provided a similar sample size to that derived from MMSE. 
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Figure 5.2: Flowchart to show the process leading to the baseline visit 
Search of patients with digoxin 
prescription. (n=2866) 
Notes identified by search for 
patients with diagnostic Read code 
Notes identified by opportunistic 
screening for NVAF. 
Notes identified by search for 
patients on computerised AF 
register 
Search of GP notes and recording 
of information 
Patient included Patient excluded 
Further information from GP notes II Basic information from GP notes 
Permission from GP to approach specific patients 
First contact with patient: letter, follow-up phone call at 2 weeks, appt. made 
Patient consents (n=423) Patient declines to take part 
I Visit 1 (HP or nurse): initial questions on exclusion criteria 
Information from visit 1 does not 
yield reason for exclusion (n=362) 
Visit 1 completed (nurse) = 
interview, bloods, ECG, followed by 
visit la (HP) = examination, follow- 
up of any queries identified by nurse 
Patient excluded due to new 
information from visit 1(n=61) 
Visit 1 completed (HP) = interview, 
bloods, ECG, examination 
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Part 2- Interview and Examination 
Patients who agreed to participant underwent a baseline visit, carried out in the 
participant's home by the team doctor alone, or by the nurse and doctor. All participants 
completed a consent form (Appendix 11). The information collected at baseline included a 
neuropsychological test battery. In addition data on possible confounders was collected in 
order to enable these to be incorporated into the analysis. Figure 5.2 depicts the flowchart 
which was used to plan the baseline visit. 
Overview of baseline and follow-up visits 
Dataforms used for the visits are provided in Appendix 12. 
Baseline visit 
The baseline visit included a validated battery of nine neuropsychological tests, as used in 
the pilot study15; a health questionnaire, including information on co-morbidities and 
contra-indications to anticoagulation; a health status questionnaire (the short-form 36 
298,299; a physical examination; a limb-lead ECG and a battery of blood tests (detailed 
later). 
Follow-up components 
The follow-up visit took place 12 months after the baseline visit. The components of the 
follow-up visit included a repetition of the validated battery of nine neuropsychological 
tests, health questionnaire and health status questionnaire. 
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Details of components included in the visits 
1. Neuropsychological test battery 
The selection and characteristics of the neuropsychological test battery used in CAFE are 
explored in Chapter 4. 
2. Health questionnaire 
Participants were taken through a previously validated health questionnaire to collect data 
on stroke risk factors and contraindications to anticoagulation. 9 This included collection of 
information on comorbidities, allowing these to be incorporated in the analysis as potential 
confounders if necessary. These questions had originally been taken from the Health 
Survey for England30, and had been validated as part of the Survey's methodological sub- 
study30. 
3. Health status/ quality of life measurement 
Measuring quality of life will always be subjective due to the nature of the variable. 
Definitions for health-related quality of life vary from those which include a holistic 
emphasis on the social, emotional and physical well-being of a patient to those which 
focus on the impact of health on the ability to lead a fulfilling life. For the CAFE study, 
health status was measured using the Short Form-36 (SF-36) since this has been widely 
used internationally and the study team were familiar with it 298 300 
4. Physical examination 
A brief respiratory, cardiovascular and neurological examination was performed, primarily 
to identify exclusion criteria which may have been missed at the notes-screening stage, for 
example past stroke or severe heart failure. 
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5. Blood tests 
In order to be able to incorporate potentially confounding variables into the analysis, the 
following blood tests were carried out: haemoglobin, haematocrit, white blood cells, 
platelets, urea, creatinine, sodium, potassium, random cholesterol, HbAIc, thyroid function 
tests, random glucose and digoxin level (for those on digoxin). 
6. ECG 
The decision was made to carry out limb-lead electrocardiograms (ECGs), which record 
leads I, II, II, AVR, AVL and AVE These could be recorded using portable machines, 
allowing the ECG to be undertaken in the patient's own homes. In addition, the use of 
limb-leads alone did not necessitate the undressing of patients and was sufficient for 
confirmation of cardiac rhythm. 
Validity of interview and examination components 
Development of interview and examination datafonns 
Data forms for all components of the baseline interview were piloted and amended 
accordingly. 
Possible sources of bias within interview and examination 
The potential for a learning effect was considered when planning the interview and follow- 
up. Existing work has demonstrated training effects when testing spatial orientation and 
inductive reasoning 301. This is a possible source of bias in this study, since there were 
repeated assessments. However, the duration between visits was 12 months, which makes 
practice effects less likely than for shorter intervals. 
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Training of observers 
Baseline visits were carried out by two observers (one doctor and one nurse), and 
participants who were visited by the nurse were also visited by the doctor in order to 
perform the physical examination. Follow-up visits were carried out by one observer, 
either the doctor or the nurse. Following piloting of the interview data forms, both 
observers carried out several (4) visits together before commencing visits alone. At regular 
intervals throughout the baseline and follow-up visits, the two observers carried out three 
visits together, to identify any emerging areas of subjectivity and to maintain consistency 
in the data obtained during the visits. 
Blinding 
The research nurse was blind to case status whilst undertaking the neuropsychological tests, 
which were carried out in the first part of the visit. As research doctor, I had originally 
searched GP records to identify participants, therefore in theory could have known case 
status, however the large number of records searched (2866) means that this was very 
unlikely. Observers usually realised case status in the later part of the visit, when questions 
about health were asked. 
Validation of cognitive function tests 
Cognitive function tests had already been externally validated, as described earlier. In 
addition, both observers separately carried out the tests twice (on a healthy volunteer and 
hospital inpatient) and compared results in order to identify areas of subjectivity. 
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Validation of blood pressure recording 
Blood pressure taking skills were taught in the hospital prior to starting visits. To monitor 
consistency of blood pressure reading skills and the accuracy of the sphygmomanometer, 
at regular intervals both observers measured the blood pressure of a third party and 
compared the readings. Readings were also compared using different 
sphygmomanometers. During the patient visits, two blood pressure readings were 
recorded and the British Hypertension Society guidelines for blood pressure measurement 
were used. 302 
Validation of ECG reading 
Training in carrying out portable ECG recordings was undertaken. ECG s carried out by 
the team nurse were checked by the team doctor. 
Validation of medication taken 
Medication taken was recorded by the team doctor/ nurse at both visits. Where repeat 
prescriptions were available, these were used. Where actual medication was available, this 
was used. This information was compared against the list of current medication obtained 
when searching GP notes, and any differences were explored further with the patient to 
identify an accurate record of current medication. 
Data cleaning 
Data cleaning took place throughout the baseline and follow-up interviews. The databases 
were designed to minimise entry errors. Examples of data cleaning tasks performed 
routinely are included in Appendix 13. 
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Ethical Approval 
The study was granted ethical approval by NHS LRECs for Sunderland and South 
Tyneside. All data was treated as strictly confidential, registered with data protection, and 
used in accordance with current guidelines. 303 
Missing Data 
Due to the rigorous methodological processes used, there was relatively little missing data 
(searched for as part of data cleaning). Where missing data was discovered, every attempt 
was made to search for the missing items, by going back to interview forms etc. Where the 
data was truly missing, an explanation was usually available (e. g. patient became tired, 
specimen coagulated prior to reaching lab). In these situations data was analysed based on 
available data only. Particular care was taken with the limited missing data for 
neuropsychological test scores. When analysing a basket of neuropsychological test scores, 
all patients who did not have complete data for all test scores were excluded from the 
analysis (these were very small numbers). When analysing tests individually, all patients 
with complete data for that test were included in the analysis. 
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Chapter 5 Summary 
" Participants were recruited via general practices. Electronic and paper GP notes were 
screened using inclusion and exclusion criteria and potential participants were invited 
by letter to take part in the study. 
9 Baseline interview consisted of a validated neuropsychological assessment, health 
questionnaire, assessment of health status, physical examination, limb-lead ECG and 
blood tests. Follow-up examination at 12 months consisted of the same 
neuropsychological assessment, health questionnaire and assessment of health status. 
" Validation of all components of both interviews was undertaken where possible. 
" Ethical approval was obtained for this study from the Sunderland Local Research 
Ethics Committee and the South Tyneside Local Research Ethics Committee. 
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Chapter 6- Results (I): General features of the cohort 
" Characteristics of general practices involved 
" Stages of exclusion, notes screening and attrition 
" Characteristics of responders and non-responders 
" Characteristics of the cohort (participants included after baseline interview) 
9 Normative data for the CAFE neuropsychological test battery 
" Correlation with National Adult Reading Test scores 
" Chapter 6 Summary 
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Characteristics of general practices involved: - 
General practices (n=44) involved in the study were located in Sunderland and South Tyneside in 
the North East of England. Summary characteristics of these practices are shown in Table 6.1. 
Characteristics for individual practices are provided in Appendix 14. 
Table 6.1. Characteristics of CAFE general practices 
GP Characteristic Descriptive statistics 
List size Mean = 6604 patients " 
Range = 1700 to 14500 patients 
Number of partners Mean = 2.8 whole-time equivalent 
Range =1 to 7 whole-time equivalent 
Number of practice nurses Mean = 1.4 full-time equivalent 
Range = 0.5 to 2.5 full-time equivalent 
Anticoagulant service provider (some or Secondary care only = 42% 
all of services) Primary care only = 8% 
Pharmacist-led* = 26% 
Shared care' = 3% 
Variety of caret = 21% 
Level of computerisation of practices None' = 3% 
Partialb = 67% 
Almost fully' = 26% 
Fully d=5% 
*Pharmacist-led clinics, with input from primary or secondary care 
'Shared care = organised care shared between primary and secondary care 
Some patients received primary care, some secondary care 
'Administration use only 
bMedication and disease registers 
`Medication, disease registers and some consultation notes 
dPaperless 
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Stages of exclusion, notes screening and attrition: 
The stages of recruitment of participants are shown in Figure 5.1. Screening of 2866 sets of GP 
notes led to 938 (33%) eligible potential participants being invited to interview. Of these, 423 
(45%) agreed and were visited at home. Sixty-one (14%) participants were excluded at the baseline 
interview (47 cases and 14 controls, primarily because exclusion criteria were uncovered during 
the interview), leaving 362 included participants (175 cases and 187 controls). Reasons for 
exclusion are outlined in table 6.2(a) (b) (c) and (d). 
The attrition rate between the baseline and 12-month follow-up visits was 13.8% for controls and 
18.4% for cases. 
Table 6.2 (a): Reasons for exclusion - those excluded at notes-screening stage 
Reason for exclusion Number 
Aged under 60 years 37 
Not currently in chronic atrial fibrillation 370 
History of stroke 336 
History of transient ischaemic attack 438 
Severe heart failure (NYHA class 3 or 4) 12 
Severe visual impairment 61 
Severe hearing impairment 5 
Established dementia 131 
Prosthetic valve 80 
Pacemaker 33 
Rheumatic heart disease 87 
Other* 81 
Reason not available** 42 
Total 1713 
* other reasons for exclusion included patient terminally ill / too frail /not suitable to participate as 
advised by the GP 
** not available due to failure to collect this information/ failure to record on the'database 
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Table 6.2 (b): Reasons for exclusion - those selected at notes-screening but not invited for 
interview 
Reason for exclusion Number 
Died prior to invitation to participate 26 
Not required (recruitment target met) 189 
Total 215 
Table 6.2 (c): Reasons for exclusion - those invited to interview and excluded prior to 
interview 
Reason for exclusion Number 
Refused - various reasons (recorded) 163 
Too ill - various illnesses (recorded) 25 
Didn't return the form - no reason 278 
Other* 49 
Total 515 
* Includes change of address/ GP 
Table 6.2 (d): Reasons for exclusion - those excluded during the baseline interview 
Reason for exclusion Number 
History of transient ischaemic attack 
(missed on notes screening) 
6 
History of stroke (missed on notes 
screening) 
4 
Failed MMSE (<24) 16 
Declined to complete interview - various 
reasons 
8 
Too ill to complete interview 2 
Not in chronic AF 16 
Other* 9 
Total 61 
* Includes illiteracy, poor vision and hearing and motivation 
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Characteristics of responders and non-responders: 
Comparisons were made between those individuals who were excluded and included at the notes- 
screening stage (Table 6.3). Comparison were also made between those who were excluded at 
notes screening and included at baseline interview (i. e. between those whose notes were screened 
and were subsequently invited to participate, and those whose notes were screened and they were 
not invited to interview) (Table 6.4). Information recorded for those excluded at notes screening 
stage was limited to demographics and reason for exclusion. 
Table 63: Characteristics of those included and excluded at notes-screening 
Variable Included at notes-screening? P-values for 
Yes (n=1153) No (n=1713) Total 
(n=2866) 
comparison of 
groups 
Male (%) 51.52 45.48 47.9 P=0.001 * 
(Chi-squared) 
Median age (years) - male 74.0 75.0 74.0 P=0.071 
(Mann-Whitney) 
Median age (years) - female 78.0 79.0 78.0 P=0.007* 
(Mann-Whitne ) 
Median age (years) - total 76.0 77.0 76.0 P<0.001* 
(Mann-Whitne ) 
*P<0.05 
Table 6.4: Characteristics of those included at baseline interview and excluded at notes 
searching 
Variable Included at Excluded at Total P-values for 
baseline notes (n=2075) comparison of 
interview searching groups 
(n=362) (n=1713) 
Male (%) 56.07 45.48 47.33 P<0.001* 
(Chi-squared) 
Median age (years) - male 74.0 75.0 75.0 P=0.177 
(Mann-Whitney) 
Median age (years) - female 77.0 79.0 78.0 P<0.001* 
(Mann-Whitne 
Median age (years) - total 75.0 77.0 77.0 P<0.001* 
(Mann-Whitne ) 
*P<0.05 
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In addition, those who were included in the study ('responders', n=362) were compared with those 
who were invited for interview, yet did not complete the interview ('non-responders', n=576). 
Comparison between these groups was possible for all variables which had been collected during 
GP notes screening, with key comparisons described here. The notes screening process had been 
designed with consideration of the likely need for these analyses. 
No significant differences (table 6.5) were found between responders and non-responders for 
documented co-morbidities (atrial fibrillation, CHF, hypertension, diabetes, thyrotoxicosis, 
Parkinson's disease, peripheral vascular disease and depression). The only significant differences 
found were a) female non-responders (median age 79 years) were significantly (p=0.001) older 
than female responders (median age 77 years), although there was no significant difference in age 
for men in these two categories; b) significantly (p=0.009) fewer non-responders had a record of 
CHD (29% of non-responders vs. 37% of responders); and c) significantly (p=0.016) fewer non- 
responders had ever taken aspirin (39.2% of non-responders versus 47.2% of responders). 
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Table 6.5: Characteristics of responders and non-responders 
Variable Completed Interview? 
Yes (n=362) No (n=576) Total P-values for 
(n=938) comparison of 
groups (2sf) 
Median age (years) - male 74.0 75.0 75.0 0.13 
(Mann-Whitney) 
Median age (years) - female 77.0 79.0 76.0 0.00* 
(Mann-Whitne ) 
Median age (years) - total 75.0 77.0 76.0 0.00* 
(Mann-Whitney) 
Coronary Heart Disease 37.0% 28.8% 32.0% 0.009* 
(Chi-squared) 
Heart Failure 6.6% 6.3% 6.4% 0.82 
(Chi-squared) 
Hypertension 38.4% 35.1% 36.4% 0.31 
(Chi-squared) 
Diabetes 10.2% 9.4% 9.7% 0.67 
(Chi-s uared) 
Thyrotoxicosis 1.9% 1.2% 1.5% 0.38 
(Chi-squared) 
Parkinson's Disease 0.6% 1.2% 1.0% 0.31 
(Chi-s uared) 
Peripheral Vascular Disease 7.7% 5.3% 6.2% (0.17) 
(Chi-squared) 
Depression (past history) 10.2% 9.7% 9.9% 0.80 
(Chi-s uared) 
Depression (current) 2.8% 3.0% 2.9% 0.86 
(Chi-squared) 
Case status of those invited 48.1% 50.7% 49.7% 0.43 
to participate - cases/ /51.9% /49.3% /50.3% (Chi-squared) 
controls 
Ever taken aspirin 47.2% 39.2% 42.3% 0.016* 
(Chi-squared) 
Ever taken warfarin 24.6% 20.3% 22.0% 0.12 
(Chi-s uared) 
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Characteristics of the cohort (participants included after baseline interview): 
General characteristics of the cohort 
The median age of the CAFE cohort (those who were included following baseline assessment) was 
75 years; 56% were male, 37% had a record of CHD, 6.6% had CHF (NYHA grade I or II); 38.4% 
had a record of hypertension and 10.2% had a record of diabetes. Further characteristics are shown 
in table 6.6 below. 
Comparison of cases and controls 
Controls and cases were comparable in most respects. Significant differences between cases and 
controls are listed in table 6.6. In addition, cases had significantly poorer scores than controls on all 
analysed components of the SF-36 (p<0.01 to p<0.001), except for the pain component, where the 
poorer score in cases was non-significant (p=0.1). With regard to treatment subgroups, 51% of 
cases and no controls were on warfarin at the time of the baseline interview, 35% of cases and 30% 
of controls were on aspirin, and 14% of cases and 70% of controls were on neither aspirin nor 
warfarin. 
There were no significant (p<0.05) differences between cases and controls for the following 
variables: - 
" Age and sex: cases and controls had a mean age of 75.4 years and 75.6 years respectively. 
54.9% of cases and 57% of controls were male. 
" Duration of NVAF (cases only): mean duration was 417 days (standard deviation 561.57 days). 
" Prevalence of hypertension: 42.6% of cases and 35.2% of controls had a GP record of 
hypertension. 
" Prevalence of peripheral vascular disease: 6.8% of cases and 7.1% of controls. 
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" Oedema on examination: 12.6% of cases and 7.0% of controls had oedema on examination at 
the baseline interview. 
" Smoking status: 13.1% of cases and 15.1% of controls were smokers. 
9 Alcohol consumption: 17.7% of cases and 22.6% of controls were daily drinkers. 
" Level of education: cases and controls were similar with respect both to age at leaving school 
and highest qualification: 62.3% of cases and 68.3% of controls left higher education at 14 
years old or younger; 73.1% of cases and 67.7% of controls had no qualifications (not 
including apprenticeship). 
Table 6.6. Characteristics of the cohort which were significantly different for cases and controls 
Mean 
Characteristic Total Study 
Population 
Cases Controls p-value 
Record of diabetes (%) 10.2 16 4.4 P=0.001 
HBA1C 6.2 6.7 5.9 P<0.001 
Cholesterol 5.6 5.3 5.8 P<0.001 
Record of coronary heart disease (%) 37.0 44.4 31.9 P=0.017 
History of swollen 
ankles (%) 
30.8 42.9 19.4 P<0.001 
Congestive 
heart 
History of marked 
shortness of breath (%) 
6.4 8.0 5.4 P<0.001 
failure Record of recent 
symptomatic heart 
failure (%) 
6.7 11.8 1.1 P<0.001 
Statistically significant differences between the two groups are discussed further under `potential 
confounders' later and have been taken into account in subsequent analyses. 
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Normative data for the CAFE neuropsychological test battery 
Normative data for tests of the CAFE battery was available for neuropsychological performance at 
an isolated point in time, rather than change in performance over time, and for some tests there was 
no normative data available at all. Therefore comparisons between CAFE data and normative data 
could only be made on a cross-sectional basis (CAFE baseline data was used for the following 
comparisons). 
1) Wechsler Memory Scale norms 
i) Logical Memory 
The Logical Memory Scale normative population was originally small and young (approximately 
200 people, aged 20-50 years), 216,225 although this was extended to 360 in age groups 16 to 74 for 
the revised version. 218 Therefore CAFE used normative data from a selection of later studies to 
obtain reference values for older age groups as shown in table 4.1. The overall mean immediate 
score (A+B/ 2) for the total CAFE population was 7.30 (SD 2.97), which is consistent with what 
would be expected considering the norms listed in table 6.7. 
Table 6.7: Normative data for the logical memory subtest of Wechsler's memory scale 
Score for normative popu lation225 
Abikoff256 Hulicka304 Haaland305 Larrabee306 Klonoff307 
Age group 
(years) 
Mean SD Mean SD Mean SD Mean SD Mean SD 
55-64 - - - - - - - - - - 
60-69 - - 7.34 2.9 - - 9.1 2.6 - - 
65-69 - - - - 7.4 2.5 - - - - 
70-74 - - - - 6.7 2.6 - - - - 
70-79 - 7.4 3.8 - - 8.5 2.4 - - 
75-79 9.11/ 11 83 - - - 5.9 2.5 - - - - 80-92 . - - - - - - - 5.7 2.9 
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ii) Digit Span 
The normal range for digits forwards is 6 +/-1,225-308,309 with a score of 5 reported as within 
marginal limits, 4 as borderline and 3 as defective. For digits backwards, raw scores of 4 to 5 are 
reported as normal, 3 as borderline defective or defective, depending on educational background 
and 2 as defective for everyone. The average reported total raw score for this test is 13 in the 70-74 
age group. 225 CAFE results are consistent with this, with a mean raw score of 13.8 for the whole 
study sample. 225-310 Sufficient data was not available to make comparisons between the CAFE 
cohort and the normative population for key characteristics. 
2) Tests of Everyday Attention (Map Search and Telephone Task) norms 
Normative population 
The normative population used for the Tests of Everyday Attention was a sample of 154 normal 
volunteers, aged between 18 and 80 years, of whom 43 volunteers were in the age-band relevant to 
CAFE (65- 80 years). CAFE was comparable to this population in that (236/361) 65.4% of the 
CAFE cohort had an IQ of 100 or greater, in comparison to 74% of the normative population. The 
CAFE cohort had a greater age range (60 to 90 years at first interview). In the CAFE cohort, 
(201/361) 55.7% were male, compared to 45% of the normative population. Comparisons with the 
normative population, recommended by the authors of the test (as were performed for the CAFE 
cohort) are made by transforming the raw scores using an approximately normal power 
transformation to obtain a scaled score and percentile. 
The map search tests are transformed to a scaled score using tables with adjustment for age, and 
these transformed scores are then converted to percentiles based on a normative population. For the 
CAFE cohort, percentiles are shown in table 6.8, and are interpreted as in the following example: 
6.12 
Map Search (ls` Minute, Left) percentile = 43.4%, implying that the CAFE cohort scored better 
than 43.4% of the normative population in their age-group. Reasons for the relatively poor 
performance in the Map Search and Telephone task subtests may be because the CAFE cohort is 
older and more frail than the normative population. 
Table 6.8: Percentiles for CAFE cohort (from normative population) 
Neuropsychological CAFE mean score Scaled score Percentile 
test battery (whole study equivalent of range (from 
population) raw score normative 
population in 
this age 
range) (%) 
Map Search 15.59+5.05 
(1 Minute, Left+Right) = 20.64 9 30.9-43.4 
Map Search 20.64+9.20+8.75 
(2 Minutes =38.59 7 12.2-20.2 
Left+Right) 
Telephone Task 6.5085 (SD=13.84) 6 6.7-12.2 
(time per target) 
Telephone Task 4.136 (SD=14.48) 7 12.2-20.2 
(dual task decrement) 
3) PASAT norms 
Limited norms are available for the PASAT and are presented as total scores only. This makes 
comparison with CAFE sub-scores difficult, since for CAFE, as with many other studies, only two 
of the four speeds available were used. 31' Other available norms were of much younger age-groups 
(mean age29.2 years) than the CAFE cohort, again making comparison very difficult 291 The only 
available norms of an older age-group (60 to 75 years) demonstrated considerably higher scores 
than the CAFE cohort (mean raw score of 37 for PASAT-2.4 and 20 for PASAT-1.2 for the 
normative population, compared to 29 and 12 for the CAFE cohort). This may be explained by the 
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fact that the normative population were younger than the CAFE cohort, and in addition the 
normative sample in this age-group was very small (n=61). 312 
4) NART norms 
Norms for a adapted version of the NART, the NAART, 216,313 have been reported as follows: - age 
60-69 years (n=29), mean number correct = 43.06, SD = 10.78; age 70+ (n=31), mean number 
correct= 45.81 (SD= 8.43). The CAFE cohort scored considerably worse than the normative 
population on this test, with mean of 28 words correct for the whole study sample. Reasons for the 
difference between CAFE findings and the normative population are difficult to establish due to 
the lack of information available on key characteristics of the normative population, although 
differences in educational level are a possible explanation. 
5) MMSE norms 
The lowest quartile cut-off for this test is a score of 28 for those aged 50-79 years and 26 for 80-89 
year olds. 225,314 CAFE data fits well with this, with a lowest quartile score of 27.0. Norms have 
also been reported according to educational level. 216 
6) Rey norms 
Several normative populations are reported for this test218: - 
" One normative population was 18-89 years, healthy and well-educated. 216,284,315 These 
norms are for those with no immediate recall, only copy and 30 minute delayed recall (as 
was used for CAFE): Age 60-69 years (n=21): Copy mean= 30.79 (SD=4.21); 30 min 
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recall mean = 14.21 (SD=7.50). Age 70+ years(n=23): Copy mean= 29.57 (SD=3.37); 30 
min recall mean= 11.74 (SD=6.1 1). 
" Others report that mean copy scores do not differ between age groups, with a mean score of 
33.90 (SD 2.4) for those aged 65 years plus 225,316 and a mean of 32.90 (SD 2.7) for those 
aged 70 + years. 216,225 
" CAFE findings compare well with both of these normative populations, with a mean copy 
score of 31.75 and a mean delayed score of 13.2 for the whole study sample. 
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Correlation with National Adult Reading Test Scores: 
As part of a factor analysis, the relationship between performance on different tests was examined. 
Of particular interest was the relationship between NART IQ and the other tests, since NART IQ is 
a recognised marker for verbal intelligence which may have an effect on cognitive performance. 
For the CAFE cohort, there was little correlation between NART IQ and performance on other 
tests in the CAFE battery (table 6.9) at baseline, suggesting that the CAFE findings are not affected 
by the verbal intelligence level of individuals in the cohort. This contrasts with other test batteries, 
such as the complete WAIS, which has been shown to correlate with education. 218 
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Table 6.9: Correlation (Spearman's) between NART IQ and performance on other 
neuropsychological tests: - 
Neuropsychological Test Spearman's P-value for Spearman's 
correlation (2dp) correlation (2dp) 
MMSE 0.39 0.00 
Logical Memory 0.34 0.00 
Immediate (raw) 
Logical Memory 0.33 0.00 
Immediate (%) 
Logical Memory 0.29 0.00 
Delayed (raw)* 
Logical Memory 0.29 0.00 
Delayed (%) 
Rey Complex Figure 0.22 0.00 
Copy* 
Rey Complex Figure 0.23 0.00 
Delayed 
Map Search (1S` Minute, 0.16 0.002 
Left) 
Map Search (1s` Minute, -0.07 0.20 
Right) 
Map Search nd Minute, -0.01 0.81 
Left 
Map Search (2" 0.10 0.05 
Minute, Right) 
Telephone Task No. of 0.04 0.23 
Targets* 
Telephone Task Time -0.07 0.17 
Taken (seconds) * 
Telephone Task Dual -0.20 0.00 
Task Decrement 
NART No. of Errors -0.98 0.00 
NART Predicted IQ 1.00 - 
Di it Span 0.49 0.00 
PASAT (2.4-seconds) 0.24 0.00 
PASAT (1.2-seconds) 0.09 0.09 
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Chapter summary 
Participants were recruited from general practices in Sunderland and South Tyneside, 
which ranged from large practices with list sizes of 14,500 patients to small, single- 
handed practices. 
" 43% of notes screened were included as potential participants, with the major reasons 
for exclusion at this stage being history of stroke/TIA or person not in chronic NVAF. 
" Stages of recruitment involved applying exclusion criteria during screening of notes in 
general practice and at baseline interview. A large proportion (55%) of potential 
participants declined to take part after invitation, and a smaller proportion (14%) were 
excluded at interview. 
9 Female responders were slightly younger than female non-responders (median 77 versus 
79 years) and responders were more likely to have a record of CHD and to have taken 
aspirin than non-responders. There were no significant differences between responders and 
non-responders for other characteristics or documented co-morbidities (atrial fibrillation, 
CHF, hypertension, diabetes, thyrotoxicosis, Parkinson's disease, peripheral vascular 
disease and depression). 
" The median age of the CAFE cohort was 75 years; 56% were male, 37% had a record of 
CHD, 6.6% had CHF; 38.4% had a record of hypertension and 10.2% had a record of 
diabetes. 
Characteristics of the cohort were examined with comparison of cases and controls. There 
were significant differences between cases and controls for measures of diabetes, 
cholesterol level, CHD, CHF and SF-36 score. These key variables were noted for 
incorporation into subsequent analysis of potential confounders (see chapter 7). 
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" CAFE baseline data compared well with normative data available on Logical Memory, 
Digit Span, MMSE and Rey Complex figure. However, for the NART and the Tests of 
Everyday Attention the CAFE cohort scored worse than the normative population. 
" There was little correlation between NART IQ and performance on other tests in the CAFE 
battery at baseline; therefore it was unlikely that verbal intelligence would confound the 
findings. 
6.19 
Chapter 7- Results (II): Baseline Results - Neumpsychological test 
battery scores 
" Statistical Methods 
" Findings of neuropsychological test results at baseline: 
o Comparison between cases and controls 
o Comparison of sub-groups 
o Summary of neuropsychological test results at baseline 
" Examination of potential confounders: 
o For the total population 
o For cases versus controls 
o For subgroups 
" Stratification according to stroke risk 
" Chapter 7 Summary 
7.1 
Statistical Methods 
Where appropriate we have used means, with use of medians when distributions were non-normal. 
Analysis of variance (ANOVA) models were used for all parametric data and, where appropriate, 
variables were entered into the model as covariates in order to address confounding. Where the 
data were non-normal, equivalent non-parametric methods were applied. Spearman's rank 
correlation coefficient (rho) or Pearson's product moment coefficient (p) were used to explore 
associations between variables. For two-group analyses Student's t-test was used to compare 
differences between means and where there were more than two groups, one-way ANOVA was 
applied with a Bonferroni correction where appropriate. As much of the data were non-normal, 
tests such as the Mann-Whitney test for independent samples were applied. Individual components 
of the neuropsychological test battery were analysed separately. 
For the section on stratification according to stroke risk, cases only were categorised as high, 
intermediate or low stroke risk according to SPAF criteria55,58,69 as described in Chapter 2. 
Firstly descriptive characteristics were calculated to determine the proportion of participants in 
each group. One-way ANOVA, and post-hoc tests were then used to compare baseline 
neuropsychological test scores between those of different stroke risks. 
Matching 
Matching by age/sex/practice was not initiated for the purpose of matched pair analysis, but to 
ensure that we had parity of groups such that the groups were comparable for major potential 
confounders. 
7.2 
Findings of neuropsychological test results at baseline: 
Comparison of cases and controls 
a) Crude comparisons 
Mean values for performance on all cognitive function tests for the whole study population were 
calculated (Table 7.1). Performance of cases and controls on all sub-tests was then compared using 
Student's t-tests. There were no significant differences between means for cases and controls 
except for one sub-test, `telephone task time taken' (p=0.001). 
Table 7.1: Mean cognitive function test scores for cases and controls (unadjusted) 
Cases (score) (2dp) Controls (score) (2dp) 
Neuropsychological Test 
Mean Median SD Mean 
score 
Median SD 
MMSE 28.4 29.0 1.68 28.45 29.00 1.60 
Logical Memory Immediate 
(%) 
25.73 18.00 23.62 24.57 17.00 23.28 
Logical Memory Delayed (%) 37.75 36.00 25.76 36.51 36.00 24.43 
Rey Complex Figure Copy 31.82 33.00 4.68 31.68 34.00 5.07 
Rey Complex Figure Delayed 12.41 12.00 6.36 13.54 13.00 6.95 
Ma Search (1' Minute, Left) 15.59 16.00 8.30 17.76 18.00 9.67 
Map Search (1' Minute, Right) 5.05 0.00 7.24 5.24 1.00 7.26 
Map Search (2 Minute, Left 9.20 9.00 6.67 9.47 8.00 7.96 
Map Search (2 Minute, 
Right) 
8.75 7.00 8.21 10.01 8.00 9.22 
Telephone Task No. of Targets 17.44 18.00 3.29 07.73 18.00 4.18 
Telephone Task Time Taken 105.37 95.00 46.16 92.71 84.00 36.10 
Telephone Task Dual Task 
Decrement 
5.32 2.35 21.31 3.33 2.20 4.25 
NART No. of Errors 22.17 22.00 10.35 21.75 21.00 9.88 
NART Predicted IQ 103.28 103.00 12.91 10359 105.00 12.23 
Digit Span 13.85 14.00 3.59 13.78 13.00 3.89 
PASAT (2.4-seconds) 29.38 29.00 15.98 28.93 29.00 18.30 
PASAT (1.2-seconds) 11.86 7.50 12.33 12.37 8.00 13.50 
b) Age-adjusted comparisons 
The results of the cognitive function tests were then adjusted for age using analysis of covariates 
(ANCOVA) techniques with age introduced as a covariate (table 7.2). 
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Adjustment was made for age only at this stage following testing with a multivariate model 
(ANCOVA): all key confounders were incorporated into the multivariate model comparing 
cognitive function in cases with controls, with confounders as covariates. There was almost no 
effect of confounders on the neuropsychological tests for both cases and controls, with only age 
showing borderline significance. Therefore the following analyses were adjusted for age only. 
After adjustment for age only, apart from for one item, the results were again not significant at the 
5% level; for `time taken to perform the telephone task' cases took a significantly longer time to 
complete than controls (P=0.004) (104.2 seconds for cases versus 92.9 seconds for controls). The 
difference between mean test scores for case and controls was of borderline significance for a 
further two sub-tests, the Rey complex copy (p=0.098) and Map 1 minute left (p=0.061). 
Table 7.2: Age-adjusted ANCOVA for the mean difference in test score between cases and 
controls. 
Neuropsychological Test 
Mean score 
(Std. Dev. ) 
Case 
Mean score 
(Std. Dev. ) 
Control 
Mean 
Terence 
in score 
Case 
Control 
p_value (if 
borderline or 
significant) or 
N/S = not 
significant 
MMSE 28.4(l. 6) 28.5(l. 6) -0.01 N/S 
Logical Memory Immediate 14.3 (5.9) 15.0 (6.0) -0.70 N/S 
Logical Memo Delayed 10.8 (6.8) 10.9 (6.4) -0.10 N/S 
Rey complex figure Copy 31.9 4.5) 31.9 (4.8) 0.00 N/S 
Rey complex figure Delayed 12.5 (6.5 13.6 (7.0) -1.10 0.078 
Map search (1 minute left) 15.9 (8.4) 17.5 (9.4) -1.60 0.061 
Map search (1 minute right) 5.0 (7.1) 5.5 (7.6) -0.50 N/S 
Map search (2 minutes left) 9.2 (7.2) 10.0 (7.9) -0.80 N/S 
Map search (2 minutes right) 8.8 (8.1) 9.7 (8.9) -0.90 N/S 
Telephone Task: No of 
Targets 
17.4 (3.3) 17.7 (2.7) -0.30 N/S 
Telephone Task: Time Taken 104.2 (43.9) 92.9 (35.0) 11.30 0.004 
Telephone Task: Dual Task 
Decrement 
5.5 (20.5) 2.9 (3.8) 2.60 N/S 
NART, No Errors 22.0 (10.2) 21.4 (9.9) 0.60 N/S 
NART, Predicted IQ 1035 (12.8) 103.5 (13.8) 0.00 N/S 
PASAT (2.4-seconds) 29.6 (16.1) 30.1(18.1) -0.50 N/S 
PASAT (1.2-seconds) 12.0 (12.3) 12.7 (13.3 -0.70 N/S 
Digit Span 13.5 (3.6) 13.8 (3.7) -0.30 N/S 
"`0.001 (Bonferroni correction) 
From these results, the overall effect of NVAF on cognitive function at baseline is minimal. 
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Analysis of subgroups according to antithrombotic therapy 
a) Crude comparisons 
In addition to comparing cases and controls, we used ANOVA techniques to compare subgroups 
of cases who were taking (a) warfarin, (b) aspirin, (c) neither treatment; and controls who were 
taking either (d) aspirin or (e) neither treatment (no controls were taking warfarin). The means are 
shown in table 7.3. Multiple comparison techniques were used to determine whether differences 
between subgroup means were statistically significant. When the crude data was analysed, there 
was a significant difference between the subgroups for five subtests (logical memory delayed raw, 
Rey copy, telephone task no. of targets, tele time taken, digit span). The multiple comparison 
analyses for these significant between-subgroup differences are shown in table 7.4. 
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Table 7.3: Mean cognitive function test scores for treatment subgroups (unadjusted) 
Mean Score (SD) (2dp) 
Neuropsychological Test Cases Controls 
Aspirin Warfarin Neither Aspirin Neither 
MMSE 28.36 (158) 28.64 (1.53) 27.92 (2.00) 28.07 (1.81) 28.57 (1.53 
Logical Memory Immediate 
(raw) 
12.98 (5.43) 15.54 (6.14) 12.80 (5.26) 14.29 (5.77) 15.21(6.13) 
Logical Memory Immediate 
(%) 
20.10 (19.64) 28.61(25.55) 19.60 (17.67) 24.27 (22.76) 2650 (24.46) 
Logical Memory Delayed 
(raw)* 
8.90 
(5.69) 
12.44 (7.22) 9.08 
(5.91) 
9.87 
(6.20) 
11.33 
(6.50) 
Logical Memory Delayed (%) 31.21 (22.09) 40.34 (27.05) 32.40 (22.41) 34.13 (22.93) 35.57 (24.93) 
Rey Complex Figure Copy* 30.46 
(5.94) 
33.07 
(3.25) 
30.20 (4.26) 32.18 (4.86) 31.81(4.86) 
Rey Complex Figure Dela ed 11.256 (6.58) 13.84 (6.30) 10.30 (6.01) 13.16 (754) 13.81 (6.81) 
Map Search (' Minute, Left) 15.54 (8.35) 16.66 (8.38) 13.48 (7.76) 18.13 (9.88) 17.16 (9.31) 
Map Search (1' Minute, Right) 4.03 (6.41) 5.33 (7.41) 6.24 (7.88) 4.29 (7.78) 5.98 (7.57) 
Map Search (2 Minute, Left 8.38 (6.38) 9.51 (6.58) 9.20 (9.04) 9.51(7.86) 10.06 (7.97) 
Map Search (2 Minute, 
Right) 
8.20 (7.63) 9.08 (8.46) 8.36 (8.22) 10.38 (8.81) 9.43 (9.06) 
Telephone Task No. of 
Targets* 
16.47 
(4.06) 
18.11 (2.36) 17.24 
(3.35) 
17.27 
(3.47) 
17.80 
(2.23) 
Telephone Task Time Taken 
(seconds) * 
118.43 
(58.12) 
92.97 (29.50) 111.68 
(36.00) 
90.25 (26.20) 94.23 (38.31) 
Telephone Task Dual Task 
Decrement 
7.90 (31.79) 3.26 (7.04) 7.46 (18.64) 2.29 (3.61) 3.245 (3.86) 
NART No. of Errors 22.39 (10.05) 20.87 (9.92) 21.12 (10.85) 22.89 (10.08) 20.74 (9.80) 
NART Predicted IQ 102.98 
(12.57 
104.89 
(12.35) 
99.64 (13.46) 100.72 
(15.93) 
104.73 
(12.81) 
Digit Span * 13.13 
(3.65) 
14.26 (358) 11.72 (256) 13.82 
(2.94) 
13.73 
(4.00) 
PASAT (2.4-seconds) 29.18 (15.84) 32.37 (15.27) 20.12 (16.00) 31.78 (18.79) 29.22 (17.83) 
PASAT (1.2-seconds) 13.16 (13.07) 12.64 (11.91) 6.88 
(10.32) 
14.56 (13.57) 12.26 (13.27) 
* Sigmticant difference between groups (p< 0.05) 
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Table 7.4: Multiple comparisons of cognitive function test scores for treatment subgroups 
(unadjusted) (only shown for those tests that had a significant difference between groups) 
p-value (where p< 0.05) 
Neuropsychological Test 
Cases Controls 
Aspirin Warfarin Neither Aspirin Neither 
Logical Memory Delayed Asp Case - 0.024 ns ns ns 
(raw) Warf Case 0.024 - ns ns ns 
Neith Case ns ns - ns ns 
Asp Contr ns ns ns - ns 
Neith Cont ns ns ns ns - 
Rey Complex Figure Copy Asp Case - 0.015 ns ns ns 
Warf Case 0.015 - ns ns ns 
Neith Case ns ns - ns ns 
Asp Contr ns ns ns - ns 
Neith Cont ns ns ns ns 
Telephone Task No. of Asp Case 0.008 0.033 ns ns 
Targets Warf Case 0.008 - ns ns ns 
Neith Case ns ns - ns ns 
Asp Contr ns ns ns - ns 
Neith Cont 0.033 ns ns ns - 
Telephone Task Time Asp Case - 0.00 0.00 0.00 ns 
Taken (seconds) Warf Case 0.00 - ns ns ns 
Neith Case ns ns - ns ns 
Asp Contr ns ns ns - ns 
Neith Cont ns ns ns ns - 
Digit Span *(p=0.05) Asp Case - ns ns ns ns 
Warf Case ns - 0.05 ns ns 
Neith Case ns 0.05 - ns ns 
Asp Contr ns ns ns - ns 
Neith Cont ns ns ns ns - 
ns = not significant (p>_0.05) 
b) Age-adjusted comparisons 
The differences in mean test scores between the groups were then analysed using ANOVA with 
adjustment for age and Bonferroni correction where appropriate. Again, multiple comparison 
techniques were used to analyse whether or not differences in means between subgroups were 
statistically significant. Table 7.5 shows the mean differences with adjustment for age using 
ANOVA on those cognitive function tests that were significant without age as a covariate. There 
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were no significant differences between test mean scores for all but one of the subtests. Only the 
statistically significant result for `telephone task time taken' persisted, with aspirin cases 
performing significantly worse than aspirin controls (p=0.004). In addition, a previously non- 
significant result for this sub-test became significant, with aspirin cases now performing 
significantly worse than controls on neither aspirin nor warfarin (p=0.011). The multiple 
comparison analyses for these significant between-subgroup differences are shown in table 7.6. 
The other significant differences demonstrated with crude analysis of the data disappeared with 
adjustment for age. 
These findings suggest that the statistically significant difference between mean scores for cases 
and controls found for the `telephone task time taken' sub-test is predominantly due to the 
statistically significant difference between mean scores for aspirin cases and aspirin controls/ 
controls on neither aspirin nor warfarin. 
Table 7.5: Mean cognitive function test scores for treatment subgroups with adjustment for 
age (as a covariate) 
Mean Score (SD) 
Neuropsychological Test Cases Controls 
Aspirin Warfarin Neither Aspirin Neither 
Logical Memory Dela ed (raw) 9.71 11.63 9.85 10.06 11.27 
Rey Complex Figure Copy 30.86 32.66 30.58 32.28 31.78 
Telephone Task No. of Targets 16.71 17.87 17.48 17.36 17.78 
Telephone Task Time Taken 
(seconds)* P 
114.42 96.99 107.68 89.20 94.56 
Di it Span 13.21 14.18 11.8 13.84 13.73 
* Significant difference between groups (p< 0.05) 
bA higher score represents better cognitive function 
"A higher score represents poorer cognitive function 
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Table 7.6: Multiple comparisons of cognitive function test scores for treatment subgroups 
(adjusted for age) (only shown for those tests that had a significant difference between 
groups) 
p-value (where p< 0.05) 
Neuropsychological Test 
Cases Controls 
Aspirin Warfarin Neither Aspirin Neither 
Telephone Task Time Asp Case ns ns 0.004 0.011 
Taken (seconds) Warf Case ns - ns ns Ns 
Neith Case ns ns - ns Ns 
Asp Contr 0.004 ns ns - Ns 
Neith Cont 0.011 ns ns ns - 
ns = not significant (p >_ 0.05) 
Summary of findings of neuropsychological test results at baseline 
There were no significant differences in cognitive function at baseline between cases and controls, 
nor between subgroups on aspirin, warfarin or neither treatment for the majority of sub-tests. This 
conclusion was drawn from analyses adjusted for age, and suggests that the effect of NVAF on 
performance of this battery of neuropsychological tests at baseline is minimal, regardless of 
antithrombotic treatment. 
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Examination of potential confounders 
Choice of variables 
It was important to address the possibility of potential confounders affecting the results, since it 
was possible that these factors may produce falsely positive fmdings, or alternatively hide true 
positive findings. The choice of which potential confounders to incorporate into the analysis was 
based on an extensive literature search of factors that may affect cognitive decline. These included 
age, duration of AF, coronary heart disease (CHID), diabetes, hypertension, cholesterol, health 
status (SF-36), CHF and education. For the purposes of the analyses reported here, sources of data 
for potentially confounding variables identified are shown in table 7.7. 
Table 7.7 Sources of data for potentially confounding variables, for the purposes of analyses 
described in this section. 
Potentially confounding Source of data for this analysis 
variable 
Age GP notes and interview 
Duration of AF GP notes :- `date of dia is of AF' 
Coronary Heart Disease (CHD) GP notes: - 
'any record of CHD? ' 
- if CHD, is there a record of myocardial 
infarction? ' 
- `i CHD, is there a record of angina? ' 
Diabetes GP notes: - 'any record of diabetes? ' 
Hypertension GP notes: - `is patient taking medication for 
hypertension' 
Cholesterol Blood sample taken at interview 
Health status SF-36 findings at interview 
Heart Failure GP notes: -any record of symptomatic heart failure in 
the last three months? ' 
Education Interview: - 
- 'how old were you when you left continuous full- 
time education? ' 
- 'highest qualification' 
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In order to find out whether any of these factors were likely to confound the analyses, the effect of 
these variables on the cognitive function test results was investigated in several stages: - 
" Assessment of key confounders in the population as a whole. 
" Assessment of key confounders as covariates to investigate their effect on the relationship 
between case status and cognitive function. 
" Assessment of key confounders as covariates to investigate their effect on the relationship 
between treatment subgroups (aspirin/ warfarin/ neither) and cognitive function. 
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1. Assessment of key confounders in the population as a whole 
Initially it was important to determine whether, within our population, there was any association 
between potential confounders and the results of the cognitive function tests. To do this, initially 
one-way analysis of variance techniques (usually Student's t-test) were carried out to examine their 
relationship with each of the neuropsychological tests. In these analyses, the neuropsychological 
tests were the `dependant variables' and the potential confounders were the `factors'. However, it 
became apparent that the data was non-normal, therefore it was necessary to use non-parametric 
tests for further analysis. Each potentially confounding variable was then taken in turn and Mann 
Whitney tests for categorical variables and correlations (Spearman's, Pearson's or both) for 
continuous variables were then carried out. This led to the following findings: - 
a) Effect of coronary heart disease on the neuropsychological test results of the whole 
population (Table 7.8) 
Overall, the proxies for CHD did not produce a significant effect on any of the neuropsychological 
variables. Statistically significant differences between those with and without proxies for CHD 
(history of CHD, history of MI, history of angina) were shown for the MMSE. However, looking 
more closely, both the medians (29.00 for those with CHD, 29.00 for those without CHD) and 
means (28.16 for those with CHD, 28.60 for those without CID) were very similar for those with 
and without CHD, such that the clinical significance of the difference between the two groups is 
negligible. The very small differences, which persist despite adjustment for age, may be 
statistically significant partly because of the large sample size. Statistically significant differences 
were also found for the Map search ls` minute right, with medians of 0.00 and 2.00. On closer 
examination of the data, the unusual medians could be explained: it appeared that those who scored 
highly on Map search 1s` minute left scored poorly on Map search 1" minute right and vice versa, 
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which is logical considering that when most participants begin circling objects on one side of the 
map, they continue to circle on that side of the map for almost one minute. However, this does not 
explain why those with and without CHD scored differently. Finally, there were statistically 
significant differences between medians for the telephone task time taken sub-test, which is 
discussed later. Overall, for the majority of subtests, there was no strong evidence suggesting an 
association between CHD and neuropsychological test score results in the whole population. 
Table 7.8: Medians (and significance of difference between medians) for those with and 
without proxies for coronary heart disease (CHD) for each of the cognitive function tests 
Neuropsychological Test 
Medians for `Any 
record of CHI)? ' 
Medians for 'If CHD 
any Hx MI? ' (diagnosis 
of CHD in GP notes and 
had suffered one or more 
myocardial infarctions) 
Medians for ` If CHD 
any Hx angina? ' 
(diagnosis of CHD and a 
diagnosis of angina in 
GP notes ) 
Yes No P- 
value 
Yes No P- 
value 
Yes No p- 
value 
MMSE 29.00 29.00 0.02* 29.00 29.00 0.74 29.00 29.00 0.014* 
Logical Memory Immediate 
(raw) 
15.00 14.00 0.76 15.50 14.00 0.15 15.00 14.00 0.40 
Logical Memory Immediate 
(%) 
21.00 16.50 0.63 21.00 17.00 0.14 21.00 16.00 0.33 
Logical Memory Delayed (raw) 11.00 10.00 0.78 11.00 10.00 0.45 11.00 10.00 0.51 
Logical Memory Delayed (%) 36.00 36.00 0.77 37.50 36.00 0.46 36.00 36.00 0.60 
Rey Complex Figure Copy 34.00 34.00 0.74 34.00 33.00 0.54 33.00 34.00 0.50 
Rey Complex Figure Delayed 12.00 12.75 0.67 12.50 12.50 0.58 12.00 13.00 0.53 
Map Search (1st Minute, Left) 17.00 18.00 0.33 17.00 17.00 0.41 17.00 17.00 0.45 
Map Search (1's Minute, Right) 0.00 2.00 0.008* 0.00 1.00 0.15 0.00 1.50 0.03* 
Map Search (2 Minute, Left 9.00 8.00 0.97 9.00 9.00 0.48 9.00 8.50 0.90 
Map Search (2 Minute, 
Right) 
7.00 8.00 0.84 5.00 8.00 0.51 7.00 8.00 0.70 
Telephone Task No. of Targets 18.00 18.00 0.26 18.00 18.00 0.80 18.00 18.00 0.31 
Telephone Task Time Taken 
(seconds) 
91.00 88.00 0.036* 92.50 88.00 0.49 94.00 88.00 0.008* 
Telephone Task Dual Task 
Decrement 
2.10 2.15 0.73 1.800 2.200 0.48 2.10 2.15 0.64 
NART No. of Errors 21.00 20.50 0.71 20.00 21.00 0.24 21.00 20.50 0.54 
NART Predicted IQ 105.00 105.00 0.83 106.00 105.00 0.18 105.00 105.00 0.61 
Digit Span 14.00 13.00 0.24 13.00 13.00 0.30 13.00 13.00 0.57 
PASAT (2.4-seconds) 28.00 29.50 0.59 28.00 29.00 0.78 28.00 30.00 0.30 
PASAT (1.2-seconds) 11.00 7.50 0.25 12.00 8.00 0.55 10.00 8.00 0.60 
* Significant difference between groups (p<_ 0.05) 
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b) Effect of diabetes on the neuropsychological test results of the whole population 
(Table 7.9) 
There were no significant differences between those with and without a record of diabetes for any 
of the neuropsychological tests. 
Table 7.9: Medians (and significance of difference between medians) for those with and 
without GP record of diabetes for each of the cognitive function tests 
Median values for 'Any record of diabetes? ' (2dp) 
Neuropsychological Test 
Yes No p-value 
MMSE 29.00 29.00 0.31 
Logical Memory Immediate 
(raw) 
14.00 15.00 0.80 
Logical Memory Immediate 
(% 
16.50 17.00 0.87 
Logical Memory Delayed (raw) 11.00 10.00 0.80 
Logical Memory Delayed (%) 28.00 36.00 0.50 
Rey Complex Figure Copy 33.50 33.00 0.90 
Rey Complex Figure Delayed 13.75 12.50 0.60 
Map Search (V Minute, Left) 16.50 17.00 0.83 
Map Search (V Minute, Right) 0.00 1.00 0.34 
Map Search (2 Minute, Left 10.00 8.00 0.09 
Map Search (2 Minute, 
Right) 
6.50 8.00 0.70 
Telephone Task No. of Targets 18.00 18.00 0.91 
Telephone Task Time Taken 
(seconds) 
97.50 88.00 0.10 
Telephone Task Dual Task 
Decrement 
2.30 2.10 0.98 
NART No. of Errors 19.50 21.00 1.00 
NART Predicted IQ 106.50 105.00 0.99 
Digit Span 13.00 13.00 0.29 
PASAT (2.4-seconds) 30.00 29.00 0.80 
PASAT (1.2-seconds) 12.00 8.00 0.78 
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c) Effect of hypertension on the neuropsychological test results of the whole population 
(Table 7.10) 
One proxy for hypertension was whether or not there was GP documentation of current 
prescription of medication specifically for hypertension. There were no significant differences 
between those who did and did not take medication to treat hypertension for any of the 
neuropsychological tests. 
Table 7.10: Medians (and significance of difference between medians) for those who were 
and were not taking medication for hypertension for each of the cognitive function tests 
Neuro s cholo ical Test 
Median values for `medication for hypertension? ' 
(2dp) 
p y g 
Yes No p-value 
MMSE 29.00 29.00 0.21 
Logical Memory Immediate 
(raw) 
14.00 15.00 0.88 
Logical Memory Immediate 
(%) 
17.00 17.00 0.64 
Logical Memory Delayed (raw) 10.00 10.00 0.98 
Logical Memory Delayed (%) 36.00 36.00 0.64 
Rey Complex Figure Copy 33.00 34.00 0.24 
Rey Complex Figure Delayed 12.00 12.50 0.57 
Ma Search (V Minute, Left) 17.00 17.00 0.78 
Map Search V Minute, Right) 0.00 1.00 0.09 
Map Search (2 Minute, Left 9.00 9.00 0.79 
Map Search (2 Minute, 
Right) 
8.00 6.00 0.60 
Telephone Task No. of Targets 18.00 18.00 0.45 
Telephone Task Time Taken 
(seconds) 
90.50 88.00 0.25 
Telephone Task Dual Task 
Decrement 
1.90 2.20 0.71 
NART No. of Errors 20.00 21.00 0.19 
NART Predicted IQ 106.00 105.00 0.14 
Digit Span 14.00 13.00 0.39 
PASAT (2.4-seconds) 29.00 29.00 0.51 
PASAT (1.2-seconds) 7.00 8.50 0.80 
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d) Effect of heart failure on the neuropsychological test results of the whole population. 
(Table 7.11) 
There was a statistically significant difference (p=0.047) in the scores for the Digit span test 
between those who did (median = 11.50) and did not (median = 13.00) have a record of 
symptomatic heart failure in the last three months in their GP notes. There were no other 
significant differences between the groups. Since Digit span measures attention and no other tests 
of attention demonstrated significant differences, and since this was the only test to show any 
significant differences between people with and without CHF, it is reasonable not to attach great 
importance to this finding. Overall, there does not appear to be an association between heart failure 
and cognitive function for the total population. 
Table 7.11: Medians (and significance of difference between medians) for those who did and 
did not have proxies for heart failure for each of the cognitive function tests 
Neuropsychological Test 
Median values for `any symptomatic heart failure in 
the last three months? ' (2dp) 
Yes No p-value 
MMSE 29.00 29.00 0.70 
Logical Memory Immediate 
(raw) 
16.00 14.00 0.22 
Logical Memory Immediate 
(%) 
23.50 17.00 0.17 
Logical Memory Delayed (raw) 11.50 10.00 0.27 
Logical Memory Delayed (%) 37.00 36.00 0.33 
Rey Complex Figure Copy 33.00 34.00 0.65 
Rey Complex Figure Delayed 12.00 12.50 0.90 
Map Search (1t Minute, Left) 17.50 17.00 0.88 
Map Search (1t Minute, Right) 0.00 0.00 0.75 
Map Search (2 Minute, Left 11.50 9.00 0.14 
Map Search (2 Minute, 
Right) 
8.50 7.00 0.92 
Telephone Task No. of Targets 19.00 18.00 0.53 
Telephone Task Time Taken 
(seconds) 
94.00 88.00 0.58 
Telephone Task Dual Task 
Decrement 
2.350 2.100 0.76 
NART No. of Errors 15.50 21.00 0.10 
NART Predicted IQ 111.50 105.00 0.09 
Digit Span 11.50 13.00 0.05* 
PASAT (2.4-seconds) 28.00 29.00 0.69 
PASAT (1.2-seconds) 9.00 8.00 0.64 
* Significant difference between groups (p< 0.05) 
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e) Effect of duration of atrial fibrillation on the neuropsychological test results of all 
cases (Table 7.12) 
Pearson's and Spearman's Correlations were used to assess the effect of duration of atrial 
fibrillation (taken from GP notes) on the individual cognitive function tests. The results were not 
significant for all neuropsychological tests except for telephone task time taken. For this test, the 
score correlated significantly (0.048) with duration of AF, however the correlation coefficient was 
very small (R=0.151). Therefore there was no overall association between duration of AF and 
cognitive decline for the total population (cases only). 
Table 7.12: Pearson's and Spearman's Correlation for the effect of duration of atrial 
fibrillation on test scores (2dp) 
Neuropsychological Test Pearson's 
Correlation 
Spearman's 
Correlation 
p-value for 
Spearman's 
Correlation 
MMSE - -0.04 0.64 
Logical Memo Immediate (raw) 0.09 0.09 0.23 
Logical Memo Immediate (%) 0.10 0.20 
Logical Memo Delayed (raw) 0.07 0.07 0.34 
Logical Memo Delayed (%) - 0.11 0.16 
Rey Complex Figure Copy 0.06 0.07 0.36 
Rey Complex Figure Delayed 0.06 0.04 0.65 
Map Search ls` Minute, Left) -0.04 -0.06 0.49 
Map Search 1'` Minute, Right) -0.04 -0.03 0.75 
Map Search 2 Minute, Left) 0.008 0.004 0.96 
Map Search (2 Minute, Right) -0.11 -0.10 0.21 
Telephone Task No. of Targets 0.03 0.03 0.73 
Telephone Task Time Taken 0.06 0.15 0.05* 
Telephone Task Dual Task 
Decrement 
0.00 0.01 0.98 
NART No. of Errors -0.01 -0.03 0.67 
NART Predicted IQ 0.01 0.03 0.66 
Digit Span -0.05 -0.004 0.96 
PASAT 2.4-seconds 0.00 0.03 0.68 
PASAT (1.2-seconds) 0.01 0.02 0.82 
* Significant difference between groups (p< 0.05) 
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J) Effect of cholesterol on the neuropsychological test results of the whole population 
(Table 7.13) 
Pearson's and Spearman's Correlations were used to assess the effect of non-fasting cholesterol 
(sample taken at baseline visit) on the individual cognitive function tests. For the majority of 
neuropsychological tests there was no correlation between score and cholesterol. Using Pearson's 
technique, cholesterol did correlate significantly with map search 2"d minute right (p= 0.040) and 
telephone task time taken (p=0.027). However when Spearman's technique, which is more 
appropriate for non-normal data, was used there were no significant results. Therefore there was 
no strong evidence to support an association between cholesterol level and cognitive function in the 
total population. 
Table 7.13: Pearson's and Spearman's Correlation for the effect of cholesterol on test scores 
(2dp). 
Neuropsychological Test Pearson's 
Correlation 
p-value for 
Pearson's 
Correlation 
Spearman's 
Correlation 
p-value for 
Spearman's 
Correlation 
MMSE 0.04 0.46 0.03 0.67 
Logical Memory Immediate (raw) -0.07 0.21 -0.03 0.66 
Logical Memory Immediate (%) -0.06 0.29 -0.02 0.75 
Logical Memory Delayed (raw) -0.02 0.73 0.03 0.66 
Logical Memory Delayed (%) -0.02 0.79 0.01 0.82 
Rey Complex Figure Copy 0.03 0.66 0.01 0.87 
Rey Complex Figure Delayed -0.06 0.27 -0.07 0.26 
Map Search 1°` Minute, Left) 0.08 0.20 0.08 0.17 
Map Search 1" Minute, Right) 0.07 0.26 0.04 0.48 
Map Search (2 Minute, Left) -0.07 0.26 -0.07 0.22 
Map Search 2 Minute, Right) 0.12 0.04* 0.12 0.07 
Telephone Task No. of Targets 0.02 0.75 -0.003 0.96 
Telephone Task Time Taken -0.13 0.03* -0.11 0.06 
Telephone Task Dual Task 
Decrement -0.07 
0.23 -0.04 0.54 
NART No. of Errors -0.05 0.38 -0.03 0.59 
NART Predicted IQ 0.02 0.78 0.01 0.81 
Digit Span -0.01 0.82 -0.03 0.60 
PASAT (2.4-seconds) 0.24 0.24 -0.06 0.28 
PASAT (1.2-seconds) -0.03 0.64 -0.04 0.52 
* Significant difference between groups (p< 0.05) 
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g) Effect of health status (SF-36 score) on the neuropsychological test results of the 
whole population 
The Short Form -36 (SF-36) was used to measure health status. Raw scores were transformed into 
the seven `domains' of health status (physical functioning, role physical, bodily pain, general 
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health, vitality, role emotional, mental health) using algorithms. The effect of health status on 
cognitive function at baseline was analysed using Spearman's correlation techniques. There was 
very little relationship between transformed SF-36 scores and neuropsychological test scores for 
the whole population. The greatest correlation was for the effect of SF-36 emotion domain on the 
sub-test `telephone task time taken'; however even for this sub-test the correlations were very weak, 
with the largest coefficient being -0.188 (p<0.01). 
Therefore overall, there was no evidence to suggest that SF-36 transformed score confounds 
measurement of cognitive function in the total population. 
h) Effect of education on the neuropsychological test results of the whole population 
(Table 7.14) 
i) Effect of the variable "How old were you when you left continuous full-time education" 
The effect of education on cognition was addressed by analysing the effect of the baseline variables, 
"How old were you when you left continuous full-time education? " and "Highest qualification". 
Using Spearman's Correlation techniques, an association between leaving school at an older age 
and better cognitive function test scores was demonstrated (see table 7.14). This association was 
small because the majority of people left school at 14 years or under, skewing the distribution of 
the scores. The correlation coefficients, though highly significant for these cognitive function tests, 
are small in size, suggesting the association is weak. 
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Table 7.14: Spearman's Correlation for the effect of education on test scores (2dp) 
Neuropsychological Test Spearman's 
Correlation 
p-value for 
Spearman's 
Correlation 
MMSE 0.24 0.00* 
Logical Memory Immediate (raw) 0.17 0.00* 
Logical Memory Immediate (%) 0.13 0.01* 
Logical Memory Delayed (raw) 0.17 0.001* 
Logical Memory Delayed (%) 0.12 0.03* 
Rey Complex Figure Copy 0.18 0.001* 
Re Complex Figure Delayed 0.20 0.00* 
Map Search (1 s` Minute, Left) 0.19 0.001* 
Map Search I" Minute, Right) 0.05 0.54 
Map Search (2 Minute, Left) 0.02 0.72 
Map Search (2 Minute, Right) 0.13 0.03* 
Telephone Task No. of Targets 0.07 0.16 
Telephone Task Time Taken -0.19 0.00* 
Telephone Task Dual Task 
Decrement 
-0.07 0.18 
NART No. of Errors -0.31 0.00* 
NART Predicted IQ 0.30 0.00* 
Digit Span 0.18 0.001* 
PASAT (2.4-seconds 0.23 0.00* 
PASAT (1.2-seconds) 0.06 0.23 
* Significant difference between groups (p< 0.05) 
ii) Effect of the variable "What is your highest qualification? " 
The majority (70.2%) of participants had no qualifications (described in Chapter 6). The remaining 
categories of qualifications (school qualifications, degree, apprenticeship etc, described elsewhere) 
therefore contained small numbers, making it difficult to examine the effect of each of the 
individual qualification categories on cognitive function tests. Therefore the categories were 
analysed as two groups: `no qualifications' and `any qualifications'. The analysis was performed 
twice, firstly considering apprenticeship in the `any qualifications' group (table 7.15), secondly 
considering apprenticeship in the `no qualifications' group (table 7.16). Mann-Whitney tests were 
performed to determine whether the difference in means between those with and without `any 
qualifications' was statistically significant (table 7.15). Those with any qualifications (regardless of 
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whether apprenticeship was included as `some qualifications' or `no qualifications') performed 
significantly better on nearly all cognitive function tests than those with no qualifications (see 
tables 7.15 and 7.16). 
Table 7.15: Means (and significance of difference between means) for those with and without 
qualifications for each of the cognitive function tests), with apprenticeship counted as a 
qualification. 
Mean scores 
Neuropsychological Test 
No 
qualifications 
Some 
qualifications 
(including 
apprenticeship) 
P-value (using 
Mann-Whitney 
- based on 
medians not 
shown here) 
MMSE 28.27 28.82 0.001* 
Logical Memory Immediate 
(raw) 
14.10 15.91 0.01* 
Logical Memory Immediate 
(%) 
23.50 29.51 0.01* 
Logical Memory Delayed (raw) 10.29 12.20 0.01* 
Logical Memory Delayed (%) 34.39 41.26 0.01* 
Rey Complex Figure Copy 31.16 33.64 0.00* 
Rey Complex Figure Delayed 11.88 15.86 0.00* 
Map Search (1" Minute, Left) 15.51 19.50 0.00* 
Map Search (1" Minute, Right) 5.12 5.60 0.31 
Map Search (2 Minute, Left) 9.44 9.56 0.70 
Map Search (2 Minute, 
Right) 
8.33 11.37 0.006* 
Telephone Task No. of Targets 17.37 17.93 0.02* 
Telephone Task Time Taken 
(seconds) 
104.57 83.85 0.00* 
Telephone Task Dual Task 
Decrement 
4.86 2.456 0.054 
NART No. of Errors 23.15 18.39 0.00* 
NART Predicted I 101.89 107.13 0.00* 
Digit Span 13.29 14.56 0.003* 
PASAT (2.4-seconds) 26.58 37.25 0.00* 
PASAT (1.2-seconds) 11.61 14.27 0.11 
* Significant difference between groups (p_< 0.05) 
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Table 7.16: Means (and significance of difference between means) for those with and without 
qualifications for each of the cognitive function tests), with apprenticeship not counted as a 
qualification. 
Mean scores 
Neuropsychological Test 
No 
qualifications 
(including 
apprenticeship) 
Some 
qualifications 
P-value (using 
Mann- 
Whitney- based 
on medians not 
shown here) 
MMSE 28.27 28.96 0.00* 
Logical Memory Immediate 
(raw) 
14.45 16.26 0.004* 
Logical Memory Immediate 
(%) 
23.54 31.02 0.003* 
Logical Memory Delayed (raw) 10.34 12.56 0.003* 
Logical Memory Delayed (%) 34.68 42.19 0.01* 
Rey Complex Figure Copy 31.40 33.58 0.00* 
Rey Complex Figure Delayed 12.30 15.58 0.00* 
Map Search (V Minute, Left) 15.94 19.19 0.01* 
Map Search (1' Minute, Right) 5.07 5.88 0.21 
Map Search (2 Minute, Left) 9.41 9.70 0.72 
Map Search (2 Minute, 
Right) 
8.58 11.38 0.02* 
Telephone Task No. of Targets 17.45 17.81 0.18 
Telephone Task Time Taken 
(seconds) 
102.91 83.60 0.00* 
Telephone Task Dual Task 
Decrement 
4.71 2.282 0.04 
NART No. of Errors 23.48 16.07 0.00* 
NART Predicted I 101.49 109.81 0.00* 
Digit Span 13.23 15.11 0.003* 
PASAT (2.4-seconds) 27.23 38.06 0.00* 
PASAT (1.2-seconds) 11.45 15.50 0.04* 
* Significant difference between groups (p< 0.05) 
Overall, those with highest educational level performed significantly better than those with less 
education. 
However, the CAFE participants have a highly skewed distribution for these variables, with the 
majority of participants having no qualifications and having left school at age 14 years or under. 
Therefore it is likely that education, although it may significantly affect cognition, will not greatly 
confound the results for CAFE because most participants have the same level of education, with 
similar distributions for both cases and controls. 
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Summary of total population confounder analyses 
Upon analysing the effect of CHD, diabetes, hypertension, heart failure, duration of AF, cholesterol, 
and health status we found no strong evidence to suggest that these variables would confound the 
measurement of cognitive function in the total study population. 
For education, there was an association between highest qualification / age at leaving education 
and cognitive function. However, because this sample consists predominantly of those within the 
same educational category, it is unlikely that this variable will confound our results. Nonetheless, 
this analysis has identified a potential source of confounding and adjustment for education was 
made in subsequent analyses of cognitive function. 
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2. Assessment of key confounders as covariates to investigate their effect on the 
relationship between case status and cognitive function 
The next stage was to determine whether or not the key confounders had an effect on the (age- 
adjusted) relationships already described between cases and controls and cognitive function. 
Because the data was predominantly non-normal, this was done using non-parametric tests. For 
categorical variables, Mann-Whitney tests were performed to determine whether or not there were 
significant differences between those with and without the confounding variable for both cases and 
controls, with the confounding variable incorporated into the model as a covariate. Where a 
significant difference was found, the frequencies of the confounding variables for cases and 
controls were examined to determine the actual difference between the two groups. For continuous 
variables, Spearman's and Pearson's correlations were used. 
a) Coronary Heart Disease 
The results of Mann-Whitney tests are shown in Table 7.17a. There were no significant 
differences between those with and without proxies for CHD for both cases and controls for most 
neuropsychological tests. 
The exceptions to this were the MMSE and telephone task time taken. For the MMSE (tables 7.17a, 
7.17b), cases without a record of CHD performed significantly better (p=0.021) than cases with 
CHD (28.69 versus 28.12); and cases without a history of angina performed significantly (p=0.027) 
better than cases with angina (28.68 versus 28.06). For the `telephone task time taken' subtest 
(table 7.17c), cases without any history of angina performed significantly (p=0.029) better than 
cases with angina (98.57 seconds versus 114.26 seconds). There was no difference for controls. 
Overall, there were no significant differences between those with and without proxies for CHD that 
were consistent across all three proxies, and for those findings which were statistically significant 
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the actual differences between the means were very small and therefore clinically insignificant 
(except angina history for the telephone task time taken sub-test). Therefore there is no strong 
evidence that proxies for CHD affect the relationship between case status and cognitive function. 
Table 7.17a : Significance levels (using Mann-Whitney) for the difference in cognitive 
function scores for those (cases and controls) with and without proxies for CHD. 
P-values for difference between those with and without proxies 
for CHI) (using Mann- Whitney) (2dp) 
Neuropsychological test 
'Any record of 
CHD? ' 
`If CHD any Hx 
MI? ' 
`If CHD any Hx 
angina? ' 
Control Case Control Case Control Case 
MMSE 0.32 0.02* 0.44 0.75 0.20 0.03* 
Logical Memory Immediate 
(raw) 
0.57 0.98 0.23 0.43 0.32 0.74 
Logical Memory immediate 
(%) 
0.42 0.96 0.15 0.51 0.23 0.75 
Logical Memory Delayed (raw) 0.92 0.59 0.76 0.43 0.91 0.40 
Logical Memory Delayed (%) 0.96 0.70 0.66 0.53 0.87 0.55 
Rey Complex Figure Copy 0.98 0.76 0.82 0.51 0.79 0.56 
Rey Complex Figure Delayed 0.42 0.73 0.63 0.78 0.70 0.69 
Map Search (V Minute, Left) 0.61 0.56 0.27 0.99 0.99 0.37 
Map Search Q` Minute, Right) 0.12 0.03 0.50 0.18 0.07 0.28 
Map Search (2 Minute, Left) 0.80 0.85 0.28 0.96 0.86 0.79 
Map Search (2' Minute, 
Right) 
0.42 0.54 0.19 0.71 0.40 0.71 
Telephone Task No. of Targets 0.43 0.42 0.68 0.45 0.68 0.31 
Telephone Task Time Taken 
(seconds) 
0.38 0.12 0.85 0.54 0.22 0.03* 
Telephone Task Dual Task 
Decrement 
0.39 0.24 0.36 0.93 0.33 0.14 
NART No. of Errors 0.89 0.60 0.08 1.00 0.79 0.33 
NART Predicted IQ 0.74 0.60 0.06 0.93 0.65 0.29 
Di it Span . 0.23 0.58 0.16 0.98 0.31 0.88 
PASAT (2.4-seconds) 0.83 0.57 0.86 0.58 0.53 0.34 
PASAT (1.2-seconds) 0.40 0.44 0.32 0.80 0.70 0.73 
* Significant difference between groups (p< 0.05) 
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Table 7.17b: Mean scores for significant results on Mann-Whitney tests (MMSE) 
Mean score for cases 
Neuropsychological test `Any record of CHD? ' 
- Yes 
`Any record of CHD? ' 
- No 
MMSE 28.12 28.69 
Table 7.17c: Mean scores for significant results on Mann-Whitney tests (telephone task time 
taken) 
Mean score for cases 
Neuropsychological test `If CHD any Hx angina? T 
Yes 
'If CHD any Hx angina? ' 
No 
MMSE 28.06 28.68 
Telephone task time taken 114.26 98.57 
b) Diabetes 
The results of Mann-Whitney tests are shown in Table 7.18a. There were no significant 
differences between those with and without diabetes for both cases and controls for most 
neuropsychological tests. The only exception to this was the `Map Search 2 °d minute, left', where 
controls with diabetes scored significantly (p=0.028) better than controls without diabetes (14.11 
versus 9.75) (table 7.18b). However there were no significant findings for the other map search 
sub-tests, which we would have expected if this finding were of importance. 
Therefore, overall there was no evidence to suggest that diabetes affects the relationship between 
case status and cognitive function. 
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Table 7.18a : Significance levels (using Mann-Whitney) for the difference in cognitive 
function scores for those (cases and controls) with and without diabetes. 
P-values for difference between those with and without diabetes 
(using Mann- Whitney) 
Control Case 
MMSE 0.33 0.52 
Logical Memory Immediate 
(raw) 
0.66 0.80 
Logical Memory Immediate 
(%) 
0.75 0.82 
Logical Memory Delayed (raw) 0.88 0.66 
Logical Memory Delayed (%) 0.23 0.998 
Rey Complex Figure Copy 0.79 0.91 
Rey Complex Figure Delayed 0.47 0.71 
Map Search (1" Minute, Left) 0.68 0.82 
Map Search (1° Minute, Right) 0.44 0.54 
Map Search (2' Minute, Left) 0.03* 0.41 
Map Search (2 Minute, 
Right) 
0.33 0.77 
Telephone Task No. of Targets 0.11 0.29 
Telephone Task Time Taken 
(seconds) 
0.47 0.38 
Telephone Task Dual Task 
Decrement 
0.50 0.77 
NART No. of Errors 0.99 0.90 
NART Predicted IQ 0.95 0.94 
Digit Span 0.28 0.62 
PASAT (2.4-seconds) 0.68 0.55 
PASAT (1.2-seconds) 0.33 0.31 
* Significant difference between groups (p< 0.05) 
Table 7.18b: Mean scores for significant results on Mann-Whitney tests (Map Search 2nd 
minute, Left) 
Mean score for controls 
Neuropsychological test 'Any record of diabetes? ' 
-Yes 
`Any record of diabetes? ' 
-No 
Map Search 2" minute Left 14.11 9.75 
c) Hypertension 
There were no significant differences between those with and without hypertension (using current 
prescription for hypertension as a proxy for hypertension) for both cases and controls for all 
neuropsychological tests (table 7.19). Therefore, there was no evidence to suggest that 
hypertension affects the relationship between case status and cognitive function. 
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Table 7.19: Significance levels (using Mann-Whitney) for the difference in cognitive function 
scores for those (cases and controls) with and without hypertension. 
P-values for difference between those with and without 
hypertension (using Mann- Whitney) (2dp) 
Control Case 
MMSE 0.52 0.26 
Logical Memory Immediate 
(raw) 
0.995 0.66 
Logical Memory Immediate 
(%) 
0.91 0.53 
Logical Memory Delayed (raw) 0.98 0.98 
Logical Memory Delayed (%) 0.88 0.62 
Rey Complex Figure Copy 0.12 0.94 
Rey Complex Figure Delayed 0.57 0.89 
Map Search (1' Minute, Left) 0.94 0.89 
Map Search (V Minute, Right) 0.33 0.17 
Map Search (2 Minute, Left) 0.75 0.92 
Map Search (2 Minute, 
Right) 
0.27 0.79 
Telephone Task No. of Targets 0.12 0.60 
Telephone Task Time Taken 
(seconds) 
0.32 0.73 
Telephone Task Dual Task 
Decrement 
0.08 0.27 
NART No. of Errors 0.29 0.39 
NART Predicted IQ 0.23 0.36 
Digit Span 0.27 0.88 
PASAT (2.4-seconds) 0.89 0.49 
PASAT (1.2-seconds) 0.51 0.71 
* Significant difference between groups (p< 0.05) 
d) Heart Failure 
The results of Mann-Whitney tests are shown in Table 7.20a. There were no significant 
differences between those with and without heart failure for both cases and controls for most 
neuropsychological tests. 
The only exceptions to this were the `Map Search 2nd minute, left' (cases) , PASAT-2.4 seconds 
(controls) and PASAT-1.2 seconds (controls). For `Map Search 2"a minute, left', cases with heart 
failure scored significantly (p=0.039) better than cases without heart failure (12.10 versus 8.62) 
(table 7.20b). However there were no significant findings for the other map search sub-tests, which 
we would have expected if this finding were of importance. For PASAT-2.4 seconds and PASAT- 
1.2 seconds, the numbers were very small - only 3 controls with heart failure versus 138 controls 
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without, therefore we decided that it was unlikely that heart failure would have an important effect 
on our findings. 
Therefore, overall there was no evidence to suggest that heart failure affects the relationship 
between case status and cognitive function. 
Table 7.20a: Significance levels (using Mann-Whitney) for the difference in cognitive 
function scores for those (cases and controls) with and without proxies for heart failure. 
P-values for difference between those with and without heart 
failure (using Mann- Whitney) (2dp) 
Control Case 
MMSE 0.44 0.86 
Logical Memory Immediate 
(raw) 
0.67 0.09 
Logical Memory Immediate 0.77 0.07 
Logical Memory Delayed (raw) 0.97 0.20 
Logical Memory Delayed (%) 0.37 0.14 
Rey Complex Figure Copy 0.05 0.60 
Rey Complex Figure Delayed 0.78 0.80 
Map Search (1's Minute, Left) 0.29 0.97 
Map Search (1" Minute, Right) 0.32 0.91 
Map Search (2 Minute, Left) 0.67 0.04* 
Map Search (2 Minute, 
Right) 
0.58 0.95 
Telephone Task No. of Targets 0.08 0.96 
Telephone Task Time Taken 
(seconds) 
0.06 0.36 
Telephone Task Dual Task 
Decrement 
0.16 0.32 
NART No. of Errors 0.18 0.16 
NART Predicted IQ 0.18 0.18 
Digit Span ý 0.13 0.15 
PASAT (2.4-seconds) 0.01 * 0.45 
PASAT (1.2-seconds) 0.05* 0.16 
* Significant difference between groups (p< 0.05) 
Table 7.20b: Mean scores for significant results on Mann-Whitney tests (Map Search 2°a 
minute, Left) 
Mean score for controls 
Neuropsychological test Heart failure? 
-Yes 
Heart failure? 
-No 
Map Search 2 minute, Left 12.10 8.62 
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J) Cholesterol (Table 7.21) 
For nearly all neuropsychological tests and for both cases and controls, there were no significant 
correlations between cholesterol level and test score. The only exceptions to this were for Rey 
Complex Figure Delayed (controls) and telephone task time taken (cases) where the correlation 
was statistically significant (0.012 and 0.032 respectively). However, for both of these tests, the 
correlation coefficient itself was very small (-0.198 and -0.184) therefore these findings are not 
clinically important. Overall, there is no evidence to suggest that cholesterol confounds the 
relationship between case status and cognitive function. 
Table 7.21: Spearman's Correlation for the effect of cholesterol on test scores for cases and 
controls. 
Cases (2d) Control s (2d p) 
Neuropsychological Test 
- 
Spearman's 
Correlation 
p-value for 
Spearman 's 
Correlation 
Spearman's 
Correlation 
p-value for 
Spearman 's 
Correlation 
MMSE 0.07 0.42 -0.02 0.77 
Logical Memory Immediate (raw) 0.05 0.53 -0.11 0.16 
Logical Memory Immediate (%) 0.06 0.52 -0.10 0.21 
Logical Memory Delayed (raw) 0.08 0.34 -0.03 0.76 
Logical Memory Delayed (%) 0.08 0.38 -0.05 0.54 
Rey Complex Figure Copy 0.04 0.63 -0.04 0.59 
Rey Complex Figure Delayed 0.06 0.50 -0.20 0.01* 
Ma Search 1"Minute, Left) 0.11 0.18 0.012 0.88 
Map Search 1" Minute, Right) 0.05 0.56 0.01 0.95 
Map Search (2 Minute, Left) -0.10 0.24 -0.05 0.52 
Map Search (2 Minute, Right) 0.15 0.07 0.04 0.61 
Telephone Task No. of Targets 0.08 0.35 -0.09 0.26 
Telephone Task Time Taken -0.18 0.03* 0.04 0.61 
Telephone Task Dual Task 
Decrement -0.09 
0.29 0.01 0.86 
NART No. of Errors -0.10 0.26 0.05 0.50 
NART Predicted IQ 0.10 0.23 -0.09 0.28 
Digit Span 0.02 0.81 -0.07 0.41 
PASAT (2.4-seconds) 0.02 0.85 -0.12 0.12 
PASAT (1.2-seconds) -0.01 0.92 -0.06 0.45 
* Significant difference between groups (p< 0.05) 
7.30 
g) Health status (Table 7.22) 
As described previously, SF-36 raw scores were transformed into the seven `domains' of health 
status (physical activity, role-physical, bodily pain, general health, vitality, emotion, mental health). 
Mann-Whitney tests demonstrated that cases and controls had significantly different scores in that 
cases had poorer scores than controls on all analysed components of the SF-36 form (limited 
physical activities due to health (p<0.001), problems in the last 4 weeks due to physical (p<0.001) 
and emotional (p<0.001) health, perspective on general health (p<0.01) and in comparison to 
others (p<0.001)); except for pain, where a poorer score in cases was non-significant (p=0.1). 
Table 7.22: Mean transformed SF-36 scores for cases and controls for each of the seven SF- 
36 domains (2dp) 
Mean transformed SF-36 score (SD) P-values for 
SF-36 domain Controls Cases 
difference between 
cases and controls 
(using Mann- 
Whitney) 
Physical Functioning 66.21 (28.96) 50.86 (30.00 0.00* 
Role Physical 71.51(37.77) 56.54 (40.25) 0.00* 
Bodily Pain 65.86 (25.58) 58.63 (28.75) 0.12 
General health 62.66 (18.54 56.58 (21.33) 0.01* 
Vitality 67.83 (19.74) 59.08 (26.81) 0.00* 
Role Emotional 89.31 (28.74) 77.90 (36.89) 0.00* 
Mental health 71.57 (12.11) 66.68 (14.51) 0.00* 
Significant difference between groups (p5 0.05) 
Spearman's correlations were then performed to determine whether these differences had an 
impact on the relationship between case status and cognitive function test score. 
There was very little relationship between transformed SF-36 scores and neuropsychological test 
scores for both cases and controls. The greatest correlation was for SF-36 and sub-test `telephone 
task time taken'; however even for this sub-test the correlations were very weak, with the largest 
coefficient being -0.281(pß. 00). 
Therefore overall, there was no evidence to suggest that SF-36 transformed score counfounds the 
relationship between case status and cognitive function. 
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h) Education 
Spearman's correlations for education (age at leaving continuous full-time education) are shown in 
table 7.23. Although there a number of statistically significant correlations, the correlation 
coefficients are small, with the largest being -0.329. In addition, similar proportions of cases 
(62.3%) and controls (68.3%) completed their education at 14 years or under. This suggests that 
education is unlikely to significantly affect the relationship between case status and cognitive 
function. Nonetheless, this analysis has identified a potential source of confounding and therefore 
adjustment for education was made in subsequent analyses of cognitive function for cases and 
controls. 
Table 7.23: Spearman's Correlation for the effect of education on test scores for cases and 
controls. (2dp) 
Cases Con trols 
Neuropsychological Test Spearman's 
Correlation 
p-value for 
Spearmans 
Correlation 
Spearman's 
Correlation 
p-value for 
Spearman's 
Correlation 
MMSE 0.21 0.005* 0.26 0.00* 
Logical Memory Immediate (raw) 0.19 0.01* 0.13 0.07 
Logical Memory Immediate (%) 0.16 0.04* 0.10 0.18 
Logical Memory Delayed (raw) 0.16 0.03* 0.20 0.008* 
Logical Memory Delayed (%) 0.11 0.17* 0.13 0.09 
Rey Complex Figure Copy 0.23 0.002* 0.14 0.07 
Rey Complex Figure Delayed 0.16 0.03* 0.23 0.002* 
Map Search (V Minute, Left) 0.06 0.41 0.26 0.00* 
Map Search (1'` Minute, Right) 0.09 0.23 0.05 0.52 
Map Search (2 Minute, Left) 0.05 0.53 0.05 0.50 
Map Search (2 Minute, Right) 0.10 0.17 0.07 0.32 
Telephone Task No. of Targets 0.05 0.49 0.09 0.24 
Telephone Task Time Taken -0.15 0.05 -0.23 0.002* 
Telephone Task Dual Task 
Decrement -0.10 
0.19 -0.09 0.23 
NART No. of Errors -0.30 0.00* -0.33 0.00* 
NART Predicted IQ 0.30 0.00* 0.31 0.00* 
Digit Span 0.25 0.001* 0.12 0.11 
PASAT (2.4-seconds) 0.19 0.01* 0.28 0.00* 
PASAT (1.2-seconds) 0.09 027 0.05 0.54* 
* Significant difference between groups (p< 0.05) 
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Summary of case/ control confounder analysis 
Key confounders (CHD, diabetes, hypertension, heart failure, cholesterol and health status) had 
little effect on cognitive function for both cases and controls. Therefore there is no evidence that 
these variables will affect the conclusions derived from the age-adjusted comparisons between 
cases and controls. The one exception to this was education, which demonstrated a significant, 
though small effect on cognitive function for both cases and controls on some sub-tests. Therefore 
adjustment for education was made on subsequent analyses of neuropsychological test results for 
cases and controls. 
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3. Assessment of key confounders as covariates to investigate their effect on the 
relationship between treatment subgroups (aspirin/ warfarin/ neither) and 
cognitive function. 
Finally, it was necessary to determine whether or not the key confounders had an effect on the 
(age-adjusted) relationships already described between cognitive function and the five subgroups 
on aspirin, warfarin or neither treatment (case warfarin (n=89), case aspirin (n=61), case neither 
(n=25), control aspirin (n=56), control neither (n=131)). As for the case/control analyses, this was 
done using non-parametric tests. For categorical variables, Mann-Whitney tests were performed to 
determine whether or not there were significant differences between subgroups when the 
confounding variable was incorporated into the model as a covariate. Where a significant 
1 1, 
'I 
difference was found, the frequencies of the confounding variables for subgroups were examined 
to determine the actual difference between the five groups. For continuous variables, Spearman's 
and Pearson's correlations were used. Most of the tables for the subgroup confounding analyses are 
not shown here since five subgroups generated vast tables which would be difficult to follow in a 
thesis such as this. 
a) Coronary Heart Disease 
Mann-Whitney tests demonstrated few significant differences between those with and without 
proxies for CHD in all five subgroups for most neuropsychological tests. The only statistically 
significant differences were that: controls (not on aspirin or warfarin) without CHD performed 
significantly (p=0.043) better than controls (not on aspirin or warfarin) with CHD (mean 9.84 
versus 5.53) on map search TO minute right; controls (not on aspirin or warfarin) without CHD 
performed significantly (p=0.015) better than controls (not on aspirin or warfarin) with CHD on 
telephone task time taken (mean 91.61 versus 110.07 seconds); aspirin cases without CHD 
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performed significantly (p=0.033) better than aspirin cases with CHD on NART errors (mean 
20.00 versus 25.36); and aspirin cases with CHD performed significantly (p=0.039) better than 
aspirin cases without CHD on NART IQ (mean 106.09 versus 99.36). When `if CHD, any record 
of angina? ' rather than `any record of CHD? ' was used as a proxy variable, an identical pattern 
emerged with the same subgroups showing significant differences on the same (few) tests. When 
the variable `if CHD, any record of MI? ' was used, a different pattern emerged, with the only 
significant differences being that: controls (not on aspirin or warfarin) with MIs performed 
significantly (p=0.048) better than controls (not on aspirin or warfarin) without MIs (mean 41.90 
versus 25.44) on the Logical Memory immediate (%); aspirin controls with MIs performed 
significantly (p=0.041) better than aspirin controls without MIs (mean 79.60 versus 96.34 seconds) 
on the telephone task time taken; (%); aspirin controls with MIs performed significantly (p=0.031) 
better than aspirin controls without MIs (mean 28.70 versus 27.71) on the MMSE; aspirin cases 
without MIs performed significantly (p=0.039) better than aspirin cases with MIs (mean 21.19 
versus 27.33) on NART errors. 
These findings are not consistent in that we would expect any significant differences to be found in 
similar neuropsychological tests for all proxies of CHD, and probably also within the same 
cognitive domains. 
It is unlikely that these findings would affect the conclusions drawn from the age-adjusted 
comparisons of the five subgroups, since only telephone task time taken was significant for that 
analysis, where aspirin cases performed significantly worse than controls (not on aspirin or 
warfarin) and aspirin controls, and only controls (not on aspirin or warfarin) were significant for 
`telephone time taken' when analysed here. In addition, some of the subgroups (particularly `cases 
-not on aspirin or warfarin', n=25) contained very small samples, making interpretation difficult. 
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b) Diabetes 
Mann-Whitney tests demonstrated no significant differences between those with and without 
diabetes for all five subgroups for most neuropsychological tests. The only exception to this was 
that cases (not on aspirin or warfarin) with diabetes performed significantly better than cases (not 
on aspirin or warfarin) without diabetes for: Logical Memory Immediate (raw) (p=0.007, mean 
18.75 versus 11.67); Logical Memory Immediate (%) (p=0.007, mean 44.75 versus 14.81); Logical 
Memory Delayed (raw) (p=0.004, mean 18.25 versus 7.33); and Logical Memory Delayed (%) 
(pß. 004, mean 66.50 versus 25.90). 
However, the numbers in this subgroup were very small, with only 4 cases (not on aspirin or 
warfarin) who had diabetes. This makes interpretation of these findings difficult. In addition, since 
there were no significant differences between subgroups when they were compared for cognitive 
function with adjustment for age only (on all tests except for telephone test time taken), it is 
unlikely that this would be affected by our finding of possibly better performance in the logical 
memory subtests for cases (not on aspirin or warfarin) with diabetes. 
c) Hypertension 
Mann-Whitney tests demonstrated no significant differences between those with and without 
hypertension for all five subgroups for all neuropsychological tests. The only exception to this was 
that warfarin cases without hypertension performed significantly (p=0.047) better than warfarin 
cases with hypertension, although the difference between actual mean scores was very small (18.54 
versus 17.44). Therefore it is unlikely that hypertension confounds the relationship between 
subgroup and cognitive function. 
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d) Heart failure 
Mann-Whitney tests demonstrated no significant differences between those with and without heart 
failure for all five subgroups for all neuropsychological tests. The only exception to this was that 
controls (not on aspirin or warfarin) without heart failure performed significantly (p=0.034) better 
than controls (not on aspirin or warfarin) with heart failure, with means of 29.73 versus 5.00. 
However, there were only two controls (not on aspirin or warfarin) with heart failure, therefore it is 
difficult to interpret these findings. Overall, it is unlikely that heart failure confounds the 
relationship between subgroup and cognitive function. 
e) Duration of AF (cases only) 
Spearman's correlations were performed to assess the relationship between duration of AF and 
cognitive function for the three subgroups. The only statistically significant correlation (p=0.021) 
was for warfarin cases, where there was a correlation with telephone task time taken. However, the 
correlation coefficient was small (Rho = 0.245). 
Overall, duration of AF did not appear to confound the conclusions derived from the age-adjusted 
comparisons of the three subgroups. 
J) Cholesterol 
Spearman's correlations were performed to assess the relationship between cholesterol and 
cognitive function for the five subgroups. Most correlations were small and not significant. The 
few exceptions to this were: aspirin cases showed a correlation between cholesterol level and map 
search - 2nd minute right score (p=0.001, Rho =0.460); aspirin controls showed a correlation 
between cholesterol level and total immediate raw score (p=0.042, Rho= -0.292); aspirin controls 
7.37 
showed a correlation between cholesterol level and Rey complex figure delayed score (p=0.017, 
Rho= -0.339); aspirin controls showed a correlation between cholesterol level and PASAT-2.4 
seconds (p=0.033, Rho= -0.304); and cases (not on aspirin or warfarin) showed a correlation 
between cholesterol and Rey complex figure copy score (p=0.029, Rho = -0.501). The correlation 
coefficients were small and there was no consistent pattern across tests measuring the same domain 
or within one of the five subgroups. 
Overall, there appears to be no effect of cholesterol level on the relationship between subgroup and 
cognitive function. 
g) Health Status 
Spearman's correlations were performed to assess the relationship between each of the SF-36 
domains (physical functioning, role-physical, bodily pain, general health, vitality, role emotional, 
{ 
mental health) and each of the neuropsychological tests for all five subgroups. The majority of 
correlations for most of the neuropsychological tests for nearly all subgroups were not statistically 
significant. Despite a considerable number of statistically significant correlations (table 7.24), only 
a minority have a reasonably large correlation coefficient (Rho >+/- 0.4) implying a noteworthy 
correlation, and these are shown in table 7.24. Interpretation of these findings is difficult. Such 
correlations were present for: vitality with MMSE and PASAT-2.4 (cases - not on aspirin or 
warfarin); emotion with telephone task time taken (aspirin controls); mental health with logical 
memory immediate raw, immediate %, delayed raw (aspirin cases and controls); mental health 
with logical memory delayed % (aspirin controls); and mental health with Rey copy and telephone 
task decrement (cases - not on aspirin or warfarin). All of these correlations were in the same 
direction, such that the `healthier' and `happier' SF-36 score correlated with better cognitive 
function. It is therefore possible that the cognitive function of subgroups is weakly associated with 
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SF-36 score. However, since the great majority of correlations were very weak and non-significant 
(therefore not shown here), our findings here do not provide strong evidence for a confounding 
effect of health status on the relationship between subgroup and cognitive function at baseline. 
Table 7.24: Spearman's correlation and p-values for subtests with significant (p <0.05) 
correlation between health status and cognitive function for subgroups. (2dp) 
Neuropsycholog Spearman's p-value 
for 
' SF-36 domain Subgroup ical Test Correlation Spearman s Coefficient correlation 
Case - not on MMSE Vitality aspirin or 0.42* 0.04 
warfarin 
Case -not on PASAT-2.4 Vitality aspirin or 0.42* 0.04 
warfarin 
Emotion Aspirin Control 
Telephone Task 
Time Taken -0.41* 0.002 
Mental Health Aspirin Case Logical Memory 0.46* 0.00 Immediate (raw) 
Mental Health Aspirin Case Logical Memory 0.45* 0.00 Immediate (%) 
Mental Health Aspirin Case ry Logical M em 0.44* 0.00 ) Delay 
Mental Health Aspirin Control Logical Memory 0.49* 0.00 
Immediate (raw) 
Mental Health Aspirin Control Logical 
Memory 0.50* 0.00 
Immediate (%) 
Mental Health Aspirin Control Logical Memory 0.57* 0.00 Delayed (raw) 
Mental Health Aspirin Control Logical Memory 0.47* 0.00 Delayed (%) 
Mental Health Aspirin Control Telephone Task -0.55* 0.00 Time Taken 
Mental Health Aspirin Control NART No. of -0.52* 0.00 Errors 
Mental Health Aspirin Control NART Predicted 0.44* 0.001 IQ 
Mental Health Aspirin Control PASAT (2.4- 0.48* 0.00 
seconds) 
Case - not on Rey Complex Mental Health aspirin or Figure Copy 0.42* 0.04 
warfarin 
Case - not on Telephone Task Mental Health aspirin or Dual Task -0.64* 0.001 
warfarin Decrement 
*Rho > +/- 0.4 
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h) Education 
Spearman's correlations were performed to assess the relationship between education ('age at 
leaving continuous full-time education) and cognitive function for the five subgroups. The majority 
were not significant. However, of the significant correlations, only those for NART errors and 
NART IQ (aspirin cases) were large enough to be noted (Rho > +/- 0.4). Only those which are 
were significant and of notable size are shown in table 7.25. Here, aspirin cases showed significant 
correlation between leaving school at an older age and performing better on this 
neuropsychological test. Since the remainder of subtests showed no noteworthy correlations 
however, these findings do not provide strong evidence to suggest that education confounds the 
relationship between subgroup and cognitive function. 
Table 7.25: Spearman's correlation and p-values for subtest s with significant (p <0.05) 
correlation between education and cognitive function for subgroups. (2dp) 
Neuropsychological Spearman's p-value for ' Subgroup Test Correlation Spearman s Coefficient correlation 
Aspirin Case NART No. of Errors -0.46* 0.00 
Aspirin Case NART Predicted IQ 0.45* 0.00 
*Rho > +/- 0.4 
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Summary of subgroup confounder analysis 
Assessment of key potential confounders (CHD, diabetes, hypertension, heart failure, cholesterol, 
and health status) through incorporation of the confounding variable into the model as a covariate 
demonstrated no strong evidence that any of the variables affected the conclusions derived from 
age-adjusted comparisons between subgroups of cases and controls on aspirin/ warfarin/ neither. 
This analysis was limited, however, by small subgroup samples (particularly cases not on aspirin 
or warfarin) which became even smaller once they were divided into those with and without 
potentially confounding variables. 
"' f 
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Stratification according to stroke risk 
1) `Descriptive statistics 
Descriptive statistics for stroke risk for the CAFE cohort according to SPAF55,58,63,69 
criteria are described in Table 7.26 and 7.27. Similar distributions of level of stroke risk 
were present for treatment subgroups. Since SPAF criteria are for assessing those with 
NVAF, only cases were included in this analysis. 
Table 7.26: Stroke risk stratification in the CAFE cohort according to SPAF criteria 
(cases only) 
Stroke risk CAFE cohort % (all cases) 
High risk 52.6 
Intermediate risk 15.6 
Low risk 31.8 
Table 7.27: Stroke risk stratification in the CAFE cohort according to SPAF criteria 
(cases only - treatment subgroups) 
Stroke Risk CAFE cohort % 
Aspirin Cases Warfarin Cases Cases (not on 
warfarin or aspirin) 
High risk 56.7 44.3 68.0 
Intermediate 
risk 
11.7 19.3 12.0 
Low risk 31.7 36.4 20.0 
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2) Comparison of neuropsychological test scores 
ANOVA techniques were used to compare the mean neuropsychological test score at 
baseline according to stroke risk (Table 7.28). There were no significant differences in test 
score between those of high, intermediate and low stroke risk. 
Therefore, interpreting these findings, there does not appear to be convincing evidence of a 
pattern suggesting a relationship between stroke risk (according to SPAF criteria) and 
performance on neuropsychological tests at baseline for cases in NVAF. 
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Table 7.28: Comparison of mean neuropsychological test score at baseline according 
to stroke risk (using SPAF criteria) for cases only (2dp) 
N h l i l Mean test score according to stroke risk europsyc o og ca 
test High risk 
Intermediate Low risk 
P-value 
MMSE 28.66 28.22 28.22 0.21 
Logical Memory 14.23 16.11 13.42 0.15 
(immediate, raw) 
Logical Memory 24.35 32.52 20.64 0.09 
(immediate, %) 
Logical Memory 10.47 12.07 10.71 0.56 
(delayed, raw) 
Logical Memory 35.85 42.41 33.84 0.34 
(delayed, %) 
Rey Complex (copy) 31.67 32.43 31.91 0.74 
Rey Complex 12.20 13.02 12.79 0.79 
(delayed) 
Map Search (1S` 15.89 15.67 16.07 0.98 
Minute, Left) 
Map Search (ls` 5.31 3.11 5.35 0.34 
Minute, Right) 
Map Search (2" 9.48 8.85 8.75 0.82 
Minute, Left 
Map Search (2° 8.90 8.37 8.71 0.96 
Minute, Right) 
Telephone Task No. 17.38 17.67 17.36 0.91 
of Targets 
Telephone Task Time 101.38 111.89 104.93 0.55 
Taken 
Telephone Task Dual 6.66 3.56 4.41 0.71 
Task Decrement 
NART No. of Errors 21.41 19.74 23.96 0.16 
NART Predicted IQ 104.22 106.19 101.09 0.18 
Digit Span 13.18 14.15 13.85 0.34 
PASAT (2.4-seconds) 29.75 28.22 30.02 0.89 
PASAT (1.2-seconds) 12.55 13.78 10.11 0.36 
7.44 
Chapter 7 Summary 
"- When neuropsychological test means were compared for cases and controls and for 
subgroups on aspirin, warfarin and neither treatment, there were few significant 
differences when crude data was examined, nor after adjustment for age. Those 
differences which were statistically significant were predominantly small and did not 
suggest important clinically significant differences between groups. 
" Key potential confounders were assessed in the total study population and there was 
little important association between these and performance on neuropsychological 
tests. In addition, the effect of key confounders (as covariates in the model) on the 
conclusions derived from age-adjusted comparisons between cases and controls and 
between subgroups was weak or absent, although the analysis of sub-groups was 
restricted by small numbers. 
" Thus the issue of confounding has been thoroughly examined for the baseline results. 
Therefore confidence can be held in the principal findings that there is no apparent 
relationship between NVAF or treatment subgroup and performance on 
neuropsychological tests at baseline. 
" When the results were stratified according to stroke risk (according to SPAF criteria) 
there was no convincing evidence of a pattern suggesting a relationship between 
stroke risk and performance on neuropsychological tests at baseline for cases in 
NVAF. 
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Chapter 8- Results (III): Follow-up Results - Neurropsychological 
test battery scores 
Statistical Methods 
". Characteristics of responders and non-responders 
" Findings for the total study population 
" Comparison between cases and controls 
o Findings for cases and controls analysed separately 
o Analysis by cognitive domain 
o Analysis comparing differences between cases and controls 
Comparison of sub-groups 
" '- Correlations of repeated neuropsychological tests 
" Examination of potential confounders 
" Stratification according to stroke risk 
" Chapter 8 Summary 
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Statistical methods used: 
Data from baseline and 12-month follow-up interviews and GP notes was combined into a 
single SPSS database. 
i) Responder / non-responder analyses. 
Descriptive statistics (medians since data was non-parametric) were calculated to explore the 
relationship between those who completed the follow-up interview and those who only 
completed baseline interview. The significance of differences between the two groups was 
determined using Mann-Whitney nominal data and Pearson Chi-squared techniques as 
appropriate. 
ii) Comparison of change in neuropsychological test scores over time, for total 
population and between cases and controls. 
Firstly descriptive statistics were calculated for the change in performance on the 
neuropsychological tests for the total study population, incorporating both cases and controls. 
Comparisons were then made of the decline in cognitive function over 12 months, between 
cases and controls. In all calculations, `change in test performance over the follow-up period' 
was the difference between an individual's score at follow-up and their score at baseline: - 
" Due to the non-normal distribution of the data, non-parametric tests were used to 
compare baseline and follow-up neuropsychological test scores. 
" When analysing the results for cases and controls, the change in performance over 
time was firstly analysed at an individual level ('within group' analyses, comparing an 
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individual's performance at 12 month follow-up to their own performance at baseline). 
The most useful way to demonstrate this was through graphical analyses. 
". Analyses of the overall change in performance for each subtest were then undertaken 
for both cases and controls. `Between group' analyses were performed comparing 
mean change in test performance over 12 months between cases and controls. 
Statistical significance of the change in performance was calculated using Wilcoxon 
Signed Rank Test because of the non-parametric nature of the data. This was applied 
to the difference between neuropsychological test scores at baseline and follow-up 
scores for cases and controls separately, in order to further investigate the statistical 
significance of change in performance over time for each group. One-sample t-tests 
were then performed to determine whether any differences noted using Wilcoxon 
signed rank were statistically significant. 
" Differences (in change in performance over the follow-up period) between cases and 
controls were then analysed using Chi-squared tests, by comparing the proportion of 
cases and controls that improved, deteriorated and stayed the same. 
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iii) Comparison of change in neuropsychological test scores over time, between 
treatment subgroups. 
Firstly descriptive statistics were calculated for the change in performance on the 
neuropsychological tests for treatment subgroups (cases on warfarin, cases on aspirin, cases 
on neither treatment, controls on aspirin and controls on neither). Again, in all calculations, 
`change in test performance over the follow-up period' was the difference between an 
individual's score at follow-up and their score at baseline. The subgroups were then 
compared: - 
", Analysis of the overall change in performance for each subtest was then undertaken 
for all treatment subgroups. Again, non-parametric tests were employed. Differences 
,, 
in change in performance over the follow-up period between the five treatment 
subgroups were compared using ANOVA techniques, with and without adjustment for 
age. 
" Chi-squared tests were then used to compare the proportion of cases on aspirin/ 
warfarin/ neither who improved/ deteriorated/ stayed the same. 
" In addition, since more than two groups were analysed, the Kruskal-Wallis test was 
used to further examine these differences, and again statistical significance was tested 
using the Mann-Whitney test for independent groups. 
iv) Neuropsychological test correlations 
In order to explore the extent of change over time for all neuropsychological tests for the total 
study population and for cases and controls, tests of correlation were used. An individual's 
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mean score at baseline was correlated against their own score at 12 month follow-up using 
Pearson's correlation techniques. 
v) Effect of potential confounders 
The effect of age and education on the change in performance on neuropsychological tests 
over the follow-up period was examined using a regression model (analysis of covariance 
general linear model) with age and education as covariates. In addition, Pearson's correlation 
techniques were used to explore the relationship between age at first interview and change in 
score over the follow-up period on each of the neuropsychological subtests for the whole 
study population. The other analyses presented in this chapter were undertaken using crude 
data, without adjustment for confounders. 
vi) Stratification according to stroke risk 
Cases only were stratified according to stroke risk (high, intermediate or low) according to 
SPAF criteria55,58,63,69 as described in Chapter 2. ANOVA and post-hoc tests (including 
Bonferonni adjustments and linear regression) were then used to compare change in 
neuropsychological test score over time between those of different stroke risks. 
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Characteristics of responders and non-responders for follow-up interview: 
Comparisons were made between participants included after baseline interview (n=362) who 
did and did not complete follow-up interview at 12 months (table 8.1). Responders were 
considered as those who were included following the baseline interview and also included 
after follow-up interview (n=305), non-responders were those who were included following 
baseline interview, but were not included at follow-up interview (n=57), either because they 
died (n=16), refused (n=24) or were too ill/ had other miscellaneous reasons for non-response 
(n=17). Comparison between these groups was possible for all variables which had been 
collected during GP notes screening, with key comparisons described here. The notes 
screening process had been designed with consideration of the likely need for these analyses 
We found no significant differences between responders and non-responders for age, sex, 
education or documented co-morbidities (CHD, CHF, hypertension, diabetes, thyrotoxicosis, 
Parkinson's disease, peripheral vascular disease, depression), although the study was not 
powered specifically to explore these characteristics. The only significant differences found 
were that for the SF-36, those who had completed the follow-up visit had higher (better) 
baseline scores than those who were not followed up for the physical functioning (p=0.015), 
role-physical (p=0.043) and general health (p=0.020) domains. 
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Table 8.1: Characteristics of responders and non-responders (2dp) 
Completed follow-up 
interview? 
P-values for 
comparison of 
groups (using 
Mann-Whitney 
Variable Yes (n=304) No (n=57) Total 
(n=361) 
and Chi 
squared 
techniques) 
Median age (years) - male 74.6 75.7 75.0 0.11 
Median age (years) - female 78.2 74.4 77.9 0.20 
Median age (years) - total 76.1 75.6 75.8 0.83 
Coronary Heart Disease (%) 36.5 40.4 37.1 0.58 
Heart Failure (%) 5.9 10.5 6.6 0.20 
Hypertension (%) 36.5 49.1 38.5 0.07 
Diabetes (%) 9.9 12.3 10.2 0.58 
Thyrotoxicosis (%) 1.6 3.5 1.9 0.35 
Parkinson's Disease (% 0.7 0.0 0.6 0.54 
Peripheral Vascular Disease 
(%) 
7.5 8.7 7.7 0.79 
Depression (past history) 
(%) 
10.5 7.0 10.0 0.42 
Depression (current) (%) 3.0 1.8 2.8 0.61 
Ever taken aspirin (%) 46.4 50.9 47.1 0.53 
Ever taken warfarin (%) 24.3 26.3 24.7 0.75 
Left school at 14 years or 
under (%) 
65.4 68.4 65.9 0.75 
No school qualifications 71.1 70.2 70.9 0.76 
Case status of those who 
completed follow-up 
- (% cases) 
46.7 56.1 48.2 0.19 
Daily smokers (%) 11.2 15.8 11.9 0.54 
Daily drinkers (%) 19.1 26.3 20.2 0.33 
SF-36 Physical activity 
(mean score) 
65 60 65 0.02* 
SF-36 Role- physical 
(median score) 
75 50 75 0.04* 
SF-36 Pain (median score) 60 50 75 0.09 
SF-36 General health 
(median score) 
65 55 60 0.02* 
SF-36 Vitality (median 
score) - 
70 65 65 0.11 
SF-36 Emotion (median 
score) 
100 100 100 0.60 
SF-36 Mental Health 
(median score) 
72 72 72 0.26 
*p<0.05 
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Findings for the total study population 
Change in performance on the neuropsychological tests between baseline and follow-up was 
not significant for most tests (table 8.2) when the total study population (cases and controls) 
was analysed without stratification. Only Map search 1" minute right showed significant 
change over the follow-up period. The direction of this change was improvement, supporting 
an explanation that this may be due to practice effects (as described in Chapter 4), and this is 
particularly feasible considering that this is the first of the map search tasks. The lack of any 
significant change in the other three components of the map search subtest also reduces the 
likelihood that this finding is due to clinically significant cognitive change. Overall there is no 
strong evidence to suggest a significant change in performance over time when the total study 
population is analysed as a whole. 
Table 8.2: Change in performance over time for the total population (2dp) 
p-value 
Mean Mean (f/u) Mean Difference 
(using 
(Baseline) (baseline - flu t) Mann- 
Whitney) 
MMSE 28.40 28.49 -0.09 0.94 
Logical 
Memory 14.81 15.78 -1.02 0.92 Immediate, 
(raw) 
Logical 
Memory 25.82 29.74 -4.11 0.70 
Immediate (%) 
Logical 
Memory 10.96 11.28 -0.41 0.13 
Delayed (raw) 
Logical 
Memory 36.98 39.67 -2.98 0.06 
Delayed (%) 
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p-value 
Mean Mean (f/u) 
Mean Difference (using 
(Baseline) (baseline - f/u t) Mann- 
Whitney) 
Rey Complex 31.83 30.32 1.50 0.64 
Figure Copy 
Rey Complex 13.16 12.26 0.89 0.53 
Figure Delayed 
Map Search 
(1st Minute, 16.83 17.66 -0.67 0.02* 
Left) '- 
Map Search 
(1st Minute, 5.25 5.46 -0.24 0.70 
Right) 
Map Search 
(2" Minute, 9.60 7.77 1.85 0.18 
Left 
Map Search 
(2° Minute, 9.20 10.25 -0.93 0.20 
Right) 
Telephone 
Task No. of 17.45 17.85 -0.44 0.93 
Targets 
Telephone 
Task Time 98.48 94.43 4.31 0.69 
Taken ' 
Telephone 
Task Dual 4.38 3.03 1.30 0.70 
Task 
Decrement 
NART No. of 21.50 23.11 -1.73 0.46 Errors 
NART 103.67 102.00 1.90 0.37 
Predicted IQ 
Digit Span 13.76 13.24 0.47 0.83 
PASAT (2.4- 30.05 27.60 2.49 0.97 
seconds) 
PSAT (1.2- 1 12.63 8.50 4.15 0.49 
seconds 
* p<0.05 
t mean differences in scores for individuals were analysed first, then the mean of these mean 
differences was calculated 
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Comparison of cases and controls 
1. Findings for cases and controls analysed separately 
i) Analysis of change over time in individuals 
Firstly, at an individual level, change in performance over the follow-up period varied between 
individuals, in that for each sub-test, some individuals improved and some deteriorated. This is 
demonstrated visually in figure 8.1. Similar patterns were shown for all sub-tests, i. e. similar 
proportions of the population demonstrating improvement and deterioration; although the 
proportion of participants showing no change varied between sub-tests, being greatest for the 
MMSE and least for map search task 1'` minute left. This suggests, as discussed in Chapter 4, that 
sensitivity of the tests to detect change in performance over time may vary between sub-tests, or 
that the subtests measure different cognitive domains, as expected. Alternatively, the variation 
between tests may be due to chance, and further analyses below explore this possibility. 
Fig 8.1. Chart to show summary of MMSE scores changes for individuals over follow-up 
period 
Change in 
MMSE a 
score over 
12 months .2 
-4 
-6 
-e 
Individual patients 
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ii) Analysis of change over time in the population 
Next, population differences were explored. The overall direction of change in test scores 
over the follow-up period was analysed and is described below. This varied widely for both 
cases and controls, in that for both groups, there was an overall improvement in some sub- 
tests and deterioration in others. However, the change in test score was only statistically 
significant (p<0.05) for a proportion of the tests: - 
a) Cases 
When Wilcoxon Signed Rank techniques were used (table 8.3), the mean difference between 
mean score at baseline and mean score at follow-up was statistically significant for: logical 
memory immediate (raw and %), Rey complex figure copy, NART (errors and IQ) and 
PASAT (1.2 seconds). 
Of these statistically significant test results, two subtests (logical memory immediate raw and 
%) showed improvement over the follow-up period, whilst four tests (Rey copy, NART errors, 
NART IQ and PASAT-1.2 seconds) showed deterioration over the follow-up period. 
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Table 8.3: Wilcoxon Signed Rank Test applied to the difference between 
neuro s cnoio ica i test scores at nasenne a na 10110w-up for cases inn 
Neuropsychologi No. No. No. Direction of Predominant 
cal test (negative (positive (ties) change direction 
rank) rank) (follow-up 
minus 
baseline) 
MMSE 38 47 53 No. Improvement 
improving > p=0.37 
No. 
deteriorating 
Logical memory 52 70 16 No. Improvement 
test (immediate, improving > *p=0.01 
raw) No. 
deteriorating 
Logical memory 51 69 17 No. Improvement 
test (immediate, improving > *p=0.04 
%) No. 
deteriorating 
Logical memory 61 62 15 No. Improvement 
test ' improving > p=0.98 
(delayed, raw) No. 
deteriorating 
Logical memory 59 64 14 No. Improvement 
test improving > p=0.60 
(delayed, %) No. 
deteriorating 
Rey (copy) 73 41 24 No. Deterioration 
deteriorating *p=0.00 
No. 
improving 
Rey (recall) 65 65 8 No. Stays same 
deteriorating p=0.20 
No. 
improving 
Map (left, 1st 67 61 7 No. Deterioration 
minute) deteriorating p=0.47 
No. 
improving 
Map (right, 1' 42 49 44 No. Improvement 
minute) improving > p=0.54 
No. 
deteriorating 
Map (left, 2" 67 58 10 No. Deterioration 
minute) deteriorating 'p=O. 18 
>No. 
improving 
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Neuropsychologi No. No. No. Direction of Predominant 
cal test (negative (positive (ties) change direction 
rank) rank) (follow-up 
minus 
baseline) 
Map (right, nd 64 58 13 No. Deterioration 
minute) deteriorating p=0.77 
No. 
im ng 
Telephone task 54 51 32 No. Deterioration 
(no. of targets) deteriorating p=0.69 
No. 
improving 
Telephone task 73 62 2 No. Improvement 
(time taken) improving > p=0.22 
No. 
deteriorating 
Telephone task 72 60 2 No. Improvement 
(dual task improving > p=0.19 
decrement) No. 
deteriorating 
NART (no. of 37 88 13 No. Deterioration 
errors) deteriorating *p=0.00 
No. 
improving 
NART (IQ) 87 36 13 No. Deterioration 
deteriorating *p=0.00 
No. 
improving 
Digit span 71 49 17 No. Deterioration 
deteriorating p=0.06 
No. 
improving 
PASAT (2.4- 71 57 7 No. Deterioration 
seconds) deteriorating p=0.08 
No. 
improving 
PASAT (1.2- 65 31 40 No. Deterioration 
seconds) deteriorating *p=0.00 
No. 
improving 
*p<0.05 
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b) Controls 
When Wilcoxon Signed Rank techniques were used (table 8.4), the mean difference between 
mean score at baseline and mean score at follow-up was statistically significant (p<0.05) for 
the same sub-tests as for cases: logical memory immediate (raw and %), Rey complex figure 
copy, NART (errors and IQ), digit span and PASAT (1.2 seconds); but also showed 
significant change in Rey complex figure delayed, map search (1S` minute left, 2°d minute left 
and 2nd minute right), telephone task (time taken and dual task decrement) and PASAT (2.4 
seconds). 
For controls, of the statistically significant test results, eight tests (logical memory immediate 
raw, logical memory immediate %, logical memory delayed raw, logical memory delayed %, 
map left ls` minute, map right second minute, telephone time taken, telephone dual task 
decrement) showed improvement over the follow-up period, and eight tests (Rey copy, Rey 
recall, map left 2°d minute, NART errors, NART IQ, Digit span, PASAT-2.4 seconds, 
PASAT-1.2 seconds) demonstrated deterioration. 
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Table 8.4: Wilcoxon Signed Rank Test applied to the difference between 
neuropsychological test scores at baseline and follow-up for controls (2dp) 
Neuropsychologi No. No. No. Direction of Predominant 
cal test (negative (positive (ties) change direction 
rank) rank) (follow-up 
minus 
baseline) 
MMSE 45 57 54 No. Improvement 
improving > p=0.42 
No. 
deteriorating 
Logical memory 56 82 18 No. Improvement 
test (immediate, improving > *p=0.03 
raw) No. 
deteriorating 
Logical memory 55 79 22 No. Improvement 
test 
, 
improving > *p=0.03 
(immediate, %) No. 
deteriorating 
Logical memory 54 80 22 No. Improvement 
test improving > *p=0.03 
(delayed, raw) No. 
deteriorating 
Logical memory 52 83 21 No. Improvement 
test improving > *p=0.002 
(delayed, %) No. 
deteriorating 
Rey (copy) 82 50 24 No. Deterioration 
deteriorating *p=0.002 
No. 
improving 
Rey (recall) 83 66 70 No. Deterioration 
deteriorating *p=0.02 
>No. 
improving 
Map (left, 1" 58 87 11 No. Improvement 
minute) improving > *p=0.01 
No. 
deteriorating 
Map (right, 1s` 51 55 50 No. Improvement 
minute) improving > p=0.997 
No. 
deteriorating 
Map (left, 2° 89 53 14 No. Deterioration 
minute) deteriorating *p=0.00 
No. 
improving 
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Neuropsychologi No. No. No. Direction of Predominant 
cal test (negative (positive (ties) change direction 
rank) rank) (follow-up 
minus 
baseline) 
Map (right, 2° 52 85 19 No. Improvement 
minute) improving > *p=0.03 
No. 
deteriorating 
Telephone task 62 58 34 No. Deterioration 
(no. of targets) deteriorating p=0.86 
No. 
improving 
Telephone task 82 66 6 No. Improvement 
(time taken) improving > *p=0.02 
No. 
deteriorating 
Telephone task 93 58 2 No. Improvement 
(dual task improving > *p=0.03 
decrement) No. 
deteriorating 
NART (no. of 42 94 17 No. Deterioration 
errors) deteriorating *p=0.00 
No. 
improving 
NART (IQ) 93 42 17 No. Deterioration 
deteriorating *p=0.00 
No. 
im ing 
Digit span 72 51 32 No. Deterioration 
deteriorating *p=0.008 
> 
No. 
improving 
PASAT (2.4- 82 64 10 No. Deterioration 
seconds) deteriorating *p=0.06 
No. 
improving 
PASAT (1.2- 67 41 46 No. Deterioration 
seconds) deteriorating *p=0.001 
No. 
improving 
*p = statistically significant (p<0.05) 
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c) Summary of findings for cases and controls analysed separately 
When the overall change in performance on neuropsychological test was analysed for cases, a 
statistically significant (p<0.05) overall improvement was found in two subtests, with 
deterioration in four subtests. Controls showed improvement and deterioration in the same 
sub-tests as for cases, but also showed improvement in a further six subtests and deterioration 
in a further four subtests (table 8.5). Therefore, although the overall pattern is of improvement 
in more subtests in controls than cases, there is also deterioration in more subtests in controls 
than cases; this is not consistent with the expected effect of AF on cognitive decline, and 
these findings are not consistent with an overall deterioration in performance associated with 
NVAF. 
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Table 8.5: Significant changes in scores based on Wilcoxon Rank Sum analysis - cases 
and controls 
Direction of change in score of neuropsychological subtests 
Significant* improvement in scores Significant* deterioration in 
scores 
Neuropsychological test p-value Neuropsychological p-value 
test 
Cases ' a) Logical memory test 0.010* a) Rey (copy) <0.001* 
(immediate, raw) b) NART (errors) <0.001* 
b) Logical memory test <0.001* c) NART (IQ) <0.001* 
(immediate, %) d) PASAT (1.2- <0.001 * 
seconds) 
Controls a) Logical memory test 0.03* a) Rey (copy) 0.002* 
(immediate, raw) b) NART (errors) <0.001* 
b) Logical memory test 0.03* c) NART (IQ) <0.001* 
(immediate, %) d) PASAT (1.2-secs) 0.001* 
c) Logical memory test 0.033* e) Rey (recall) 0 015* 
(delayed, raw) f) Map (left, 2°d . <0.001 * d) Logical memory test 0.002* minute) 
(delayed, %) 
g) Digit span 0.008* e) Map (left, 1 minute) 
f) Map (right, 2°d minute) 
0.011* h) PASAT (2.4-secs) 0.059* 
g) Telephone task (time 
0.026* 
taken) 0.018* 
h) Telephone task (dual 0.025* 
task decrement) 
*p = statistically significant (p<0.05) 
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2. Analysis by cognitive domain 
Subtests which measured the same cognitive domain were grouped together (table 8.6). The 
overall direction of change (i. e. whether there was improvement or deterioration over the 
follow-up period) varied between subtests which assessed the same cognitive domain. Any 
change in performance would be expected to be cognitive domain-specific and represented in 
all tests evaluating that domain (see chapter 5). In addition, as with previous analyses, most 
changes in performance over the follow-up period were not statistically significant. 
Table 8.6: Analysis of change in test scores by cognitive domain 
Neuropsychological Improvement or Cognitive Domain deterioration? 
test Cases Controls 
Logical immediate raw Improvement Improvement 
Verbal Logical immediate % Improvement Improvement 
short-term 
Logical delayed raw NS Improvement 
Memory Logical delayed % NS Improvement 
Digit span subtest NS Deterioration 
Non-verbal Rey complex copy Deterioration Deterioration 
Rey complex delayed NS Deterioration 
Map search test 1St min rt. NS Improvement 
Map search test Pt min It. NS NS 
Selective Map search test 2°d min rt. NS Deterioration 
Map search test 2"d min It. NS Improvement 
Attention Telephone task no. targets NS NS 
Telephone task time taken NS Improvement 
Divided/ Telephone dual task NS Improvement 
Sustained decrement 
General PASAT -1.2 seconds NS Deterioration 
PASAT -2.4 seconds Deterioration Deterioration 
Premorbid NART errors Deterioration Deterioration 
Intelligence NART IQ Deterioration Deterioration 
General MMSE NS NS 
cognitive 
function 
Information PASAT -1.2 seconds NS Deterioration 
processing PASAT -2.4 seconds Deterioration Deterioration 
NS = not significant (p>0.05) 
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3. Analysis comparing differences between cases and controls 
The difference between change in test score over the follow-up period for cases and controls 
was analysed using Chi squared techniques (table 8.7). There were no statistically significant 
differences between the proportion of cases and controls that improved, deteriorated or stayed 
-the same for each subtest over the 12-month follow-up period. This suggests that there is no 
meaningful difference in change in performance on neuropsychological tests between cases 
and controls. 
Table 8.7: Difference between change in test score of cases and controls 
Neuropsychological 
Mean Difference (SD) in 
performance over follow-up 
Chi- squared statistic (p- 
test period (baseline - flu) 
value) for difference 
between cases and controls 
Cases Controls 
MMSE 0.10 -0.07 
0.46 (0.79) 
Logical Memory 
-1.01 -1.05 
0.11 (0.95) 
Immediate (raw) 
Logical Memory 
-3.86 -4.32 
0.27 (0.89) 
Immediate (%) 
Logical Memory 0.03 -0.80 
2.94 (0.23) 
Delayed (raw) 
Logical Memory 
-0.89 -4.81 
3.08 (0.22) 
Delayed (%) 
Rey Complex 1.70 1.32 0.31 (0.86) Figure Copy 
Rey Complex 0.66 1.09 1.17 (0.56) 
Figure Delayed 
Map Search (1st 0.76 -1.91 
4.61 (0.10) 
Minute, Left) 
Map Search (1st 
-0.55 0.03 
0.09 (0.96) 
Minute, Right) 
Map Search (2°d 1.04 2.56 2.49 (0.29) 
Minute, Left 
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Mean Difference (SD) in 
performance over follow-up 
period (baseline - flu) 
Cases Controls 
Map Search (2°a 
-0.31 -1.47 
6.0 (0.50) 
Minute, Right) 
Telephone Task 
-0.088 -0.75 
0.7 (0.97) 
No. of Targets 
Telephone Task 3.86 4.71 1.70 (0.44) 
Time Taken 
Telephone Task 1.46 (0.48) 
Dual Task 2.99 -0.19 
Decrement 
NART No. of -1.69 -1.76 
0.28 (0.87) 
Errors 
NART Predicted 2.63 1.25 0.31 (0.86) 
IQ 
Digit Span 0.34 0.59 
3.54 (0.17) 
PASAT (2.4- 2.60 2.39 
0.22 (0.90) 
seconds) 
PASAT (1.2- 4.61 3.74 
1.02 (0.60) 
seconds) 
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Analysis of subgroups according to antithrombotic therapy 
Chi-squared tests (table 8.8) showed no statistically significant differences in most 
neuropsychological test scores, between cases on aspirin, warfarin or neither treatment. The one 
exception was for the performance on PASAT-2.4 seconds for cases only, where more cases on 
aspirin deteriorated than improved, whilst equal numbers of cases on warfarin/ neither improved 
nor deteriorated. 
The Kruskal-Wallis test was used to examine the differences in performance on 
neuropsychological test between all five subgroups (table 8.9), and showed no significant 
changes for any test over the test period, except for map search Ist minute left (p=0.037). 
Examining the rank data for this subtest, the greatest change in performance over time was for 
aspirin cases, and the least was for controls on neither aspirin or warfarin. Overall, there is no 
strong evidence for an association between treatment subgroup and cognitive decline. 
Table 8.8: Differences in change in test score between treatment subgroups 
Mean Difference in performance over follow- Chi- squared 
up period (baseline - flu) (2dp) statistic (p- 
l f ue) or va 
Neuropsyc. test to 0 ö ° difference 
y ý" o 00" yr- between 
treatment 
c subgroups 
MMSE -0.21 -0.24 -0.04 -0.08 -0.65 13.2 (0.10) 
Logical Memory -1.04 -1.41 -1.16 -1.01 0.50 4.6 (0.33) 
Immediate (raw) 
Logical Memory -5.61 -4.49 -6.05 -3.67 2.45 2.9 (0.58) 
Immediate (%) 
Logical Memory -0.42 0.00 -0.86 -0.75 1.20 1.75 (0.78) 
Delayed (raw) 
Logical Memory -2.91 -0.74 -3.91 -5.16 3.35 1.6 (0.81) 
Delayed (%) 
8.22 
Mean Difference in performance over follow- Chi- squared 
up period (baseline - flu) statistic (p- 
value) for 
Neuropsyc. test y y ö °ö difference 
y; = ;" 0 o- to y between 
: "ý yy o treatment 
subgroups 
Rey Complex 1.48 1.89 3.00 0.65 1.55 4.65 (0.33) 
Figure Copy 
Rey Complex 1.13 0.49 0.84 1.20 0.20 1.60 (0.81) 
Figure Delayed 
Map Search (1st 2.89 -0.51 -0.68 -2.65 0.60 5.50 (0.24) 
Minute, Left) 
Map Search (1s` -0.68 -0.90 -0.34 0.32 1.00 2.72 (0.61) 
Minute, Right) 
Map Search (2°d 0.18 1.38 4.23 2.08 1.70 0.76 (0.94) 
Minute, Left 
Map Search (2°d 1.36 -0.90 -1.27 -1.77 -1.90 3.13 (0.54) 
Minute, Right) 
Telephone Task -0.65 0.25 -2.67 -0.13 0.00 10.6 (0.32) 
No. of Targets 
Telephone Task 3.99 5.23 0.77 6.12 -1.25 5.8 (0.22) 
Time Taken 
Telephone Task 6.36 1.12 -1.09 0.19 2.36 4.91 (0.30) Dual Task 
Decrement 
NART No. of -1.49 -2.48 -1.00 -2.00 0.65 3.74 (0.44) 
Errors 
NART Predicted 1.85 3.24 0.07 1.61 2.32 3.84 (0.43) 
IQ .a,. 
-0.30 0.56 0.68 0.4954 1.05 6.95 (0.14) Digit Span 
PASAT (2.4- 6.11 0.27 4.61 1.5727 3.00 15.0 (0.005*) 
seconds), 
PASAT (1.2- 3.47 5.59 2.80 4.3241 3.75 5.60 (0.23) 
seconds) 
*p = statistically significant (p<0.05 
8.23 
Table 8.9: Rank of differences in change in test score between treatment subgroups 
using Kruksall-Wallis Test 
Mean rank for difference in performance 
over follow-up period e 
for 
difference 
Neuropsyc. test y s; , º Ä 
0 ; aý 
2y o b 
0n oo on y 
between 
treatment ý" 
y ý. y aý ö -" ý' ö 
fD 
d subgroups ° yo 'ý' y oö (2dp) 
MMSE 144.70 157.13 149.26 145.95 109.97 0.26 
Logical Memory 153.27 135.41 144.34 146.62 174.05 0.45 
Immediate (raw) 
Logical Memory 148.03 140.29 142.10 144.95 175.57 0.57 
Immediate (%) 
Logical Memory 145.96 155.60 142.20 138.60 168.27 0.52 
Delayed (raw) 
Logical Memory 145.72 158.60 143.25 135.07 168.73 0.29 
Delayed (%) 
Rey Complex 143.22 155.18 166.67 135.17 141.32 0.25 
Figure Copy 
Rey Complex 149.29 140.42 144.16 151.63 138.48 0.9 
Figure Delayed 
Map Search (1st 173.61 146.85 146.44 128.72 161.85 0.04* 
Minute, Left) 
Map Search (1st 141.92 141.41 139.95 149.80 149.23 0.94 
Minute, Right) 
Map Search (2°d 136.69 137.85 166.33 145.57 138.60 0.41 
Minute, Left 
Map Search (2°d 168.01 146.69 144.65 136.28 137.10 0.31 
Minute, Right) 
Telephone Task 126.79 156.37 129.50 149.67 154.35 0.22 
No. of Targets 
Telephone Task 133.33 153.07 135.42 151.12 130.45 0.51 
Time Taken 
Telephone Task 133.90 141.92 129.64 151.21 150.77 0.57 
Dual Task 
Decrement 
NART No. of 147.68 133.33 148.93 148.92 150.52 0.76 
Errors 
NART Predicted 139.62 155.57 136.83 139.60 145.42 0.71 
IQ 
125.35 150.52 151.15 143.77 171.07 0.28 
Digit Span 
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Mean rank for difference in performance 
over follow-up period p-value 
for 
difference 
Neuropsyc. test y toy n aý y y 
o° r ýs o on ° 
between 
00 010 
' 
treatment 
" subgroups 
(2dp) 
PASAT (2.4- 164.12 133.91 154.56 141.75 145.48 0.37 
seconds) 
PASAT (1.2- 142.74 150.97 137.02 143.14 142.40 0.93 
seconds) 
*p = statistically significant (p<0.05) 
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Correlations of repeated neuropsychological tests 
Pearson's correlations of the scores at baseline and follow-up for each of the 
neuropsychological tests (cases and controls) are shown in table 8.10. For nearly all subtests, 
there was a highly significant correlation (p<0.01) between test score at baseline and test 
score at 12-month follow-up. The exceptions to this, where the correlation between score at 
baseline and score at follow-up was not significant, were map search test (1St minute right, 2nd 
minute left, 2nd minute right) for cases, and telephone task no. of targets for controls. 
These findings suggest that there is very little correlation between extent of change in score 
over time for both cases and controls, for the majority of neuropsychological tests in the 
CAFE battery. 
_\ 
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Table 8.10: Correlations of test scores at baseline and 12-month follow-up (2dp) 
Cases Controls 
Neuropsychological Pearson's Pearson's 
test correlation p-value correlation p-value 
coefficient coefficient 
MMSE 0.60 0.00* 0.54 0.00* 
Logical Memory 0.72 0 00* 0.78 0.00* Immediate (raw) . 
Logical Memory 0.63 0.00* 0.71 0.00* Immediate (%) 
Logical Memory 0.71 0 00* 0.75 0.00* Delayed (raw) . 
Logical Memory 
y 
0.69 0 00* 0.69 0.00* Dela ed %) . 
Rey Complex Figure 0.53 0 00* 0.41 0.00* Copy . 
Rey Complex Figure 0.63 0.00* 0.74 0.00* Delayed 
Map Search (1st 0.21 0 00* 0.39 0.00* Minute, Left) . 
Map Search (1st 0.16 0 07 0.30 0.00* Minute, Right) . 
Map Search (2° 0.03 0.71 0.22 0.01* 
Minute, Left 
Map Search (2° 0.13 0.14 0.49 0.00* 
Minute, Right) 
Telephone Task No. of 0.41 0 00* -0.15 0.06 Targets . 
Telephone Task Time 0.58 00* 0 0.48 0.00* Taken . 
Telephone Task Dual 0.22 01* 0 0.67 0.00* Task Decrement . 
NART No. of Errors -0.81 0.00* -0.68 0.00* 
NART Predicted IQ 0.89 0.00* 0.75 0.00* 
Digit Span 0.71 0.00* 0.72 0.00* 
PASAT (2.4-seconds) 0.64 0.00* 0.74 0.00* 
PASAT (1.2-seconds) 0.55 0.00* 0.51 0.00* 
*p = statistically significant (p<0.05) 
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Potential impact of confounders 
Because this is a longitudinal study, many potentially confounding factors are removed 
because comparisons are made between an individual at follow-up and themselves at baseline. 
In addition, most relevant characteristics (for example comorbidities such as history of CHD) 
were unlikely to change over this time. Therefore, the collection of data on potential 
confounders was more extensive at baseline that at follow-up. Nevertheless, it is important to 
recognise the limitations of this reliance on baseline data, and that some characteristics may 
change over the follow-up period. Therefore it was felt appropriate to explore certain key 
variables in the follow-up data - these had been identified in literature searches and following 
the baseline confounder analysis: 
1. Congestive Heart Failure (CHF) 
The prevalence of proxy variables for CHF was examined to see whether they changed over 
the follow-up period. The only proxy variables available at both baseline and follow-up 
interviews were `current symptom of ankle swelling - yes or no? ', and `current symptom of 
shortness of breath - none, yes but no effect, slight, marked or severe? '. 
For ankle swelling, 77% of participants at follow-up gave the same response as at baseline. 
" For shortness of breath, 52% of participants gave an identical response to that given at 
baseline. When the answers were grouped as either `no shortness of breath' or `slight 
shortness of breath', and `marked' or `severe shortness of breath', 89% of participants 
gave the same response as at baseline. 
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Since the consistency of these responses over the follow-up period was reasonable, given the 
subjective nature of the variable, it was felt that CHF would have been unlikely to confound 
the results and therefore no further analysis was undertaken on these variables. 
2. Age 
Age did not confound the results when put into a general linear regression model. In addition, 
Pearson's correlation techniques (table 8.11) showed little relationship between age (at first 
interview) of the total population and change in neuropsychological test score over the 
follow-up period, except for a statistically significant but extremely small correlation between 
age and Rey copy, digit span and PASAT- 1.2 seconds. However, even these slight effects 
appeared insignificant when the analyses were checked graphically. 
The effect of age on the change in cognitive performance over the follow-up period was 
examined because of the observed effect of age on the baseline results. However, it is clear 
that any effect of age on change in cognitive performance over the follow-up period will be 
almost identical for all participants since the follow-up period, thus the change in age, for all 
was very similar. 
These findings suggest that it is unlikely that age confounds the results of change in cognitive 
performance over the follow-up period. 
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Table 8.11. Pearson's correlation for age and change in neuropsychological test score 
over the follow-up period (2dp) 
Neuropsychological test 
Pearson's Correlation 
p-value Coefficient 
MMSE 0.04 0.45 
Logical Memory 0.04 0.50 
Immediate (raw) 
Logical Memory 0.01 0.92 
Immediate (%) 
Logical Memory Delayed 
-0.04 0.54 (raw) 
Logical Memory Delayed 
-0.01 0.91 (% 
Rey Complex Figure 0.14 0.02* 
Copy 
Rey Complex Figure 0.06 0.32 
Delayed 
Map Search (1st Minute, 0.10 0.08 
Left) 
Map Search (15t Minute, 
-0.02 0.71 Right) 
Map Search (2" Minute, 
-0.01 0.89 Left 
Map Search (2" Minute, 
-0.002 0.98 Right) 
Telephone Task No. of -0.04 0.54 Targets 
Telephone Task Time 
-0.09 0.12 Taken 
Telephone Task Dual 0.09 0.12 
Task Decrement 
NART No. of Errors -0.003 0.96 
NART Predicted IQ 0.07 0.26 
Digit Span -0.14 0.02* 
PASAT (2.4-seconds) 0.09 0.14 
PASAT (1.2-seconds) 0.15 0.01* 
*p = statistically significant (p<0.05) 
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3. Educational level 
Educational level did not confound the results when put into a general linear regression model. 
The analysis of the effect of this variable on follow-up data was performed because of the 
suggestion of a possible confounding effect at baseline. However, it is highly unlikely that 
educational level would change over the follow-up period in a cohort of elderly people, 
therefore any potential confounding effect would be extremely small. 
4. Change in treatment over the follow-up period 
Since this was an observational rather than an interventional study, it was not possible to 
control treatment of participants over the follow-up period. However, exploration of the 
possibility of an individual's treatment with antithrombotic therapy was important since GPs 
involved in the study may have been influenced by their practice's participation in the study 
and treatment of patients may have been reviewed as a result. In addition, other factors (e. g. 
guidelines and targets) may have led to changes in treatment of individuals. 
Of 362 participants at baseline, four changed from aspirin to warfarin over the follow-up 
period, 13 started aspirin (previously on neither aspirin nor warfarin), three started warfarin 
(previously on neither aspirin nor warfarin) one stopped taking warfarin (and did not start 
aspirin) and two stopped taking aspirin (and did not start warfarin). These changes were too 
small to impact upon the findings of the 12-month follow-up. Therefore, it was decided that 
all analyses should be made according to the treatment subgroup of the participants at 
baseline. 
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Stratification according to stroke risk 
One-way ANOVA tests were performed to compare the change in performance on 
neuropsychological tests between those of different stroke risk (Table 8.12), and post-hoc 
tests including Bonferroni adjustments were used to explore these findings further. Of these 
comparisons, only three showed a statistically significant difference between the change in 
performance of those of different stroke risks. These were Logical Memory (immediate raw, 
p=0.001), Logical Memory (immediate %, p=0.038) and Map Search (1S` minute right, 
p=0.045). Analysing these three tests further: 1) those of intermediate stroke risk had 
significantly different changes in performances than those of low stroke risk for Logical 
Memory (immediate raw, p=0.004), Logical Memory (immediate %, p=0.047) and Map 
Search (1st minute right, p=0.020); 2) those of high stroke risk had significantly different 
change in performance than those of intermediate stroke risk for Logical Memory (immediate 
raw, p=0.041) and Map Search (1St minute right, p=0.027). (Note: equal variance were not 
assumed when calculating these p-values). 
Interpretation of these findings is difficult, but overall there does not appear to be a consistent 
relationship between stroke risk and change in performance on neuropsychological tests over 
the follow-up period. 
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Table 8.12: Comparison of mean change in neuropsychological test score over the 
follow-up period according to stroke risk (using SPAF criteria) (2dp) 
Mean change in test score over follow-up 
Neuropsychological period according to stroke risk 
P-value test 
High risk 
Intermediate Low risk risk 
MMSE -0.01 0.50 0.11 0.46 
Logical Memory -0.97 1.77 -2.39 0.001* 
(immediate, raw) 
Logical Memory -4.48 5.45 -7.49 0.04* 
(immediate, %) 
Logical Memory -0.14 1.13 -0.24 0.48 
(delayed, raw) 
Logical Memory -2.06 3.77 -1.40 0.43 
(delayed, %) 
Rey Complex (copy) 2.07 1.32 1.43 0.76 
Rey Complex 0.71 0.25 0.86 0.91 
(delayed) 
Map Search (1s` 0.90 3.57 -0.76 0.34 
Minute, Left) 
Map Search (1s` 0.10 -5.19 0.62 0.05* 
Minute, Right) 
Map Search (2" 1.19 0.43 1.09 0.95 
Minute, Left 
Map Search (2nd -0.99 1.10 0.07 0.71 
Minute, Right) 
Telephone Task No. 0.23 0.09 -0.65 0.39 
of Targets 
Telephone Task -1.23 14.60 6.37 0.21 
Time Taken 
Telephone Task 3.92 1.27 2.42 0.88 
Dual Task 
Decrement 
NART No. of Errors -1.70 -1.60 -1.72 0.997 
NART Predicted IQ 3.13 1.95 2.20 0.61 
Digit Span 0.43 -0.32 0.61 0.37 
PASAT (2.4- 3.81 2.29 1.07 0.65 
seconds) 
PASAT (1.2- 5.82 7.90 1.33 0.05 
seconds) 
*P<0.05 
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Chapter 8 Summary 
" The only significant differences between those who did and did not complete the 
follow-up interview were that those who completed the follow-up had better baseline 
scores for the physical activity and general health domains of the SF-36. 
" When the total study population was analysed without stratification, change in 
performance on the neuropsychological tests between baseline and follow-up was not 
significant for most tests. 
9 When cases and controls were analysed separately, the overall direction of change in 
test scores over the follow-up period varied widely, in that for both groups, there was 
an overall improvement in some sub-tests and deterioration in others. However, the 
change in test score was only statistically significant (p<0.05) for a proportion of the 
tests: cases demonstrated overall improvement in two subtests and deterioration in 
four subtests; controls showed improvement and deterioration in the same sub-tests as 
for cases, but also showed improvement in a further six subtests and deterioration in a 
further four subtests. These findings are not consistent with an overall deterioration in 
performance on neuropsychological testing in atrial fibrillation compared to sinus 
rhythm, and thus support the null hypothesis that there is no consistent association 
between NVAF and cognitive decline over 12 months. 
9 The overall direction of change (improvement or deterioration) varied between 
subtests which assessed the same cognitive domain. 
9 There were no statistically significant differences between the proportion of cases and 
controls that improved, deteriorated or stayed the same for each subtest over the 12- 
month follow-up period. 
" There were no statistically significant differences in most neuropsychological test 
scores, between cases and controls on aspirin, warfarin or neither therapy. 
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" For nearly all subtests in the CAFE neuropsychological test battery, there was a highly 
significant correlation (p<0.01) between test score at baseline and test score at 12 
month follow-up, suggesting very similar scores at baseline and score at follow-up for 
both cases and controls (for the majority of neuropsychological tests in the CAFE 
battery). 
" Age and education did not confound the results when put into a regression model. In 
addition, Pearson's correlation techniques showed little relationship between age at 
baseline interview of the total population and change in the majority of 
neuropsychological test scores over the follow-up period. 
" The number of participants who changed treatment subgroup according to 
antithrombotic therapy was small and did not impact upon the findings of the study. 
" There did not appear to be a consistent relationship between stroke risk (according to 
SPAF criteria) and change in performance on neuropsychological tests over the 
follow-up period. 
" Overall, these results demonstrate no consistent or significant change in cognitive 
performance over the 12-month period for the total study population, and no 
consistent or significant difference in change in cognitive performance between cases 
and controls, nor between treatment subgroups. These findings support the null 
hypothesis that decline in cognitive function over time (12 months) in people with 
NVAF is no different to that of controls. 
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Chapter 9- Discussion 
" Summary of findings 
" Context of existing literature 
o Literature which conflicts with the findings of this study 
o Literature which is consistent with the findings of this study 
" Exploration of results 
o Study limitations 
o Other explanations for study findings 
" Future areas for research 
" Conclusions 
" Chapter 9 Summary 
9.1 
Summary of findings 
The baseline results of this study demonstrated no difference in performance on 
neuropsychological tests between cases in NVAF and controls in sinus rhythm, with no effect 
of antithrombotic therapy. In addition, the follow-up results showed improvement in more 
sub-tests in controls than cases, but also more deterioration; the pattern of change seen when 
comparing cases and controls is not consistent with the expected effect of AF on cognitive 
decline, and these findings are not consistent with an overall deterioration in performance. 
Overall, the findings of this study provide no evidence to suggest an association between 
NVAF and performance on neuropsychological tests, nor change in performance over time. 
Context of Existing literature 
i) Literature which conflicts with the findings of this study 
a) Studies of NVAF and cognitive impairment 
Previous, predominantly cross-sectional studies have demonstrated an association between 
NVAF and poor performance on neuropsychological assessment. The findings of these 
studies are described in Chapter 2. The quality of previous studies is shown in table 9.1. The 
results of this study, both cross-sectional and longitudinal, conflict with these findings by 
failing to demonstrate a convincing difference at baseline or 12-month follow-up between 
patients with NVAF and controls. Furthermore, there was no demonstrable difference 
between patients on different forms of antithrombotic therapy. Possible reasons for these 
important findings, in the context of existing literature, include: - 
Design: The most appropriate design for any study of cognitive function includes 
measurement of change in performance over time; 169 and the ideal study design for exploring 
this subject is an inception cohort study comparing cases in NVAF and matched controls in 
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sinus rhythm. Nearly all previous studies were cross-sectional in design. The only exception 
was a highly selective study comparing pre- and post-operative cognitive function after 
cardiac surgery in those who did and did not develop NVAF, with a follow-up period of just 
six weeks. 16 Participants have been shown to exhibit greater cognitive decline with age when 
analysed cross-sectionally and sequentially, than when the analysis of the cohort is undertaken 
using a longitudinal approach. 331 This suggests that these previous cross-sectional analyses 
may over-estimate the extent of cognitive decline. In addition, two of the previous studies did 
not aim to explore the association between NVAF and cognitive function from the outset, 
instead reporting the results of a sub-analysis of their cohort; 18'20and only one study17 
included matched controls. 
Sample: Most previous studies used small samples (4420,4219,1617,6916 cases used 
compared with 174 in this study), although the Rotterdam study used 195 cases; 18 and two of 
the studies used highly selected inpatient populations. 16,19 The CAFE pilot study in 
Gateshead had a sample of 81 (27 cases). 15 Differences in patient characteristics include 
differing prevalence of diabetes (10% in CAFE versus 13.1%20,11%18 and 27%16 of the total 
sample of previous studies), and some age difference (although all participants were aged 55 
or over). Five of the previous studies excluded those with previous stroke/ TIA, as did this 
study; although two did not (prevalence of 8.8%20 and 3.2%18 of total sample). In addition, 
many of these studies had more extensive exclusion criteria (and nevertheless found a positive 
association with cognitive decline), therefore the more limited exclusion criteria in the CAFE 
cohort are unlikely to have caused sufficient selection bias to affect the findings. 
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Representativeness: The CAFE cohort was maximally representative to ensure 
generalisability. Such generalisability was attained by recruiting participants in the 
community and minimising exclusion criteria, including co-morbidities where possible. In 
two previous studies, 16,19 sampling was of inpatients or secondary care registers, whilst one 
study20 was of men only. 
Potential confounders: Although others analysed the effect of potential confounders, the 
analysis of possible confounding effects in this study is far more comprehensive. 
Duration of NVAF: The CAFE cohort was restricted to those with recent onset NVAF (<5 
years), whilst others17-20 did not report the duration of NVAF and may have included 
longstanding cases with potentially more progressive cognitive decline. 
Neuropsychological tests: CAFE used a battery of tests measuring a wide range of cognitive 
domains (selective and divided/ sustained attention, verbal and non-verbal short and long- 
term memory, information processing and premorbid intelligence) in contrast to the limited 
neuropsychological assessment used by most previous studies. However, unlike CAFE, some 
previous cross-sectional studies have included measures of executive function including the 
Trail-Making Tests16,20 and Wisconsin Sorting Card Test; 17 although two studies relied only 
on the MMSE for assessment of cognitive decline. 18,19 Therefore it is unlikely that the 
absence of a specific measure of executive function in our study is responsible for the 
difference between our results and those of previous studies. 
Antithrombotic therapy: CAFE cases had higher levels of treatment with antithrombotic 
therapy (81.6%) than those of other older studies (26%18,50%20, none15, others not reported), 
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probably because treatment levels have increased since these studies, with greater awareness 
of appropriate management of NVAF. This treatment may reduce the risk of cognitive decline, 
although the subgroup analysis reported here provides no evidence for this. 
b) Study of stroke risk and cognitive performance 
A recent paper reporting further cross-sectional analysis of the Framingham Offspring Study 
cohort43 demonstrated an inverse relationship between stroke risk and performance on 
neuropsychological tests measuring a range of cognitive domains (visual-spatial memory, 
attention, organisation, scanning and abstract reasoning). In particular, the presence of NVAF 
was found to be associated with poorer performance on tests of abstract reasoning and visual- 
spatial memory, although the study was not designed to look specifically at NVAF and the 
number of participants with NVAF was small (n= approximately 65). These findings support 
the suggestion that stroke risk is related to impairment of cognitive domains beyond executive 
function alone. Therefore it can be hypothesized that any cognitive impairment due to AF will 
also be present across multiple cognitive domains. Of the domains measured in the 
Framingham study, visual-spatial memory, attention and organisation are all measured as part 
of the CAFE neuropsychological test battery. For CAFE the measure of visual-spatial 
memory was a very similar test to that used by the Framingham study (visual reproduction of 
a figure with immediate and delayed recall), although the CAFE measures of attention were 
unrelated to the Framingham measures. However, since both studies (Framingham and CAFE) 
measured multiple domains, with some similarity in the domains measured, and because 
Framingham found changes in multiple domains, it is unlikely that the negative findings of 
the CAFE study are due to inadequate measurement of the executive function domain, as may 
have been suggested by previous literature. 
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ii) Literature which is consistent with the findings of this study 
The only study on this subject to demonstrate lack of association between NVAF and 
cognitive impairment was the InCHIANTI study, which reported that after adjustment for age, 
atrial fibrillation was not significantly more prevalent in those with low cognitive 
performance with subcortical features than those with high cognitive performance or without 
subcortical features. 21 This study does support our findings, although it is smaller than CAFE 
and is focused on general cardiovascular risk factors rather than NVAF alone. 
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Exploration of findings: 
The CAFE study found no apparent relationship between NVAF and change in performance 
on our neuropsychological tests over 12 months, with no effect of antithrombotic therapy. 
These findings could reflect a lack of association between cognitive decline and atrial 
fibrillation. Other explanations are discussed below: - 
A) Study Limitations 
1. Length of follow-up period 
The follow-up period of 12 months may have been too short to observe a significant change in 
cognitive function. The study team has therefore obtained funding from the Stroke 
Association and have just started three-year follow-ups of the original CAFE cohort in order 
to determine whether cognitive function declines over a longer follow-up period. 
2. Neuropsychological test battery 
Important cognitive domains in vascular cognitive impairment: 
Literature suggests that vascular cognitive impairment is related to executive function, speed, 
attention and information processing more than other domains. 317 However, öne recent report 
from the Framingham study demonstrated an association between stroke risk (including 
NVAF) and lower cognitive performance across multiple cognitive domains, including visual- 
spatial memory. 43 In addition, previous cross-sectional studies (discussed above) 
demonstrated significant associations between NVAF and cognitive function despite several 
of these studies relying on MMSE alone, with no measure of executive function, speed or 
processing. Nevertheless, it is important to explore these domains further: - 
9 Executive function: Although the MMSE does contain a crude measure of executive 
function, and the Rey Figure has some executive components (problem solving, planning) 
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ideally the CAFE neuropsychological test battery would have included more extensive 
measures of executive function, and in a future study such measures would be added. 
Such measures may be more sensitive in detecting small changes in cognitive function 
due to NVAF. It is worth noting that although previous literature has suggested executive 
function is an important domain in vascular cognitive impairment, it does not suggest that 
this is the only domain that may be affected. 
" Speed of processing: The CAFE neuropsychological test battery contained several valid 
measures of attention, speed and information processing. However, it would have been 
useful to have more measures of speed of processing (e. g. computerised tests), since 
changes in speed of processing is also reported to be a relatively early change in the 
natural history of vascular cognitive decline. However, several of the CAFE subtests had 
speed components, and these did not show significantly greater change over time than 
tests of other domains. 
Practice effects: 
Possible explanations for the widely varying direction of changes in score for controls (equal 
numbers of tests improve and deteriorate) may include learning effect for some tests, as well 
as increased confidence due to familiarity with the study and observer. 271 For example, 
practice effects of 10% improvement have been demonstrated for the Rey Figure when 
retested after 1 month for the same figure, therefore CAFE may have benefited from using the 
Taylor figure (a similar figure to the Rey) at follow-up216 A study of elderly patients found 
the copy was not reliable with retesting at one year, although the delayed recall was 
moderately reliable at this time interval 216,278 Another example of the effect of practice is for 
the Logical Memory test: an average gain in score of 1 point after one year in a young 
group, 225,246 and 0.7 points in one year in an older group (mean 69 years) has been 
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demonstrated due to practice effects. 225,318 Therefore the CAFE follow-up findings may 
underestimate cognitive decline for this subtest. 
Differential protective effect of good cognitive reserve: 
Good cognitive reserve may mask early verbal memory dysfunction more than visuo-spatial 
dysfunction, 319 although this is not likely to affect the results of this study since there was no 
convincing change in either domain. 
NART pronunciation: 
It may have reduced bias to have used a tape-recorder to double-check NART pronunciations. 
In addition, it may have been helpful to have used the Cambridge Contextual Reading Test 
(CCRT) (see Chapter5), which has been shown to be more accurate than NART in measuring 
premorbid intelligence in those with mild dementia. 
Combined scores: 
In CAFE, as with most studies using Wechsler tests, the digits forwards and digits backwards 
scores were combined to obtain one score, with the assumption that the two tests behave 
similarly. However, it has been suggested that as age increases after 80 years, forward span 
remains stable but backwards deteriorates. 225.274 Therefore combining the scores may have 
hidden important differences. In future studies the scores might therefore be analysed 
separately. 
Auditory tests and hearing problems: 
It is possible that tests involving auditory material (Telephone Tasks, PASAT) may be 
affected by hearing problems and/ or interference on the cassette tapes. However, the 
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Telephone task had been validated using the most inexpensive tape recorder on the market, 
providing reassurance that high quality equipment was not required. In addition, participants 
in CAFE were asked if volume level was appropriate, and those with severe hearing problems 
were excluded from the study (test validation by the authors had included mild hearing 
impairment, which did not have an effect on the results295). Similarly, those with visual 
problems may have had difficulties with the Map Search test. 212 As suggested by the test 
authors, 295 CAFE participants who reported difficulty in seeing the symbols were excluded. 
Informant information: 
Further validation of the CAFE battery with an informant questionnaire, such as the Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE)320 may have been helpful. 
Subtests of larger batteries: 
Because some of the CAFE sub-tests represent sub-tests of other, larger scales (e. g. Logical 
Memory and Digit from WMS), the literature on these individual sub-tests was limited, and 
tended to refer to the whole scale total scores (e. g. Wechsler's `Memory Quotient') etc. rather 
than detailed information on the subtest used in CAFE. However, there are a number of other 
test batteries which use Subtests in this way. 225 
Combining scores with demographic information: 
CAFE, unlike some other studies, did not use demographic information (education, sex) in 
conjunction with NART errors to arrive at IQ. 216,218,239 Doing this may perhaps have given 
better estimates of premorbid cognitive functioning. 
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Bilateral infarcts and the WMS: 
Logical Memory and digits forwards measure memory functions which are equally 
represented in both hemispheres, therefore damage to one side of the brain only (e. g. 
unilateral silent infarcts) may have no effect on the performance of this sub-test 266 Therefore 
lack of deterioration in this subtest may not necessarily reflect absence of brain injury, rather 
is more likely to suggest absence of bilateral brain injury. This may have led to 
underestimation of the extent of silent infarcts in this study, although ultimately would not 
affect the primary outcome measure, that is the extent of change in the neuropsychological 
tests over the follow-up period. 
Reliability of Telephone task: 
Although reliability of telephone search while counting (dual task decrement) was satisfactory 
for two groups of non-brain-damaged subjects (0.51 and 0.61) it was lower in a group of 
participants with stroke (0.40). 228 This may lead to underestimation of cognitive decline in 
this study, since the hypothesized pathological mechanism for cognitive decline in our cohort 
is through silent infarcts. 
Task motivation: 
Neuropsychological tests are dependent upon patient motivation and compliance, therefore it 
would have been helpful to have had an explicit measure of task motivation in the test battery. 
However, for this study there was no financial or other incentive to perform badly, unlike 
studies of other groups where such incentives may exist (e. g. in cases of head injury). 
Measures of task motivation and test validity include clinical judgement, performance 
patterns present in existing neuropsychological testing and more formal measures. 261 
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Variability in administration: 
The two tests subject to the greatest variability in administration are the LMS (*unrevised 
WAIS) and Rey figure (criteria are few and therefore there is considerable variability between 
scorers. 225,261 However, CAFE used the revised version of the LMS, reported as more reliable, 
and incorporated objective interrater checks for scoring the Rey Figure. 
3. Confounding factors 
It has been suggested that detection of both participants in a preclinical stage of dementia and 
those with prevalent dementia could be missed because of insensitivity of neuropsychological 
tests to age, education and sex. To improve the accuracy of detecting dementia, it is 
recommended that test results need to be used in combination with analysis of potential 
confounders, particularly age, sex and education. 169 In the CAFE baseline analysis, these 
potential confounders were thoroughly analysed. 
Whilst there were differences between cases and controls for diabetes, cholesterol, CHD, CHF 
and SF-36 score, these did not confound the findings based on the age-adjusted comparisons 
between cases and controls and between treatment subgroups. 
Although mental health status was measured using the SF-36, a more specific measure of 
depression may be preferable when studying cognitive decline; therefore the Geriatric 
Depression Scale321 has been incorporated into further follow-up visits of this cohort. 
4. Attrition and `healthy survivor' effects 
The attrition rate between baseline and follow-up at 12 months was 16%. It is possible that 
the factor(s) influencing whether or not participants were included at follow-up also 
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influenced their cognitive performance; or that cognitive performance affected completion of 
12-month follow-up assessments. 
Although clearly there was no 12 month cognitive data for those who were lost to follow up, 
analysis comparing those who did and did not complete follow-up did not suggest marked 
differences that would be likely to affect the findings in this way. With hindsight, it may have 
been appropriate to model the expected cognitive decline of those lost to follow-up, by 
assuming normal distribution of baseline cognitive function and with use of the Markov chain 
Monte Carlo technique for modelling longitudinal studies. 198,322 In this way it would have 
been possible to estimate the change in cognitive function of the cohort taking into account 
those lost to follow-up. However, it was felt that the baseline cognitive function of this cohort 
was not sufficiently normal for appropriate use of this method. Instead, the results were 
presented with the effect of attrition made explicit. 
In addition, although 16% appears to be a high attrition rate, when compared to other studies 
of elderly cohorts, which have attrition rates of up to 80%, 160 this attrition rate is not 
excessive. Nevertheless, it is possible that our findings may have been affected by the healthy 
survivor effect, since studies have shown that those with cognitive impairment and dementia 
have higher mortality than those without. 174,176,323,324 For this reason, attrition due to 
mortality in any study of cognitive function may lead to bias and underestimation of the 
extent of cognitive impairment in both cases and controls. However, this survival effect is 
likely to be stronger in more severe dementia, 18 and therefore should not greatly affect our 
cohort. Nonetheless it is possible that some healthy survivor effect may have contributed to 
our negative findings, but is unlikely to fully explain them. 
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5. Selection and response bias 
Notes screening 
Screening of 2866 sets of notes in general practice led to inclusion of only 362 participants in 
the study at baseline. This led to concern that selection bias may have taken place such that 
those who were included had specific characteristics, different to those who were not included, 
which may influence their performance on neuropsychological tests. However, analysis 
comparing those who did or did not respond to invitation to participate did not suggest 
significant differences that would be likely to affect the findings in this way. 
Only limited information had been recorded for those who were screened but not selected for 
invitation to participate, therefore the possibility of selection bias could not be ruled out. 
However, the protocol for screening of notes was objective and systematic, and used only the 
study's inclusion criteria. In this way, there is no logical reason why selection bias would 
have occurred. 
Nature of participation in the study: 
Response bias is possible due the nature of participation in this study, through recruitment methods 
and protocol design: 
" Patients were invited to participate by letter counter-signed by their GP, therefore the 
relationship of the potential participant with their GP and health services in general may have 
influenced their decision to participate. 
" Invitation by letter would have prevented those who are unable to read from participating in the 
study, although these would have been excluded from the study in any case. 
" Patients were visited at home in an attempt to avoid the inconvenience of travelling to a 
research centre, which may have dissuaded people from participating. Despite this however, it 
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is possible that the more frail potential participants would be less inclined to participate, and 
this was explored further in the analysis of potential confounders. 
Characteristics of general practices: 
The method of selection of general practices (choosing larger practices first) is unlikely to have led 
to response bias since ultimately the majority of practices in the study area were selected, 
representing a wide spectrum of characteristics including large and small practice list size, single- 
handed GPs and group practices. 
Differences between the total study population characteristics and characteristics of the population 
from which the sample was drawn: 
The characteristics of the total study population may bias the results if they differ from the general 
population from which the sample is drawn. This issue is explored further under `inclusion and 
exclusion criteria' (below). 
Differences between characteristics of responders and non-responders: 
Possible sources of non-response bias are suggested by the significant differences in those who did 
and did not complete baseline interview in that: a) female non-responders (median age 79 years) 
were significantly (p=0.001) older than female responders (median age 77 years); and b) non- 
responders had significantly (p=0.009) less record of CHD (29% of non-responders vs. 37% of 
responders). Exploring these differences further: - 
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a) Since there was no significant difference in age for men in these two categories, and because the 
difference between the two groups for women was small (though statistically significant), it is 
unlikely that age difference would considerably bias the results. 
b) However, it is possible that the greater morbidity from CHD in the responder group may affect 
the findings. A high prevalence of morbidity from CHD would be expected in our cohort because 
the inclusion criteria for cases necessitate a diagnosis of NVAF, which is often associated with 
CHD. Greater morbidity from CHD in the responder group is more surprising however. Reasons 
for this may include: that those with known cardiac problems might be more interested in 
participating in a study which is described to them as exploring links between the heart and 
memory; that those with CHD have more contact with the health services and therefore feel more 
comfortable with further involvement with health professionals or are inclined to `give something 
back'; that those with CHD experience symptoms of cognitive decline and are interested in 
involvement in the study for that reason. This latter possible explanation would bias the study 
results, as would an association between CHD and cognitive decline even if patients were unaware 
of symptoms. 
Ways to remove this potential source of bias include changes to recruitment methods. However, 
ischaemic heart disease is a major risk factor for NVAF, and in order to recruit a representative 
sample of older people with NVAF, it would have been inappropriate to exclude those with CHD. 
Therefore any potential confounding effect of CHD was thoroughly explored in the analysis of 
baseline cognitive function results. 
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6. Inclusion and exclusion criteria 
The inclusion criteria for this study were selected to maximise generalisability of the results to 
the general population (by recruiting in the community and minimising exclusion criteria), 
whilst making it possible to address the specific research question. In establishing these 
criteria, it was inevitable that the results would need to be interpreted with explicit awareness 
of the limitations that any selection criteria impose. Particular criteria that undoubtedly have 
an influence on the study's findings are: - 
1) Exclusion of those who have suffered any stroke or transient ischaemic attack. 
This study was explicitly designed to exclude those with the major proven risk factors for 
cognitive decline and dementia, since their inclusion would make it very difficult to establish 
a causal link with NVAF rather than the proven risk factor. For this reason those with prior 
cerebrovascular events and severe heart failure were also excluded. In excluding those with 
stroke, selection bias or `harvesting' may have been introduced, since this group of patients 
may indeed have been those at highest risk of cognitive impairment due to NVAF. The 
proposed causal mechanisms for cognitive decline in NVAF include silent cerebral infarction, 
therefore those who suffer stroke by the same pathological mechanism may have been at risk 
of considerable cognitive decline due to NVAF. This issue is highlighted by the Rotterdam 
Study, 18 which found that NVAF was associated most strongly with Alzheimer's Disease 
with cerebrovascular disease (OR= 4.1), and had a weaker association with vascular dementia 
(OR=1.9). Exclusion of those with stroke may therefore have significantly underestimated 
the risk of cognitive decline in this cohort. However, four of seven other published 
studies15,16,17,19 that found a positive association between NVAF and cognitive decline also 
excluded those with stroke/ TIA and thus have the same potential for selection bias. In 
addition, although those with stroke may have had silent infarcts related to NVAF, with 
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resultant cognitive decline, the literature suggests that post-stroke dementia is due to a wide- 
range of pathologies including haemorrhage, multiple infarcts, single strategic infarcts and 
small vessel disease, thus inclusion of patients with a history of stroke would have made 
interpretation of. cognitive impairment in this group difficult. 317,325 In addition, inclusion of 
this group would have been logistically difficult and other effects of stroke (perceptual, motor 
and sensory including visual problems) would have made completion of the 
neuropsychological tests impossible or misleading. 
2) Exclusion of those with established dementia or MMSE<24. 
The aim of our study was to explore the hypothesised relationship between NVAF and 
potentially preventable cognitive decline and thus patients already diagnosed as having 
dementia were excluded. However, this group may have had dementia due to NVAF, 
therefore their exclusion may have led to underestimation of the extent of cognitive decline in 
those with NVAF. Nevertheless, completion of the neuropsychological test by this group 
would have been extremely difficult and accurate comparison of baseline and follow-up 
results would not have been possible. 
In summary, the design of our prospective cohort study made the use of certain exclusion 
criteria unavoidable, and may therefore have led to underestimation of the extent of cognitive 
decline in our population. However, it is unlikely that this alone is sufficient to explain our 
negative findings. 
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7. Imaging 
Ideally, this study would have included magnetic resonance imaging (MRI) of the brains of all 
or some participants. This would have provided insight into possible pathological 
explanations for the findings. However lack of resources, despite many applications for 
funding, made this impossible. 
Since the findings were negative, proof of the hypothesized pathological mechanism (i. e. 
silent cerebral infarction) by brain imaging would have been less helpful than had the findings 
been positive. In addition, one study of 80 year-olds demonstrated that, although related to 
intelligence, ischaemic effects (periventricular and deep white-matter hyperintensities) alone 
are only responsible for part of the great variation in cognitive decline between individuals. 326 
Therefore the true measurement of change in cognitive function, as in this study, is more 
appropriate than imaging alone. 
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B) Other explanations for study findings 
1. Speed of cognitive processing: 
Literature suggests that neuropsychological test scores which have a speed component may 
change over a shorter follow-up period that those which measure other cognitive functions. 317 
However, even when those tests of the CAFE battery which had a speed component were 
grouped together, there were no significant findings. 
2. Paroxysmal NVAF: 
ECG recording was not repeated at follow-up, therefore those with paroxysmal AF may have 
been included in CAFE. However, studies show that those with paroxysmal AF had similar 
rates of stroke and stroke risk factors to those with permanent AF, 327 with no significant 
effect of intermittency on risk of thromboembolism. 328 Therefore this would be unlikely to 
bias our findings. 
3. Duration of NVAF: 
The time since onset of NVAF reflects the time since onset of potential risk of cognitive 
decline, therefore this may bias the results. All of the participants in this study had known 
duration of NVAF of <5 years. However, data from the SPAF study confirms that the 
duration of NVAF is not significantly related to risk of thromboembolism, 328 therefore it is 
unlikely that this would have an effect on silent infarcts and vascular cognitive decline. 
4. Other antithrombotic drugs: 
This study did not analyse effect of other antiplatelet agents such as dipyridamole or 
clopidogrel, only the antithrombotic drugs aspirin and warfarin. However, one study of 
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dipyridamole demonstrated that it was no more effective at reducing the risk of stroke than 
aspirin alone. 329 In addition, the CAPRIE (clopidogrel versus aspirin in patients at risk 
of ischaemic events) study demonstrated that clopidogrel was only more effective than 
aspirin in preventing stroke in a subgroup of patients with peripheral arterial 
disease. 332 Therefore it is unlikely that this would have had a great effect on our findings, 
particularly when the use of this drug is still relatively low. 
5. Problems with searching the literature: 
There were few studies reporting a lack of association between a potential risk factor and 
cognitive decline (i. e. negative findings) - this may be due to publication bias, and re- 
emphasises the need to report negative findings such as those from this study. 
6. Mortality and cognitive decline: 
As discussed in Chapter 3, cognitive impairment and decline is associated with mortality 
therefore it is possible that our findings may have been affected by the healthy survivor effect. 
This could potentially have led to underestimation of the extent of cognitive impairment in 
both cases and controls. For this reason, attrition due to mortality in any study of cognitive 
decline will lead to bias. Fortunately, this study's rate of attrition due to mortality was 
relatively low (4.4%). 
C) Summary of exploration of findings 
Of the limitations discussed above, one of the most important is that after careful examination 
of the literature I now feel that the duration of follow-up may have been too short, such that a 
true association between NVAF and cognitive decline, though not apparent at 12 months, may 
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be demonstrated with longer follow-up. In addition, the majority of CAFE participants were 
on antithrombotic therapy and this may have protected them against cognitive decline 
(although this did not appear to be the case when the treatment subgroups were analysed). 
Nevertheless, despite these and other limitations, this work was carried out with rigour using a 
representative, reasonably large sample and longitudinal design; therefore in my opinion the 
findings that there is no association between NVAF and cognitive decline over (specifically) 
12 months are valid. In addition, there is evidence to accept the null hypothesis that: 1) the 
cognitive function of people with NVAF is no different to that of age and sex-matched 
controls in sinus rhythm, when assessed by detailed neuropsychological testing; and 2) the 
decline in cognitive function over time (over 12 months) in people with NVAF is no different 
to that of controls. However, the findings of this study do not provide evidence to reject the 
hypothesis that decline in cognitive function over a longer period of time (i. e. more than 12 
months) in people with NVAF is different to that of controls, nor that there is an association 
between untreated NVAF and cognitive decline. 
Future areas for research 
" The work reported in this thesis informs future research studies by demonstrating the 
usefulness of longitudinal studies of representative populations in exploring change in 
cognitive function, and the necessity of an adequate interval between baseline and follow-up. 
In addition, it highlights the importance of measuring multiple cognitive domains. 
" More large, longitudinal cohort studies of atrial fibrillation and cognitive decline are needed to 
confirm or refute the negative findings from the study reported here. A further follow-up (at 3 
years) of the CAFE cohort is underway. 
In particular, future studies should be of adequate duration, and should use an internationally 
recognised `gold-standard' neuropsychological test battery that contains sensitive assessment 
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tools to detect small changes in cognitive function within the follow-up period. The 
development of such a test battery, which as yet is not available, should be a research 
priority. 160 
Conclusions 
The results of this study fail to confirm the findings of previous research addressing the 
association between NVAF and cognitive decline, which to date has been predominantly 
restricted to small cross-sectional studies of selective populations with neither careful 
consideration of potential confounders nor of the effect of antithrombotic therapy. 
The findings of the CAFE study accept the original null hypotheses that: 1) the cognitive 
function of people with NVAF is no different to that of age and sex-matched controls in sinus 
rhythm, when assessed by detailed neuropsychological testing; and 2) the decline in cognitive 
function over time (over 12 months) in people with NVAF is no different to that of controls. 
These results are likely to be more reliable and valid than those of the preceding studies since 
they derive from a larger, representative community-based population and represent 
longitudinal data. CAFE's results are also more likely to represent the real relationship 
between cognitive decline and NVAF in today's UK population since these findings 
incorporate current treatment levels with antithrombotic therapy. As such, they contrast with 
previous studies that were performed prior to initiatives such as the National Service 
Framework for Coronary Heart Disease330, and may now be out of date. 
In conclusion, this study finds no convincing difference in cognitive function nor cognitive 
decline over 12 months, between cases with recent onset NVAF and controls, nor between 
patients on anticoagulant/ antiplatelet therapy and those untreated. 
9.26 
Chapter 9 Summary 
9 The findings from this study conflict with previous studies in this field. However, 
previous studies were of lesser quality and less appropriate design. No previous high 
quality longitudinal studies of this research question have been published. 
9 As with all studies of this nature, there are a number of potential areas of bias and 
possibilities for underestimation of the true extent of cognitive decline in this cohort. 
Limitations to this study included short duration of follow-up, neuropsychological tests 
used and attrition of participants. These limitations need to be weighed against the 
advantages of generalisability of the results of this study to the general population, and the 
logistics of undertaking a substantial piece of research in the community. Despite these 
inevitable problems, a very extensive analysis of our results persistently demonstrated no 
clinically important differences between those with and without NVAF, nor between those 
with and without treatment with antithrombotic therapy. Therefore, in spite of the 
limitations described, in my opinion the findings that there is no association between 
NVAF and cognitive decline over (specifically) 12 months are valid. In addition, there is 
evidence to accept the null hypotheses that 1) the cognitive function of people with 
NVAF is no different to that of age and sex-matched controls in sinus rhythm, 
when assessed by detailed neuropsychological testing; and 2) the decline in 
cognitive function over time (over 12 months) in people with NVAF is no different 
to that of controls. However, the findings of this study do not provide evidence to reject 
the hypothesis that decline in cognitive function over a longer period of time (i. e. more 
than 12 months) in people with NVAF is different to that of controls, nor that there is an 
association between untreated NVAF and cognitive decline. 
" Further research suggested by our findings includes more longitudinal studies of cognitive 
decline in NVAF, and include completion of the three-year follow-up of this study cohort. 
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Summary of thesis 
S. 1 
This chapter represents a collation of the summaries of all previous chapters in this thesis. 
Background 
" To inform the work reported in this thesis, an extensive review of relevant literature was 
undertaken, with separate searches addressing; 1) studies of atrial fibrillation (AF), silent 
cerebral infarction and cognitive decline; 2) studies of the epidemiology of AF and 3) studies 
of other risk factors for cognitive decline. 
9 There is evidence for associations between AF, silent cerebral infarction and cognition, but to 
data this has been largely from cross-sectional studies, including the pilot study carried out 
prior to the work reported in this thesis. In order to adequately explore the aetiology of 
cognitive decline, longitudinal studies of representative populations, measuring cognitive 
function over an appropriate period of time are needed. The work reported in this thesis is such 
a study. 
9 AF is a common condition, the prevalence of which increases as the population ages. Studies 
of people with AF report previous stroke/ TIA, age>75 years, history of hypertension, left 
ventricular dysfunction and diabetes as risk factors for stroke in AF. It is plausible that these 
may also be risk factors for silent stroke leading to cognitive decline in those with AF. 
" Despite the proven efficacy of anticoagulant and antiplatelet therapy in preventing stroke in 
people with AF, there is significant underprescribing of these treatments. The work reported in 
this thesis addresses the role of anticoagulant and antiplatelet therapy in preventing cognitive 
decline in addition to stroke. 
" There are many studies of risk factors for cognitive decline other than AF. The most widely 
studied risk factor is hypertension, for which evidence suggests there may be a modest 
association with cognitive decline. There is also strong evidence supporting the association 
between age and cognitive decline. 
S. 2 
"A comprehensive review of the literature on the epidemiology of cognitive decline consisted of 
a formal systematic review of cognitive decline in the general elderly population. In addition 
specific searches for literature covering issues of relevance to the work reported in this thesis 
were undertaken where appropriate. 
"A number of issues in cognitive function research methodology were identified, including the 
challenge of high attrition rates in elderly populations, the need for longitudinal studies when 
looking at change over time and the effect of cognitive function on mortality leading to 
survivor bias. 
" Key findings from the systematic review were that cognitive decline is almost universal, that 
quality of studies in this area varies widely, that studies in this area are vulnerable to bias, 
particularly selection and survivor bias, and that there is a need for a gold-standard battery of 
neuropsychological tests in order to make studies of cognitive decline comparable. 
9 The CAFE study neuropsychological test battery was selected because it had developed for the 
purpose of examining cognitive impairment due to cerebrovascular disease, had been used in 
the CAFE pilot study, had been validated, was portable and measured a range of cognitive 
domains (general cognitive function, pre-morbid intelligence, verbal long term memory, short 
term memory, information processing and attention, selective attention, divided attention and 
non-verbal memory). 
" The tests in the CAFE battery were the Rey Complex Figure, the Mini Mental State 
Examination, the Logical Memory and Digit Span subtests of the Wechsler Memory Scale 
(WMS), the Map Search and Telephone Task subtests of Tests of Everyday Attention, and the 
Paced Auditory Serial Addition Test. In addition the National Adult Reading Test (NART) was 
used to measure premorbid intelligence. 
"A literature search was undertaken to examine the clinical significance, reliability, sensitivity 
and validity of performance on the Subtests of the CAFE battery. Overall, there was reasonable 
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evidence of reliability and validity of the subtests for use on a cross-sectional basis. However, 
the literature search revealed very few reports on reliability, sensitivity or validity of the 
subtests in measuring change over time. In addition, the literature on clinical significance or 
clinical importance of performance on the subtests was extremely limited. 
" Reports on the sensitivity of the tests in detecting dementia were far more plentiful than reports 
specifically addressing mild cognitive impairment or decline. 
" CAFE baseline data compared well with normative data available on Logical Memory, Digit 
Span, MMSE and Rey Complex figure. However, for the NART and the Tests of Everyday 
Attention the CAFE cohort scored worse than the normative population. There was little 
correlation between NART IQ and performance on other tests in the CAFE battery at baseline; 
therefore it was unlikely that verbal intelligence would confound the findings. 
-" Overall, the CAFE neuropsychological test battery provides an acceptable method of 
measuring cognitive function in the cohort. Although evidence for reliability and validity of 
these tests in measuring change over time is limited, this appears to be the case for the majority 
of neuropsychological tests. Therefore choice of the tests was made on other grounds, namely 
the range of cognitive domains tested, and practical factors such as ease of administration, 
portability and time constraints. 
S. 4 
Methods 
" Participants were recruited via general practices. Electronic and paper GP notes were screened 
using inclusions and exclusion criteria and potential participants were invited by letter to take 
part in the study. 
" Baseline interview consisted of a validated neuropsychological assessment, health 
questionnaire, assessment of health status, physical examination, limb-lead ECG and blood 
tests. Follow-up examination at 12 months consisted of the same neuropsychological 
assessment, health questionnaire and assessment of health status. 
" Validation of all components of both interviews was undertaken where possible. 
9 Ethical approval was obtained for this study from the Sunderland Local Research Ethics 
Committee and the South Tyneside Local Research Ethics Committee. 
Results- baseline 
" Participants were recruited from general practices from in Sunderland and South Tyneside, 
which ranged from large practices with list sizes of 14,500 patients to small, single- 
handed practices. 
9 43% of notes screened were included as potential participants, with the major reasons for 
exclusion at this stage being history of stroke/TIA or person not in chronic NVAF. 
" Stages of recruitment involved applying exclusion criteria during screening of notes in 
general practice and at baseline interview. A large proportion (55%) of potential 
participants declined to take part after invitation, and a smaller proportion (14%) were 
excluded at interview. 
" Female responders were slightly younger than female non-responders (median 77 versus 
79 years) and responders were more likely to have a record of CHD and to have taken 
aspirin than non-responders. There were no significant differences between responders 
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and non-responders for other characteristics or documented co-morbidities (atrial 
fibrillation, CHF, hypertension, diabetes, thyrotoxicosis, Parkinson's, peripheral vascular 
disease and depression). 
" The median age of the CAFE cohort was 75 years; 56% were male, 37% had a record of 
CHD, 6.6% had CHF; 38.4% had a record of hypertension and 10.2% had a record of 
diabetes. 
" Characteristics of the cohort were examined with comparison of cases and controls. There 
were significant differences between cases and controls for measures of diabetes, 
cholesterol level, CHD, CHF and SF-36 score. These key variables were noted for 
incorporation into subsequent analysis of potential confounders. 
Results- follow-up 
9 The only significant differences between those who did and did not complete the follow-up 
interview were that those who completed the follow-up had better baseline scores for the 
physical activity and general health domains of the SF-36. 
" When the total study population was analysed without stratification, change in performance on 
the neuropsychological tests between baseline and follow-up was not significant for most tests. 
" When cases and controls were analysed separately, the overall direction of change in test scores 
over the follow-up period varied widely, in that for both groups, there was an overall 
improvement in some sub-tests and deterioration in others. However, the change in test score 
was only statistically significant (p<0.05) for a proportion of the tests: cases demonstrated 
overall improvement in two subtests and deterioration in four Subtests; controls showed 
improvement and deterioration in the same sub-tests as for cases, but also showed 
improvement in a further six subtests and deterioration in a further four subtests. These 
findings are not consistent with an overall deterioration in performance on neuropsychological 
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testing in atrial fibrillation compared to sinus rhythm, and thus support the null hypothesis that 
there is no consistent association between NVAF and cognitive decline over 12 months. 
" The overall direction of change (improvement or deterioration) varied between subtests which 
assessed the same cognitive domain, and there were no statistically significant differences 
between the proportion of cases and controls that improved, deteriorated or stayed the same for 
each subtest over the 12-month follow-up period. 
9 There were no statistically significant differences in most neuropsychological test scores, 
between cases and controls on aspirin, warfarin or neither therapy. 
" For nearly all subtests in the CAFE neuropsychological test battery, there was a highly 
significant correlation (p<0.01) between test score at baseline and test score at 12 month 
follow-up, suggesting very similar scores at baseline and score at follow-up for both cases and 
controls (for the majority of neuropsychological tests in the CAFE battery). 
" Age and education did not confound the results when put into a regression model. In addition, 
Pearson's correlation techniques showed little relationship between age at baseline interview of 
the total population and change in the majority of neuropsychological test scores over the 
follow-up period. 
" The number of participants who changed treatment subgroup according to antithrombotic 
therapy was small and did not impact upon the findings of the study. 
" There did not appear to be a consistent relationship between stroke risk (using SPAF criteria) 
and change in performance on neuropsychological tests over follow-up. 
" Overall, these results demonstrate no consistent or significant change in cognitive performance 
over the 12-month period for the total study population, and no consistent or significant 
difference in change in cognitive performance between cases and controls, nor between 
treatment subgroups. These findings support the null hypothesis that decline in cognitive 
function over time (12 months) in people with NVAF is no different to that of controls. 
S. 7 
Discussion 
9 The findings from this study conflict with previous studies in this field. However, previous 
studies were of lesser quality and less appropriate (cross-sectional) design. No previous high 
quality longitudinal studies of this research question have been published to date. 
" As with all studies of this nature, there are a number of potential areas of bias and 
possibilities for underestimation of the true extent of cognitive decline in this cohort, and 
limitations to this study included duration of follow-up, neuropsychological tests used and 
attrition of participants. These limitations need to be weighed against the advantages of 
generalisability of the results of this study in the general population, and the logistics of 
undertaking a substantial piece of research in the community. Despite these inevitable 
problems, a very extensive analysis of our results persistently demonstrated no clinically 
important differences between those with and without NVAF, nor between those with and 
without treatment with antithrombotic therapy. Therefore, in spite of the limitations 
described, in my opinion the findings that there is no association between NVAF and 
cognitive decline over (specifically) 12 months are valid. In addition, there is evidence to 
accept the null hypotheses that: 1) the cognitive function of people with NVAF is no 
different to that of age and sex-matched controls in sinus rhythm, when assessed by 
detailed neuropsychological testing; and 2) the decline in cognitive function over time 
(over 12 months) in people with NVAF is no different to that of controls. However, the 
findings of this study do not provide evidence to reject the hypothesis the decline in 
cognitive function over a longer period of time (i. e. more than 12 months) in people with 
NVAF is different to that of controls, nor that there is an association between untreated 
NVAF and cognitive decline. 
" Further research suggested by our findings includes more longitudinal studies of cognitive 
decline in NVAF, and include completion of the flu=-year follow-up of this study. 
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Appendix 1: Search strategies for literature searches. 
i) AF as a risk factor for cognitive decline/ dementia 
(search 1) 
Combination of the four strategies for aetiological and prognostic studies of AF and 
cognitive decline/dementia last carried out on March 2"d 2004. 
1, incidence. tw., 
2, exp mortality/ 
3, follow-up-studies. hw. 
4, mo. fs. 
5, prognos$. tw. 
6, predict$. tw. 
7, course. tw. 
8,1 or 2 or 3 or 4 or 5 or 6 or 7 
9, (odds and ratio$). tw. 
10, (relative and risk). tw. 
11, (case and control$). tw. 
12, exp cohort-studies/ 
13, exp risk/ 
14,9or10or11or12or13 
15, supraventric$. tw. 
16, atria$. tw. 
17, flutter. tw. 
18, fibrill$. tw. 
19, arrhythmi$. tw. 
20, dysrhythmi$. tw. 
21, tachy$. tw. 
22, sick sinus. tw. 
23, atrial fibrillation. sh. 
24, atrial flutter. sh. 
25, exp TACHYCARDIA, SUPRAVENTRICULAR/ 
26, sick sinus syndrome. sh. 
27, ((15 or 16) and (17 or 18 or 19 or 20 or 21)) or 22 
28,23 or 24 or 25 or 26 
29,27 or 28 
30, "Alzheimer-Disease"/ 
31, exp "Dementia-Vascular"/ 
32, "Lewy-Body-Disease"/ 
33, "Pick-Disease-of-the-Brain"/ 
34, "Kluver-Bucy-Syndrome"/ 
35,30 and 31 and 32 and 33 and 34 
36,30 or 31 or 32 or 33 or 34 
37, dement$. mp. [mp=title, abstract, name of substance, mesh subject heading] 
38, alzheimer$. mp. [mp=title, abstract, name of substance, mesh subject heading] 
39, (lewy$ and bod$). mp. [mp=title, abstract, name of substance, mesh subject 
heading] 
40, ((cognit$ or memory$ or mental$) and (declin$ or impair$ or los$ or 
deteriorat$)). mp. [mp=title, abstract, name of substance, mesh subject heading] 
A. 2 . 
41, (chronic and cerbrovascular). mp. [mp=title, abstract, name of substance, mesh 
subject heading] 
42, ('organic brain syndrome" or "organic brain disease"). mp. [mp=title, abstract, 
name of substance, mesh subject heading] 
43, "benign senescent forgetfulness". mp. [mp=title, abstract, name of substance, mesh 
subject heading] 
44, (cerebr$ and deteriorat$). mp. [mp=title, abstract, name of substance, mesh subject 
heading] 
45, (cerebr$ and insufficien$). mp. [mp=title, abstract, name of substance, mesh 
subject heading] 
46, (Pick$ and disease). ab, sh, ti. 
47, Binswanger. ab, sh, ti. 
48, Korsakoff$. ab, sh, ti. 
49, "Korsakoff$-Syndrome"/ 
50,37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 
51,36 or 50 
52,8 or 14 
53,29 and 51 
54,52 and 53 , 
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ii) Prognosis and natural history (used for searches 1 
and 2) 
From Oxford Centre for Evidence Based Medicine 
1. incidence. tw. 
2. exp mortality/ 
3. follow-up-studies. hw. 
4. mo. fs. 
5. prognos$. tw. 
6. predict$. tw. 
7. course. tw. 
8.1 or2 or 3 or 4 or 5 or 6 or7 
iii) Aetiology, causation and harm (used for searches 
1 and 2) 
From Oxford Centre for Evidence Based Medicine 
1. (odds and ratio$). tw. 
2. (relative and risk). tw. 
3. (case and control$). tw. 
4. exp cohort-studies/ 
5. exp risk/ 
6.1 or 2 or 3 or 4 or 5 
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iv) Atrial fibrillation (used for searches 1 and 2) 
Strategy for atrial fibrillation (Mark Sudlow MD thesis) 
1. supraventric$. tw. 
2. atria$. tw. 
3. flutter. tw. 
4. fibrill$. tw. 
5. arrhythmi$. tw. 
6. dysrhythmi$. tw. 
7. tachy$. tw. 
8. sick sinus. tw. 
9. atrial fibrillation. sh. 
10. atrial flutter. sh. 
11. exp TACHYCARDIA, SUPRAVENTRICULAR/ 
12. sick sinus syndrome. sh. 
13. ((1 or 2) and (3 or 4 or 5 or 6 or 7)) or 8 
14.9 or 10 or 11 or 12 
15.13 or 14 
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v) Stroke risk in atrial fibrillation (used as part of 
search 2) 
Combination of AF strategy above and McMaster's aetiology strategy 
1. case-control-studies. hw. 
2. cohort-studies. hw. 
3.1or2 
4. prognosis. tw. 
5. survival-analysis. hw. 
6.4 or 5 
7.3or6 
8. supraventric$. tw. 
9. atria$. tw. 
10. flutter. tw. 
11. fibrill$. tw. 
12. arrhythmi$. tw. 
13. dysrhythmi$. tw. 
14. tachy$. tw. 
15. sick sinus. tw. 
16. atrial fibrillation. sh. 
17. atrial flutter. sh. 
18. exp TACHYCARDIA, SUPRAVENTRICULAR/ 
19. sick sinus syndrome. sh. 
20. ((8 or 9) and (10 or 11 or 12 or 13 or 14)) or 15 
21.16 or 17 or 18 or 19 
22.20 or 21 
23.7 and 22 
24. *Cerebrovascular Accident/ 
25.23 and 24 
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vi) Risk factors for cognitive decline (search 3 and 
Chapter 3 search -different inclusion criteria used) 
This search combined a strategy for cognitive decline and dementia with a maximally 
specific aetiology strategy from Oxford Centre for Evidence Based Medicine, 
designed to retrieve articles on general risks for cognitive decline, not specifically AF. 
Search last performed on 2"d March 2004. 
1. "Alzheimer-Disease"/ 
2. exp "Dementia-Vascular"/ 
3. "Lewy-Body-Disease"/ 
4. "Pick-Disease-of-the-Brain"/ 
5. "Kluver-Bucy-Syndrome"/ 
6.1 and 2 and 3 and 4 and 5 
7.1 or 2 or 3 or 4 or 5 
8. dement$. mp. [mp=title, abstract, cas registry/ec number word, mesh subject 
heading] 
9. alzheimer$. mp. [mp=title, abstract, cas registry/ec number word, mesh subject 
heading] 
10. (lewy$ and bod$). mp. [mp=title, abstract, cas registry/ec number word, mesh 
subject heading] 
11. ((cognit$ or memory$ or mental$) and (declin$ or impair$ or los$ or 
deteriorat$)). mp. [mp=title, abstract, cas registry/ec number word, mesh subject 
heading] 
12. (chronic and cerbrovascular). mp. [mp=title, abstract, cas registry/ec number word, 
mesh subject heading] 
13. ("organic brain syndrome" or "organic brain disease"). mp. [mp=title, abstract, cas 
registry/ec number word, mesh subject heading] 
14. "benign senescent forgetfulness". mp. [mp=title, abstract, cas registry/ec number 
word, mesh subject heading] 
15. (cerebr$ and deteriorat$). mp. [mp=title, abstract, cas registry/ec number word, 
mesh subject heading] 
16. (cerebr$ and insufficien$). mp. [mp=title, abstract, cas registry/ec number word, 
mesh subject heading] 
17. (Pick$ and disease). ab, sh, ti. 
18. Binswanger. ab, sh, ti. 
19. Korsakoff$. ab, sh, ti. 
20. "Korsakoff$-Syndrome"/ 
21.8or9or10or11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22.7 or 21 
23. case-control-studies. hw. 
24. cohort-studies. hw. 
25.23 or 24 
26.22 and 25 
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vii) Neuropsychological tests 
This search was to determine clinical significance of and reliability in measuring 
change of the subtests in the CAFE test battery(on e-alert therefore last searched 
immediately prior to submission of thesis). 
1. exp Reproducibility of Results/ 
2. exp *Neuropsychological Tests/cl, mt, st, sn [Classification, Methods, Standards, 
Statistics & Numerical Data] 
3. exp *Wechsler Scales/sn, st [Statistics & Numerical Data, Standards] 
4. *Attention/ or Tests of everyday attention. mp. 
5. Rey figure. mp. 
6. Tests of everyday attention. mp. 
7. National Adult Reading Test. mp. 
8. MMSE. mp. 
9. Mini Mental State Examination. mp. 
10.8 and 9 
11.8 or 9 
12. Paced Auditory Serial Addition Test. mp. 
13. Clincal significance. mp. 
14. clinical relevance. mp. 
15. measurement of change. mp. 
16.1or14or15 
17.2 and 3 and 5 and 6 and 7 and 11 and 12 
18.2or3or5or6or7orllor12 
19.16and18 
20. limit 19 to (human and english language and abstracts) 
A. 8 
viii) Post-stroke dementia 
1. Cognition Disorders/ 
2. limit 1 to ovid full text available 
3. DEMENTIA/ 
4. limit 3 to ovid full text available 
5. Cerebrovascular Accident/ 
6.2or4 
7.5and6 
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Appendix 2: Forms used for Chapter 3 literature 
search 
i) Box 1: In/out form 
Study ID Endnote reference number 
First 
Author. Year Reviewer 
Participants Yes/No 
1 Human, predominantly aged 60 years and over. 
2 Representative community sample. 
3 Not subgroups of the population which have been selected on the 
basis of existing specific illness. 
A 1 and 2 and 3 present? 
Outcome Yes/No 
4 Rate of cognitive 
decline 
5 Nature of cognitive 
decline 
B 4 or 5 present? 
Study designs and methodological quality Yes/No 
6 Cohort study 
7 Prospective, with follow-up 
8 Community-based 
C 6,7 and 8 present? 
Tick here if further discussion with 
second observer needed prior to 
final decision. 
`YES' to all of A, BandC=IN 
'NO'to any of A, B orC=OUT 
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ii) Box 2: Data extraction sheet 
Instruction: complete the following sheet for all included papers. Note: it may not be 
possible to answer all questions for all papers. Answers to questions marked with an 
* will be transposed onto the summary spreadsheet. 
General Information: - 
Reviewer: Date of extraction: Study ID*: 
First author of paper: Year of Publication: 
Eligibility Check: 
Participants are human, representative community sample, not a group which have 
been pre-selected on the basis of existing specific illness and over 60 years? 
Yes/No 
Outcome measures are the rate (+/- nature) of cognitive decline? Yes / No 
Study design is a prospective cohort study? Yes / No 
If yes to all, continue: 
Participants and setting: 
Target population of the study: 
Research question of the study? 
*State outcomes (if any) other than cognitive decline which are used in the study: 
Are all participants in the study suitable for inclusion, or is only a specific group 
within the main study suitable (e. g. controls)? 
*Inclusion criteria (should be all-inclusive, but may need to re-evaluate based on 
studies obtained): 
*Exclusion criteria (should be minimal, but may need to re-evaluate based on studies 
obtained): 
*Recruitment procedure (relevant to response bias etc): 
*Characteristics of the participants included at baseline: 
Age range = 
Ethnicity = 
Sex = 
(i) Other special characteristics of relevance = 
A. 11 
Methods 
Study design (should be prospective cohort study): 
*Sample size required/ attained: 
*Follow-up: 
Total length of follow-up from baseline to final assessment = 
Mean follow-up time= 
Number of follow-up assessments = 
*Neuronsychological test battery: 
How was cognition measured (give full details e. g. name of battery, where developed. 
whether widely used, tests included, which aspects of cognition are recorded etc)? 
Were measurements at baseline and follow-up identical? (If not, how did they differ? ) 
*State other measures carried out at baseline: 
*State other measures carried out at follow-up: 
Analysis and Results 
*What was the attrition rate? 
*What was the level of non-participation? 
*What % were followed up? 
*What were the baseline cognitive function score(s)? 
*What were the follow-up cognitive function score(s)? 
*What was the rate of decline in cognitive function score(s)? 
State any sub-group differences in the rate of cognitive decline: 
*State any findings on the nature of cognitive decline - which aspects of cognition 
affected most (e. g. memory, attention, concentration), sub-group differences if any: 
A. 12 
Miscellaneous: 
Are these results duplicated in another paper in this review (if so, state study ID 
number)? 
*Other notes and calculations: 
A. 13 
iii) Box 3: Appraisal checklist and quality assessment form 
(This information will be useful if an assessment of quality is required. An overall 
score is not appropriate. ) 
o sý o 
CD 
0 
I 
Participants and settin : 
Is sample representative of the normal population? X X X 
Is the sample of patients well defined at the level of both invitation to X X X 
participate and agreement to participate? 
Methods 
Power calculation performed? X X X 
Objective and unbiased outcome criteria used: 
Clear, logical definitions for outcomes shown before the study started? X X X 
Had the neuropsychological test battery been validated? Are they sensitive X X X 
to change and reliable for the purposes? 
Did an appropriate professional carry out the neuropsychological testing? X X -X 
Was training provided if necessary? 
Was the follow-u : 
Sufficiently long (long enough for outcomes to occur)? X X x 
Sufficiently complete (proportion of cohort followed up)? X X X 
Analysis and Results 
Were statistical techniques used appropriate? (need to be suitable for x X X 
anal sis of change) 
Was there adjustment for important prognostic factors/ confounders? X X X 
Was there adequate Fu such that the level of non-participation does not x X X 
influence the findings (thus reducing non-response bias? ) 
Was the attrition rate dealt with adequately? X x X 
Does the analysis account for the passage of time? X X X 
Was the study designed/ conducted so that other, unaccounted-for factors x X .X 
were unlikely to influence the outcome? 
Are the estimates for risk of cognitive decline sufficiently precise X 
(confidence intervals given? ) 
i ll 
Other notes on quality: 
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Appendix 3: Neuropsychological tests 
i) Outline of the neuropsychological test battery: 
The following is a brief outline of how the tests are carried out. This does not contain the 
level of detail required to carry out the tests (such as is provided in test manuals), and is 
included here only to provide the reader with a basic idea of what the tests consist of and 
the logistics of the patient visits. 
MMSE 
This pen and paper test consists of asking the participant to answer questions/ perform 
short tasks in order to gain a measure of general cognitive function. 
Logical Memory and Digit Span subtests of the Wechsler Memory Scale 
Logical memory involves reading a tape recording of a short story to the participant, who 
is then immediately asked to recall information about the story. They are then asked to 
recall any information after a delay of 30 minutes from the original playing of the tape and 
again asked to recall information about the story. The participant is scored according to the 
amount of information they remember, and both raw scores and percentile scores can be 
obtained. The test is repeated with a different story. Note: for the CAFE study, 
the more recent 25 points for each story version was used. 
Digit span involves reading out ever increasing strings of numbers, with the participant 
repeating each string immediately after the observer. The participant is scored according 
to the number of correct strings recalled. The process is then repeated with the participant 
asked to recall the string in reverse. Again, number of correct strings are recorded. 
A. 15 
Rey Complex Figure 
The participant is asked to copy a complicated figure and then to recall the figure (asked to 
draw it again) after 30 minutes. The figure is scored using a scoring sheet according to the 
accuracy and position of the components of the drawing. 
Map Search and Telephone Task subtests of Tests of Everyday Attention 
For the Map Search Task, the participant is provided with a map, on which there a number 
of symbols. The participant is asked to circle as many symbols as possible with a red pen 
for one minute, and then with a blue pen for one further minute. The number of symbols 
circled in the 1" and 2nd minute is recorded. 
The Telephone Task consists of the participant being provided with a telephone directory, 
with two symbols shown after each telephone number. The participant is asked to circle 
any pairs of symbols, and the time taken is recorded. The task is repeated with a different 
telephone directory and the patient is then distracted by being asked to count beeps played 
on a tape recorder whilst circling the symbols. 
Paced Auditory Serial Addition Test 
This test consists of a tape recording of a list of numbers being played. The participant is 
asked to add consecutive numbers together and call out the answer. This test is repeated at 
two different speeds. 
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i) Rey figure 
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iv) NART word card (patient reads the following words aloud) 
chord _ thyme aeon - 
ache - 
heir 
_ placebo _ 
depot 
- radii abstemious _ 
aisle _ assgnate _ 
detente 
_ 
bouquet 
_ 
hiatus 
_ 
idyll 
psalm _ subtle - puerperal - 
capon _ procreate - aver _ 
deny 
_ gist - gauche - 
nausea s_ gouge - - topiary 
debt 
_ superfluous _ . 
leviathan. 
- 
courteous simile - 
beatify 
- 
5arcfy - 
banal 
- prelate 
eqiuvocal - quadruped 
sidereal _ 
naive - cellist _ 
demesne 
_ 
catacomb _ 
facade syncope _ 
gaoled - zealot 
labile 
_ 
drachm 
- campanile 
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Appendix 4: Further information on 
neuropsychological tests 
Table of orientation of test score directions 
Neuropsychologic Direction Direction of Direction of ranks of follow-up 
al test of score follow-up minus baseline score 
minus 
baseline score 
MMSE High is Positive is Negative rank = deterioration 
good improvement Positive rank = improvement 
Logical memory High is Positive is Negative rank = deterioration 
test (immediate, 
raw) 
good improvement Positive rank = improvement 
Logical memory High is Positive is Negative rank = deterioration 
test good improvement Positive rank = improvement 
(immediate, %) 
Logical memory High is Positive is Negative rank = deterioration 
test good improvement Positive rank = improvement 
(delayed, raw) 
Logical memory High is Positive is Negative rank = deterioration 
test good improvement Positive rank = improvement 
(delayed, %) 
Rey (copy) High is Positive is Negative rank = deterioration 
good improvement Positive rank = improvement 
Rey (recall) High is Positive is Negative rank = deterioration 
good improvement Positive rank = improvement 
Map (left, 1st High is Positive is Negative rank = deterioration 
minute) good improvement Positive rank = improvement 
Map (right, 1S High is Positive is Negative rank = deterioration 
minute) good improvement Positive rank = improvement 
Map (left, 2° High is Positive is Negative rank = deterioration 
minute) good improvement Positive rank = improvement 
Map (right, 2° High is Positive is Negative rank = deterioration 
minute) good improvement Positive rank = improvement 
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Neuropsychologic Direction Direction of Direction of ranks of follow-up 
al test of score follow-up minus baseline score 
minus 
baseline score 
Map (total) High is Positive is Negative rank = deterioration 
good improvement Positive rank = improvement 
Telephone task High is Positive is Negative rank = deterioration 
(no. of targets) good 
improvement Positive rank = improvement 
Telephone task Low is Negative is Negative rank = improvement 
(time taken) good improvement Positive rank = deterioration 
Telephone task Low is Negative is Negative rank = improvement 
(dual task good improvement Positive rank = deterioration 
decrement) 
NART (no. of Low is Negative is Negative rank = improvement 
errors) good improvement Positive rank = deterioration 
NART (IQ) High is Positive is Negative rank = deterioration 
good improvement Positive rank = improvement 
Digit span High is Positive is Negative rank = deterioration 
good improvement Positive rank = improvement 
PASAT (2.4- High is Positive is Negative rank = deterioration 
seconds) good improvement Positive rank = improvement 
PASAT (1.2- High is Positive is Negative rank = deterioration 
seconds) good improvement Positive rank = improvement 
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Table of Cognitive domains and anatomical areas for the CAFE battery 
Neuropsychological Test Cognitive Domain Anatomical Area 
Logical Memory Verbal short-term memory Left hemisphere 
immediate (Raw and %) 
Logical Memory delayed Verbal short-term memory Left hemisphere 
(Raw and %) 
Digit Span Verbal short-term memory Left hemisphere 
Map 1 Visual selective attention Subcortical and cortical 
brain regions, anterior 
cingulate gyrus of frontal 
lobe (target detection, 
inhibition/ selection), right 
cerebral hemisphere 
(alertness/ maintenance) 
Map 2 as above as above 
Map 3 as above as above 
Map 4 as above as above 
Rey Complex Copy Non verbal memory Right hemisphere 
Rey Complex Delayed Non verbal memory Right hemisphere 
National Adult Reading Premorbid intelligence Left hemisphere 
Test (Errors and IQ) (language) 
Mini Mental State General cognitive function - 
Examination 
Telephone task 1 (no. of Selective attention Anterior circulate gyrus of 
targets) frontal lobe (+/- 
subcortical region) of right 
hemisphere 
Telephone task 2 (time as above as above 
taken) 
Telephone task 3 (dual Divided attention as above 
task decrement) 
Paced Serial Addition Test Information processing as above plus left 
(2.4-seconds) and attention hemisphere 
Paced Serial Addition Test as above as above 
(1.2-seconds) 
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Appendix 5: GP Checklist 
UNIVERSITY OF 
NEWCASTLE 
! '1 A t' L? 
V "L' " Cognition and Atrial Fibrillation 
Evaluation -a study of silent cerebral infarction and cognitive decline in AF) 
Checklist for New Practices 
Consent form signed? 
Has information on study given to 
" practice manager 
" all partners 
" all practice nurses? 
If labels to be used, has info been given to all using labels (as above)? 
" practice manager 
" all partners 
" all practice nurses? 
Practice info collected? 
" List size 
" Number of fulltime partners 
" Number of part-time partners 
" Number of practice nurses 
" Fully computerised 
" Partially computerised? - to what extent 
" Warfarin monitoring done where - pharmacist led/ GP/ hospital 
Further information on 
practice 
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Appendix 6: Consent form for GPs 
UNIVERSITY OF 
NEWCASTLE 
lsa4l 
Silent Cerebral Infarction and Cognitive Decline 
in Atrial fibrillation Study 
General Practitioner Consent Form 
Name: Dr 
Practice: 
" Have you read the information sheet provided? 
YES/NO 
" Have you had the opportunity to ask questions and discuss the study? 
YES/NO 
" Have you received satisfactory answers to all your questions? 
YES INO 
" Have you received enough information about the study? 
YES/NO 
" Who have you spoken to? 
" Do you understand that your patients are free to withdraw from the study 
at any time without affecting your future medical care? 
YES / NO 
" Do you agree to allow us to access patient's notes and records and select 
patients (who we will then invite to take part in the study)? 
YES/NO 
Signed: 
_ // 
Witness: 
Date 
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Appendix 7: Letters to participants 
i) Letter to controls 
(SRH headed paper) 
GP's name and address Department of Medicine for the Elderly, 
Dr Helen Park 
School of Clinical Medical Sciences 
Sunderland Royal Hospital 
Kayll Road, 
Sunderland 
SR4 7 TP 
Telephone 0191 565 6256 
Or 0191 222 7446 
Dear (title, surname), 
Re Atrial fibrillation and cognitive decline: a study of memory 
problems in older people 
The University of Newcastle and Sunderland Royal Hospital are working 
with your GP to find out about memory problems in older people. We 
are trying to find out about whether or not there is a connection between 
the heart and memory problems. We are writing to ask for your help 
with this important work, which we hope will eventually allow doctors to 
prevent some memory problems from happening. 
We are inviting people from your practice and other local practices to 
help us, not because there is anything wrong with their hearts, but 
because we want to know about everyone in the community, whether 
they are ill or not. We have used the list of patients registered with the 
practice to choose who to invite. 
If you are happy to be involved with the study, one of the team here 
(either Dr Park or the team nurse) would like to visit you at home in 
order to go through a few questions about your health. We would like to 
carry out some simple memory tests. We would also like to check your 
blood pressure and perform an electrical tracing of your heart called an 
ECG (which stands for electrocardiogram). This test is very routine and 
certainly will not cause you any discomfort. We would also like to take a 
blood test. The visit will take one to two hours of your time. 
After this visit, it may also be useful to do other tests of the heart and 
brain, which we will contact you about after the visit. 
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We will keep all of the information that you give us confidential. Your 
individual details will not be identifiable in any way in any reports arising 
from the study. However, we should like to send the results of your tests 
to your general practitioner. The information in the tests may be helpful 
to your own doctor as a general health check. 
A suggested date and time when either Dr Park or the team nurse 
would like to visit is given on the sheet with this letter. We hope that this 
will be convenient for you. Please get in touch with Dr Park at the 
telephone numbers or address given at the head of this letter if the time 
is inconvenient, so that we can make other arrangements for you. 
Please get in touch you have any questions, worries or if there is any 
reason why you do not wish to take part in the study. There is no 
obligation to take part. If you decide you do not want to help with the 
study this will not affect any care you receive from your GP. 
However, it is important for the study that everyone from the invitation 
list can take part if they are able to, and we are very grateful for your 
help. 
Yours sincerely, 
Signature and name of GPs in the practice 
Dr Helen Park 
Signature 
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ii) Letter to cases 
(SRH headed paper) 
GP's name and address 
Dr Helen Park 
Dear (title, surname), 
Department of Medicine for the Elderly, 
School of Clinical Medical Sciences 
Sunderland Royal Hospital 
Kayll Road, 
Sunderland 
SR4 7TP 
Telephone 0191 565 6256 
Or 0191 222 
, 
7446 
Re Atrial fibrillation and cognitive function: a study of memory 
problems in older people 
The University of Newcastle and Sunderland Royal Hospital are working 
with your GP to find out about memory problems in older people. We 
are trying to find out about whether or not there is a connection between 
the heart and memory problems. We are writing to ask for your help 
with this important work, which we hope will eventually allow doctors to 
prevent some memory problems from happening. 
We are inviting people from your practice and other local practices to 
help us. We are particularly interested in talking to healthy people who 
have an irregular heart beat (known as 'atrial fibrillation' or 'AF). We 
have used the list of patients registered with the practice to choose who 
to invite. 
If you are happy to be involved with the study, one of the team here 
(either Dr Park or the team nurse) would like to visit you at home in 
order to go through a few questions about your health. We would like to 
carry out some simple memory tests. We would also like to check your 
blood pressure and perform an electrical tracing of your heart called an 
ECG (which stands for electrocardiogram). This test is very routine and 
certainly will not cause you any discomfort. We would also like to take a 
blood test. The visit will take one to two hours of your time. 
After this visit, it may also be useful to do other tests of the heart and 
brain, which we will contact you about after the visit. 
We will keep all of the information that you give us confidential. Your 
individual details will not be identifiable in any way in any reports arising 
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qhý' 
from the study. However, we should like to send the results of your tests 
to your general practitioner. The information in the tests may be helpful 
to your own doctor as a general health check. 
A suggested date and time when either Dr Park or the team nurse 
would like to visit is given on the sheet with this letter. We hope that this 
will be convenient for you. Please get in touch with Emma Hutchinson 
on 0191 222 5425 if the time is inconvenient, so that we can make other 
arrangements for you. 
Please get in touch if you have any questions, worries or if there is any 
reason why you do not wish to take part in the study. There is no 
obligation to take part. If you decide you do not want to help with the 
study this will not affect any care you receive from your GP. 
However, it is very important for the study that everyone from the 
invitation list can take part if they are able to, and we are very grateful 
for your help. 
Yours sincerely, 
On behalf of the partners at X GP practice 
Signature 
Dr Helen Park 
Signature 
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iii) Shortened letter 
GP name 
GP address 
Date 
Dear 
Dr Helen Park 
Department of Medicine for the 
Elderly 
Sunderland Royal Hospital 
Kayll Road 
Sunderland SR4 7TP 
Telephone 0191 565 6256 ext 
AI 
Or 0191 222 7182 
Re The CAFE study: a study of memory problems in older people 
About the study: We are performing a large research study about 
memory in older people, to find out whether there is a connection 
between the heart and people's memory. You may have seen our 
poster in Dr 's waiting room. 
We would like to ask for your help with this important work, which may 
eventually allow doctors to prevent some memory problems from 
happening. 
What we need from you: If you agree to be involved, one of us (either 
Dr Park or the team nurse) would visit you at home to go through some 
questions about your health including some memory questions, and 
carry out a short health examination including a blood pressure check. 
The visit will take one and half hours of your time. 
; 
ýt 
We would like to take a blood test at the visit. However, we would still 
like you to be involved, even if you would prefer not to have the blood 
test. We would also like to do a scan of the heart at a later date, but we 
would still like you to be involved, even if you would prefer not to have 
this test. All of the information that you give us will be strictly 
confidential. However, we will send the results of your tests to your 
general practitioner for his/her records. 
What happens now? 
We hope that you will be able to help us. If so, please complete the 
reply slip enclosed and return it to us in the addressed envelope (stamp 
not needed). We will then contact you to arrange a convenient time for 
Dr Park or the study nurse to visit you at home. 
We are very grateful for your help. 
Yours sincerely, 
Dr Helen Park On behalf of the partners at GP practice 
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iv) Reply slip 
REPLY SLIP 
If you are willing to help us with any part of this study, 
please tick the box and return this slip in the envelope provided 
(stamp not needed) as soon as possible. We will then contact 
you to arrange a convenient time to visit you at home. 
"I am interested in being involved in the study 
Name 
Study ID 
Please write here the phone number at which you may be contacted 
If you have any questions about this form or any part of the 
study, please ring Dr Helen Park, telephone: 0191 222 5425 
Thank you for your time 
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v) Letter to general practitioners 
Headed paper 
Date 
GP name and address 
Dear Dr 
Re Silent cerebral infarction and cognitive impairment in atrial fibrillation study 
We wish to explore a possible link between cognitive impairment and atrial 
fibrillation (AF), and are seeking your help. 
Background 
Several small studies have reported an association between cognitive decline and AF, 
including a pilot study by Dr O'Connell and Professor Gray. If this is indeed the case, 
it has important consequences for treatment and prevention. However, there are no 
prospective studies using detailed neuro-imaging (e. g. MRI). 
We intend to carry out such a study in Sunderland. We have received ethical approval 
from Sunderland LREC and funding for a Regional Fellowship from NHS R&D. 
Why we need your help 
We need help to identify patients with NVAF and controls who we will assess 
prospectively with standardised measures of cognitive function and relevant investigations 
(including echo and MRI brain scan). 
The project will involve access to patient notes to identify cases and controls. If you 
agree to be involved, we will help your practice to identify patients with AF using a 
combination of digoxin screening and opportunistic pulse palpation, perhaps 
supported by note flagging. We would then seek your permission to approach and 
consent patients. We would visit at home, and some will also be invited to Sunderland 
Royal Hospital for investigations. 
The results of all investigations will be made available to you. 
The team 
" Dr Janice O'Connell: Department of Geriatric Medicine, School of Clinical 
Medical Sciences, University of Newcastle upon Tyne / Sunderland Royal Hospital 
" Professor Richard Thomson: Department of Epidemiology and Public Health, 
University of Newcastle upon Tyne 
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" Professor Christopher Gray: Department of Geriatric Medicine, School of Clinical 
Medical Sciences, University of Newcastle upon Tyne / Sunderland Royal Hospital 
" Mr Tony Hildreth: Medical Statistician, City Hospitals Sunderland 
" Dr Helen Park: Research Training Fellow and Study Co-ordinator, University of 
Newcastle upon Tyne / Sunderland Royal Hospital 
We hope you will be able to help with this study. We will telephone you at the 
surgery in two weeks time in order to discuss this with you further, but in the 
meantime please contact Dr Helen Park (telephone 0191 222 7182 or 0191 565 6256 
ext 41243) if you have any queries. 
Many thanks for your help with this study. 
Yours sincerely, 
Dr Helen Park 
Dr Janice O'Connell 
Professor Richard Thomson 
Professor Christopher Gray 
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Sample GP newsletter 
ý GSj 
UN IVERSIT Y OF ; -I 
NI: WCAS"II. {; 
IA. 
I 
LA 
'lýýI 
Department of Clinical Geriatrics, Sunderland Royal Hospital, Sunderland 
Dear Colleague 
Many thanks for your continued 
help with the CAFE (Cognition 
and Atrial Fibrillation) study. 
Update: 
We have just reached the end of 
the one-year follow-up visits, car- 
ried out in the patient's own home. 
We appreciate your help in putting 
across to your patients the impor- 
tance of this research in terms of 
preventing dementia in the future. 
The majority of patients seemed 
to enjoy the follow-up visit and 
were interested in the study's pro- 
gress. (Note: the follow-up visit 
consisted only of a repeat of the 
'memory quiz' and health ques- 
tionnaire; there was no ECG / 
examination/ blood test at this 
visit). 
Contact details: 
Dr Helen Park 
do Dr O'Connell's secretary 
i Department of Medicine for the Elderly, 
Health 
Sunderland Royal Hospital 
Kayll Road 
Sunderland SR4 7TP 
Tel: 0191 5656256, leave a 
message with Dr O'Connell's secretary 
ýö 
Il`1 j \j 6; : Ai IPi 
CAFE statistics: Practices involved : 44 
Patients who have completed baseline: 362 
Patients who have completed follow-up: 307 
Dissemination of the results: 
The baseline data has been analysed and we are currently 
in the process of writing up these results for publication. We 
will inform you once this has been finalised 
Once all of the follow-up data has been entered into our da- 
tabase we will begin this analysis, which will be ongoing 
over the summer months. 
In addition to publication in journals, we intend to dissemi- 
nate CAFE results through presentation at conferences in 
the UK We will be taking a poster to the Annual Scientific 
Meeting of the Faculty of Public Health Medicine in June 
2002 and we are in the process of submitting abstracts to 
other relevant meetings within the fields of geriatric medi- 
cine and public health medicine. 
We will keep you up-to-date with any publications as they 
arise. 
OR 
Emma Hutchinson 
Department of Epidemiology and Public 
The Medical School 
University of Newcastle 
Newcastle upon Tyne NE2 4HH 
Tel: 0191 2227182 
'127 
c1iI: 
l1 
;1 
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vii) Poster for GP surgery waiting rooms 
CAFit-A study of 
Memory peo b/ems in 
Oldef people 
e ý; al (°eriatrlcs, Su. underland Rovval Hospital, Sunderland 
What is the Cafe Study? 
This practice is involved with work being carried out by Sunderland Royal Hospital and the 
University of Newcastle, working with older people in the Sunderland area. 
We are trying to find what may cause memory problems as people get older, so that 
ultimately we may help to prevent memory problems. 
We need your help: - 
To do this we need people aged over 60 years who have a reasonable memory. We are 
working with your GP to identify people, and you may receive a letter asking for your help. 
If you receive a letter, please help! 
3 
F' 7 L 
WHAT DO I NEED TO DO? 
Ii yoaa .a letter please return the reply slip and 
we, will i{1¬ 1 visit YOU at home to (go ti iougI1 a 
gfen ernl health, check and memory quiz. 
UNIVERSITY OF 
NEWCASTLE 
(Rý 
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Appendix 8: Patient information leaflet 
Taking part in research -a Patient Information Sheet 
Study Title: Silent Cerebral infarction and Cognitive impairment in 
atrial fibrillation -a study of memory changes in people with or without 
an irregular heartbeat. 
You have been asked to take part in a research project looking at memory changes in older 
people. Here is some information to help you to decide whether or not to take part. Please 
take time to read the information carefully and discuss it with relatives, friends and your 
GP if you wish. Ask us if there is anything you do not understand or if you would like 
more information. Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
Do I have to take part? 
Your participation is entirely voluntary and if you decide not to participate this will not 
affect your future medical care. If you do take part, you can still withdraw at any stage 
during the study without having to give a reason and again this will not affect your future 
care. 
Why is the study being carried out? 
It is possible that an irregular heartbeat, without treatment, could be linked with poorer 
memory in older people. If this is true, some memory problems could be prevented by 
good use of treatment for an irregular heartbeat. We want to test this theory by looking 
closely at different aspects of memory and brain function in a large number of people, 
some of whom have an irregular heartbeat. You have been chosen randomly as one of this 
large group of 480 people in the Sunderland area. 
Who is organising the study? 
A team based at Sunderland Royal Hospital and the medical school at Newcastle 
University is carrying out the study. The funding for the study is partly from the Northern 
and Yorkshire Regional Research and Development Directorate, and partly from other 
sources. The study is taking place over a period of 3 years. 
What will happen to me ifI take part? 
If you do take part in the study one of the team will visit you at home at a time/date, which 
is convenient for you. You will be asked to answer some questions about your general 
health. You will also be asked to answer some detailed questions about memory and carry 
out a memory quiz. If you are willing, a small blood sample, blood pressure reading and 
harmless tracing of the heart (ECG) will be carried out - however, we would still like you 
to be involved in the study, even if you do not wish to have these, and would prefer to 
simply go through the interview and memory quiz. 
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At a later date you may be asked to attend Sunderland Royal Hospital for a harmless scan 
of the heart called an echocardiogram, which is similar to ultrasound scans of pregnant 
women. This will not affect your ability to drive, your diet, or any other aspect of your life. 
We would still like you to be involved in the study, even if you would prefer not to have 
the echocardiogram. 
One year later we will visit you at home again, to go through the same questions and 
memory quiz (there will be no blood test or heart tracing). 
What type of study is it? 
This will be an `observational study', which means that no drugs or new treatments are 
being used, i. e. we will simply be observing people in the study over the course of one 
year. 
Possible risks 
There are risks involved in this study that are minor - there may be slight bruising to the 
forearm after the blood sample has been taken. Otherwise, all of the tests are harm-free. 
Insurance policies: as in all health checks, we will be measuring your blood pressure - if 
we detect high blood pressure, this occasionally has an affect on private medical insurance 
policies. If you have such a policy you should let the insurers know and they will be able 
to tell you whether this affects your insurance or not. 
Possible benefits 
You will receive a thorough health check, and any problems picked up can be passed on to 
your GP so that appropriate treatments can be started. 
In the future, the information that we get from the study may help to reduce the chance of 
memory problems in people with an irregular heartbeat. 
It is possible that the tests and questions may uncover some health problems unrelated to 
the study. We will pass on all information (confidentially) to your GP, so that he/she can 
treat you appropriately. 
You will be told if important new information about this study becomes available which 
might affect your willingness to continue taking part. If at any time we consider it in your 
best interest, we will withdraw you from the study. We will then explain the reasons. 
Payments 
Sunderland Royal Hospital and the Newcastle University will be provided with funds from 
the grant-giving bodies, to contribute towards the overheads involved in carrying out the 
study. 
GP notification 
Your GP has helped us to find people to be involved in the study, therefore he/she is aware 
that you have been asked to take part. With your permission, we will pass on the GP your 
answers to the health-check questions and the results of your tests. 
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Restrictions 
Taking part in the study will not restrict your diet, or affect whether or not you can give 
blood. 
What if something goes wrong? 
In the unlikely event that you are harmed by taking part in the study, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then you 
may have grounds for legal action. Regardless of this, if you have any cause to complain 
about any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are available to you. 
Confidentiality - who will know I'm taking part in the study? 
We will keep all the information (including test results) strictly confidential. Medical 
records of results relating to the study will not be disclosed to any third party other than 
your GP. We will ensure that we comply with any national data protection regulations. 
What will happen to the results of the study? 
We will publish the information from the study in medical journals, so that they are 
available to doctors, nurses and other relevant health professionals. These publications will 
include no reference to individual patients. 
For more information: 
Consumers for Ethics in Research (CERES) publish a leaflet entitled `Medical Research 
and You'. This leaflet gives more information about medical research and looks at some 
questions you may want to ask. A copy may be obtained from CERES, PO Box 1365, 
London N16 OBW. 
If at any time you have any questions about the study, or your rights as a participant, you 
should contact: 
Dr Helen Park on telephone 0191565 6256 ext 42109; or 0191222 5425. 
Thank you very much for taking part in this study. 
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Appendix 10: GP notes exclusion checklist 
General Information 
GP records number 
Name 
Case or control 
Aged over 60? If no = excluded 
Cases only: 
AF 
_Currently 
has AF? If no = excluded 
_Currently 
has chronic AF? If no = excluded 
Was diagnosis made before January 1995? If yes = excluded 
Cases and controls: 
Stroke 
_Any 
record of the patient having a stroke (WHO criteria)? If yes = excluded 
_Any 
record of the patient having a TIA (WHO criteria)? If yes = excluded 
Heart Failure 
If any symptomatic heart failure in the last 3 months, do notes state the followin : 
" less than ordinary activity results in symptoms? If yes = excluded 
" any physical activity causes discomfort? If yes= excluded 
" symptoms are present at rest? If yes = excluded 
Severe visual or hearing impairment 
Do the records suggest that the patient has severe visual impairment If yes = 
excluded 
Do the records suggest that the patient has severe hearing impairment If yes = 
excluded 
Dementia 
_Any 
record of the patient having established dementia? If yes = excluded 
A. 46 
Prosthetic valves/rheumatic fever: 
An record of a prosthetic valve? If es = excluded 
Any record of a pacemaker? If yes = excluded 
Any record of having suffered from rheumatic fever? If yes = excluded 
Other reason for exclusion in study? (If yes, please state reason below 
Is patient excluded from study? 
If reason for exclusion not in list, please state here: - 
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Appendix 11: Consent form for participants IVERSITY OF 
NEWCASTLE 
4 
0 
Department of Epidemiology 
and Public Health 
Atrial fibrillation and cognitive decline: a Study of Memory Problems in 
Older People: Patient Consent Form 
Name: 
" Have you read the patient information sheet or has this been read to you? 
YES/NO 
" Have you had the opportunity to ask questions and discuss the study? 
YES/NO 
" Have you received satisfactory answers to all your questions? 
YES/NO 
" Have you received enough information about the study? 
YES/NO 
" Who have you spoken to? 
" Do you understand that you are free to withdraw from the study at any 
time without affecting your future medical care? 
YES/NO 
" Do you agree to your GP being informed of your participation in the study? 
YES/NO 
" Do you agree to take part in the study? 
YES/NO 
Signed: Date // 
Witness: Date // 
A. 48 
Appendix 12: Interview dataforms 
A. 49 
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Appendix 12: Interview dataforms 
PRIVATE AND CONFIDENTIAL 
UNIVERSITY OF 
NEWCASTLE y AosnIrýr 
s 
/ ol ,ý A. F 
.3 h-. - 2' 
(Cognition and Ati al Fibrillation Evaluation -a 
study of memory problems in older people) 
17 
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Study Details: 
Tick when completed: 
Interview 
Neuropsychological tests 
ECG done 
Bloods taken 
Blood results received 
Physical Examination 
Patient's status in study: 
Casa 
Control 
Excluded from study 
Included in study 
STUDY NUMBER: 
ýý - 
t 
k 
LJ 
A. 52 
K. 
STUDY NUMBER _i 
SECTION 1- Personal details 
Today's date: 
1. Surname 
2. Forenames 
3. Date of birth: 
i 
- 2. Sex: 
3. Marital status: 
Day Month Year 
Male 
Female 
Single /. Never married I 
Married 2 
Widow / Widower 3 
Divorced 4 
Separated 5 
Family' history: 
Is there a family history (mother, father, siblingsjof : 
4. Stroke? Yes 1 
5. Heart attacks? Yes 1 
6. Raised blood pressure? Yes 1 
7. Memory problems, including dementia? Yes 1 
1 
2 
no 2 
no 2 
no 2 
no 2 
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STUDY NUMBER 
SECTION 2- Current Health Problems and Past Medical 
History 
1. Have you ever had a stroke (sometimes known as cerebral haemorrhage, 
cerebral thrombosis, brain haemorrhage, subarachnoid haemorrhage, 
cerebrovascular accident (CVA), or a mini-stroke or TIA)? Yes 1* 
No 2 
2. Have you recently notijed any of the following (excluding symptoms known 
to be due to migraine): 
temporary weakness in one or both arms! legs 
Yes 1* 
temporary numbness/ unusual feeling in a specific area of the body 
(including face) Yes 1* 
temporary visual problems (e. g. blurring in one eye, Yes 1* 
double vision) 
temporary slurred speech or other speech problem Yes 1* 
3. In the past month, have you experienced any of the following symptoms 
(interviewer- see protocol for details of information needed from this 
question): 
shortness of breath: - Yes I 
if yes, circle most appropriate: - 
no limitation of activity; ordinary activity does not cause symptoms 
" slight limitation of activity; ordinary activity results in symptoms 
" marked limitation of activity; less than ordinary activity results in 
symptoms 
" unable to*carry out any physical activity without discomfort 
symptoms at rest. 
swollen ankles (consistent with oedema) 
palpitations (consistent with arrythmia) 
No 2 
No 2 
No2 
No 2 
Yes I 
No 2 
1 
2 
3 
4 
No 2 
Yes 1 No2 
pain in the calves/thighs on walking (consistentwith claudication) Yes I No 2 
fainting/dizziness Yes I No2 
If yes = consider patient exclusion (see medical history exclusion 
protocol) 0 
Extra information - e. g. if it is not clear whether symptom/ history is an 
exclusion or not, so to be discussed with rest of study tea, write details here: 
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STUDY NUMBER! 
Section 3- Mini mental state examination 
Scare Orientation 
3.1( ) what is the (year)(season)(month)(date)(day)? -5 pts 
3.2( ) where are we (country)(county)(town)(hospital)(flr) -5 pt 
Registration 
3.3( ) name 3 objects(PLATE, SHOE, CHAIR): 1 second to say each. Then ask 
patient to repeat all 3 after you have said them. 1 point for each correct. 
Then repeat them until he/she learns them. Count trials and record. -3 
pta 
Attention and calculation 
3.4( ) serial 7's (100,93,86,79,72,65). 1 point for each correct. Stop at 5 answers. 
Or spell ' backwards. number correct equals letters before first 
mistake - i. e., lorw =2 correct). -5 pts total 
Recall 
LD" 
3.5( ) Ask for objects above. I point for each correct. -3 pts 
Language tests 
3.6( ) Name - pencil, watch -2 pts 3.7( ) repeat - no ifs, ands or buts -I pt 3.8( ) follow a3 stage commandc"Take the paper in your right hand, fold it in half, 
and put it on the floor) -3 pts 
Read and obey the following (show separate sheet if necessary): 
1 pt 
1 
3.10( ) Write a sentence spontaneously below -1 pt 
3.11( Copy the design below in the space next to it. -1 pt 
() Total max. =30 points (less than 24 = exclusion) 
3.12 Assess level of conciousness along a conintuum (make mark on line): 
Alert drowsy stupor coma 
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STUDY NUMBER " ... ___ _ ý. 
_ 
__ 
SECTION 4- Contraindications to anticoagulation 
4.1. Have you ever had indigestion for more than a few days? 
Yes 1 
No 2 
4.2. Have you ever had pain or discomfort in the place shown in the picture, or 
excessive wind or fullness after eating or drinking? 
in, % s 
v \-wo, 
Yes 1 
No 2 
4 0. 
Sketch 
4.3. Have you ever had heartburn (discomfort or pain in the chest) after eating 
or drinking? 
Yes I 
No 2 
4.41-lave you had any of the above symptoms in the last six months? 
Yes 1 
No 2 
4.51-lave you ever been diagnosed as having a gastric (stomach) or duodenal 
ulcer? 
Yes I 
No 2 
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4.6.1-lave you ever had a barium meal examination? (You have to drink a 
white liquid before the X-rays are taken) 
Yes I 
No 2 
4.7. Have you ever had an endoscopy or gastroscopy? (A tube with a light 
source is swallowed to look inside the stomach) 
Yes I 
No 2 
4.8.1-lave you ever vomited (thrown up) any blood? 
li 
Yes 1 
No 2 
4.9.1-lave you vomited (thrown up) any blood in the last six months? 
$ 
Yes I 
No 2 
4.1 OHave you ever noticed any blood in your urine (water)? 
Yes 
No 2 
4.11. Have you noticed any blood in your urine (water) in the last six 
months? 
Yes I 
No 2 
4.12. Have you ever noticed any blood in your faeces (motions, bowels)? 
Yes I 
No 2 
4.13.1-lave you noticed any blood in your faeces (motions, bowels) in the last 
six months? 
Yes I 
No 2 
I 
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STUDY NUMBER 
SECTION 5- Medication 
5.1. Do you currently take aspirin tablets every day or more often? 
Yes I 
No 2 
Only for those who currently take aspirin every day or more often: 
5.2. Up to today's date, for how long have you been taking aspirin tablets for? 
Months Years 
5.3. Those taking aspirin - what dose of aspirin do you take? 
5.4.1-las there ever been any time in your life when you have taken aspirin 
tablets every day or more often? 
5.5. Do you ever take aspirin tablets these days? 
Yes 1 
No- 2 
Yes I 
No 2 
Only for those who have at some time taken aspirin every day or 
more often, but are not currently taking it: 
5.6. For how long in total did you take daily aspirin? 
Months Yearsm 
5.7. Why did you stop taking daily aspirin? 
5.8. When did you stop taking daily aspirin? 
m 
Month Year 
5.9. Do you currently take warfarin tablets? Yes I 
No 2 
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For those who are taking or have ever taken warfarin, if the patient has 
an INR book available : 
5.13. How many person years was the patient's INR within the following 
ranges: s 
<2.0 person years 
2.0 to 2.99 person years 
4.0 to 4.99 person years 
<5.0 person years 
'; 3.0 to 3.99 person years 
5.14. List any other medication currently taken (ask patient to show the 
battles): 
Name of Drug Dose Indication 
A. 59 I 
STUDY NUMBER 
SECTION 6- smoking and drinking 
6.1. Which of the following best describes your cigarette smoking habits? 
I smoke'daily I 
I smoke occasionally, but not every day 2 
I used to smoke daily, but do not smoke at all now 3 
used to smoke occasionally, but do not smoke at all now 4 
have never smoked 5 
6.2. Do you currently smoke a pipe? 
Yes I 
No 2 
6.3. Do you currently smoke cigars? 
Yes I 
No 2 
Only for those currently smoking cigarettes every day: 
6.4. About how many cigarettes (manufactured or hand-rolled) do you smoke 
each day? 
m 
6.5. How often do you drink alcohol? 
(please include any night-caps you may take, or alcohol that you put 
in tea or coffee) 
I drink alcohol every day I 
I drink alcohol on most days 2 
drink alcohol about 2 or 3 times a week 3 
drink alcohol about once a week 4 
drink alcohol once or twice a month or less 5 
I used to drink alcohol regularly, but do not drink at all now 6 
used to drink alcohol occasionally, but do not drink at all now 7 
I have never drunk alcohol 8 
ý_ 
I 
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6.6. Haveyou had any of the following alcoholic drinks since this time last 
week? 
Assume that one sma11 can is hay a pint, and please include night-caps or 
alcohol taken with tea or coffee. 
Shandy (canned) pints 
Shandy (mixed) pints 
Beer or lager pints 
Low alcohol beer or lager pints 
Cider pints 
Wine glasses 
Low alcohol wine : glasses 
Martini, Cinzano, sherry, Babycham etc. glasses 
Spirits (gin, whisky, vodka, rum, etc. ) measures 
Other (write how much and of what in box below) 
t 
.L L 
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STUDY NUMBER 
SECTION 7- views on your health/quality of life/psychological 
health 
If not sure, give nearest possible answer. 
7.1. In general would you say your health is: 
(please circle one number) 
Excellent 1 
Very good 2 
Good 3 
Fair 4 
Poor 5 
7.2. Compared to one year ago, how would you rate your health in general 
now? 
(please circle one number) 
Much better now than one year ago I 
Somewhat better now than one year ago 2 
About the same as one year ago 3 
Somewhat worse than now than one year ago 4 
Much worse now than one year ago 5 
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The following questions are about activities you might do during a typical day. 
7.3. Does your health now limit you in these activities? If so, how much?. 
(circle one number on each line) 
i 
ACTIVITIES 
Yes, 
Limited 
A Lot 
Yes, 
Limited 
A Little 
No, Not 
Limited 
At All 
Vigorous activities, such as running,. lifting 
heavy objects, participating in strenuous sports 1 2 3 
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing 
golf 
1 2 3 
Lifting or carrying groceries 1 2 3 
Climbing several flights of stairs 1 2 3 
Climbing one flight of stairs 1 2 3 
Bending, kneeling or stooping 1 2 3 
Walking more than a mile 
.f 
1 2 3 
Walking half a mile 1 2 3 
Walking one hundred yards .1 2 3 
Bathing or dressing yourself 1 2 3 
7.4. During the past 4 weeks, have you had any of the following problems with your 
, work or other regular daily activities as a result ofyaur physical health? 
(circle one number on each line) 
YES NO 
Cut down on the amount of time you spent on work 
or other activities 
1 2 
Accomplished less than you would like 1 2 
Were limited in the kind of work or other activities 1 2 
Had difficulty performing the work or other activities 
for example, it took extra effort) 
1 2 
el 
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771 
7.5. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)? 
(circle one number on each line) 
YES NO 
Cut down on the amount of time you spent on work 
or other activities 
1 2 
Accomplished less than you would like 1 2 
Didn't do work or other activities as carefully as usual 1 2 
I 
7.6. During the past 4 weeks. to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbours 
or groups? 
(circle one number) 
Not at all I 
Slightly 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
7.7. How much bodily pain have you had during the past 4 weeks? 
None I 
Very mild 2 
Mild 3 
Moderate 4 
Severe 5 
Very severe 6 
7.8. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework) 
Not at all 1 
A little bit 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
r 
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.. ,a 
7.9. These questions are about how you feel and how things have been with 
you during the past 4 weeks. For each question, please give the one answer 
that comes closest to the way you have been feeling. How much during the 
nnct d wa=ke- 
All Most A Good Some A None 
of the of the Bit of of the Little of the 
Time Time The Time of the Time 
Time Time 
Did you feel full of life? 1 2 3 4 5 6 
Have you been a very 1 2 3 4 5 6 
nervous person? 
Have you felt so down in 1 2 3 4 5 6 
the dumps that nothing 
could cheer ou up? 
Have you felt calm and 1 2 3 4 5 6 
eaceful? 
Did you have a lot of 1 2 3 4 5 6 
energy? 
Have you felt downhearted 1. 2 3 4 5 6 
and low? 
Did you feel worn out? 1 2 3 4 5 6 
Have you been a happy 1 2 3 4 5 6 
person? 
Did you feel tired? 1 2 3 4 5 6 
7.10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities. (Eke visiting with friends, 
relatives, etc. )? 
All of the time I 
Most of the time 2 
Some of the time 3 
A little of the time 4 
None of the time 5 
7.11. How TRUE or FALSE is each of the following statements for you? 
Definitely Mostly Don't Mostly Definitely 
True True Know False False 
I seem to get ill more easily 1 2 3 4 5 
than other people 
I am as healthy as anybody I 1 2 3 4 5 
know 
I expect my health to get. 1 2 3 4 5 
worse 
My health is excellent 1 2 3 4 5. 
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SECTION 8- Educational level 
We should like to know about your present or last job. 
8.1. On the lines after "Full job title" please give the full title by which the job 
is known, for example: 'packing machinist; 'poultry processor'; 'jig and tool 
fitter'; supervisor of typists' 'accounts clerk'; rather than general titles like 
'machinist'; 'process worker'; 'supervisor'; or'clerk'. Give rank or grade if the 
person has one. 
Full job title: 
8.2. On the lines after "Main things done in job" please write down the main 
things you actually do or did in the job. 
Main things done in job: 
Armed forces- enter 'commissioned officer' or'other rank' as appropriate at 
"Full job title" and leave the second section blank. 
Civil servants- give grade at "Full job title" and discipline or specialism, for 
example 'electrical engineer'; 'accountant'; 'chemist'; 'administrator' at "Main 
things done in job" 
8.3. At what age did you finish your continuous full-time education? 
Not yet finshed 
Never went to school 
14 years or under 
15 years 
16 years old 
17 years old 
18 years old 
19 years or over 
I 
2 
3 
4 
5 
6 
7, 
8 
1 
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8.4 Please look at this card and tell me whether you have passed any of the 
qualifications listed. Look down the list and tell me the first one you come to 
that you have passed. 
Degree (or degree level qualification) }I 
Teaching qualification }2 
HNC/HND, BEC/TEC Higher, BTEC Higher } 
City and Guilds Full Technological Certificate } 
Nursing Qualifications (SRN, SCM, RGN, RM, } 
RHV, Midwife) 
.} 
'A' levels /SCE Higher }3 
ONC/OND/BEC/TEC not higher } 
City and Guilds Advanced/Final level } 
'O' level passes (grade A-C if after 1975) }4 
GCSE (grades A- C) } 
CSE Grade 1} 
SCE Ordinary (Bands A-C) } 
Standard Grade (Level 1-3) } 
SLC Lower } 
} SUPE Lower or Ordinary 
School Certificate or Matric } 
City and Guilds Craft/Ordinary level } 
CSE Grades 2-5 }5 
GCE `O' level (Grades D&E if after 1975) } 
GCSE (Grades D, E, F, G) } 
SCE Ordinary (Bands D &E) } 
Standard Grade (Level 4,5) } 
Clerical or commercial qualifications } 
Apprenticeship } 
CSE Ungraded 6 
Other qualifications (specify) }7 
No qualifications }8 
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Only for those who are married, or have been married: 
We should like to know about the present or last job done by your spouse. 
8.5. On the lines after "Full job title" please give the full title by which tlke 
job is known, for example: 'packing machinist; 'poultry processor'; 'jig and 
tool fitter'; supervisor of typists' 'accounts clerk'; rather than general titles like 
'machinist'; `process worker'; 'supervisor; or'clerk'. Give rank or grade if the 
person has one. 
Full job title: 
8.6. On the lines after "Main things done in job" please write down the main 
things your. spouse actually does or did in the job. 
Main things done in job: 
Armed forces- enter 'commissioned officer' or'other rank' as appropriate at 
"Full job title" and leave the second section blank. 
Civil servants- give grade at "Full job title" and discipline or specialism, for example 
`electrical engineer'; `accountant'; `chemist'; `administrator' at "Main things done in 
job" 
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STUDY NUMBER :_ ý__ ..... -. 
/ Thompson I of South I Gosfcrth, 1 employed I as a cook I in a 
. 
school ! cafeteria I 
tad 
/at the High St ! Police Station I that she had been held up I on Clarence Street ! the - .= 
t before / and robbed I of f ift , -siz'pounds. I She had 
tour/ small children, I -the rent was 
`ik, ' and they had not eaten /for two days. / The police, / touched by the woman's story;! ý" 
Kok up a collection / for her.! 
öbcrt 
1 M. iiI r1 was driving /a tcn-ton I lorry 1 town a road 1 at night 1 in the Norfolk t 
A. 
ijrazds. I carrying cogs to Norwich 1, when his axle I broke. / His lorry skidded ! off the 
JI 
`i 
LCL, 
into a ditch. l He Evas thrown I against the dashboard ! and was badly shaken. ! There 
%S no traffic / and he doubted that help would come. I Just then his two-way radio ! bused. / 
'He quick ly. answered. I "This is 12 ". 1 
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Score (max. 36) L LJ 
iGzrs, e (screwdriver & spanner) QR petrol station (gas pump) symbols (Max. score 80) 
1 minute (red pen) left. 
right 
2 minutes blue pen) left 
right 
f S. TESTS OF EVERYDAY ATTENTION 
TELEPHONE SEARCH 
Single task (plumbers) 
No. of correct targets (mot. 20) N 
Time taken (seconds) t 
Time per target (seconds) t! N= tt 
LIJ 
LIJ 
l., __IJ 
I.. _I I 
LII 
L LI_I _i 
I 
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L PHONE SEARCH 
& (restaurants) 
STUDY NUMBER, __ 
i 
o of correct targets Ni 
ume taken i ti 'L 
ime per target 
(t t tl "-- 
ý`. l 
--! --}--ý 
"OuNrING 
Dual task counting 
5483 6 1 . 12 2 
5.7 59 2 6 11 3 
63 51 
'-` 3 
- 
61 12 25 .75 
'9 26 11 3635 
' 5 48 " 
2 5 "7 59 12 6 11 -" 
3 6355483 61 . 
12 
3 No of strin; s zttcmpted t . __u 
Tl ;ý No. coizc: ct y 
-ýz Proportion correct y1x= pý --1--ý -ý--ý 
Adjusted double score to Ip=Z --1--ý --ý 
z: ý `)u21 task decrement Z- tt L I__U 
3' - 
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IOWORDS 
ju1cifcort: 
ord _ 
: ache - 
epot 
is1e 
ijouquet 
fps3im 
_ ICaPon 
(nausea 
- (debt 
- 
courteous 
=fy -. 
egiuvoc1I 
- naiv c 
1catacomb _ 
(o1ed 
7. DIGIT SPAN 
aRWARD 
1t2 
. 3-0 
ý; -3-1 
"2-3-5 
. n-=-%3 
-2-=-8-7 
I -9-2-6-; -i 
R 
STUDY NUMBER Di 
thane aeon - 
heir placebo _ 
radix abstemious - 
assignate - 
detente 
- 
hiatus - 
idyll 
subtle _... , puerperal - 
procreate - aver - 
gist _ , gauche 
gouge - 
topiary - 
superfluous - 
leviathan 
_ 
simile - 
beatify - 
banal - prelate - 
quadruped - sidereal - 
cellist _ 
demesne - 
facade 
_ syncope 
zealot _ 
labile - 
drachm _ campanile - 
.ý 
ýý 
,. 
., 
No. of errors L I_J 
Pass- Score DIGITS BACKWARD' 
I Pass. ( Scare 
Fal 2.1, cr 0 Fail 1 2,1. or 0 
I 
II 
I 
Z-3 
! 
I Iý-2-a 
-ý 13-2-7-9 Ii 
__ 
II 
3! =-ý-e-a I1 
II . 1-: -2-3-5 ! i i-t-ö-=-1 ji 
5ý 1 7-2-4-8-5-6 1 
11 
_ _2-a 
Ij 
ýýý-a-ý-i-. -? -= 
i 
l 
19-=-3-7-6-2-S-3 
t. laz 
ct ! F-r: i,., rd 1ý To A. 73 
TEXT CUT 
OFF IN 
ORIGINAL 
i 
" ]LLOGCALMEMORY T= 
3t3 minute t cmil STUDY NU iSER !I 
STORY' A' 
Anna / Thompson I of South / Gosforth. / employed / as a cook I in a school /c feteria 
reported I at the High St I Police Station / that she had been held up / on Clarence St / the 
night before I and robbed I of fifty-sit pounds. I She had four i small cbiidren. / the rent wes 
due I and they had not eaten I for two days. / The police, / touched by the women s story, I-,. 
took up a cdUection 1 for herJ 
r 
STORY 'B' 
Robert / Miller I was driving /a tcn-ton / lorry f down a road f at night I in the Norfolk / 
Braids. / carrying cgs to Norwich. I when his nxlc l broke. / Es lorry skidded 1 off the rocd 
into- n ditch. t He was thrown 1 against the dashboard 1 and was badly shaken. I These was no 
tr-Oc /and he doubted that help would come. I Just then his-two-way radio 1 buzzed. I he 
quickly answered, /'"This is 12"J 
3 (bi REY FIGURE 
311 minute recall 
Set. separate sheet Scare (ma:,. 36) Ll I 
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8 (a) PASAT 2.4 SECONDS 
answer 110 
aCj 
7 i`. 
19 
110 
=ä t7 
___ 
9 
14 
19 
6 I1 7 
1 Is 6 
10 s 
348 
9 
! 10 s 
371 
2S2 
STUDY NUMBER. 
answer 1 no. 12nswer Ina 
_19 
682 
115 
13 
19 
3 
_: 
13 -f7 
110 
9 
j 
14 
$S 
ý1 12 7 
113 18 
13 4 
31 II S 
_I19 
12 
`7 
16 
I1 
10 
$6 
l3 
14 
S 
11 
Is 
12 1 
13 6 14 3 
9281 
57 
19 
9 
IS 
5 12 12 
39 14 S 
I"I6 
Raw score correct ....... 1 60 
answer 
11 
S 
12 
16 
11 
19 
12 
13 
14 
9 
14 
{4" 
T 10 
I11 
17 
11 
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8 (b) PASAT 1.2 SECONDS 
no. answer no answer no. answer no answer 
2 7 9 6 8 2 11 
7 9 8 15 3 "9 3 
31 10 5 13 7 10 9 12 
4 7 14 S 12 7 16 
8 12 4' 13 8 13" 4' 11 
9 2 6 3 11 S -ý 9 
5 6 9 11 9 12 7 12 
6 
9 
11 
15 
7 
6 
16 
13 
1" 
4 
10 
5 
6 
8 
13 
14 
1 10 5 11 8 12 1 9 
3 4 8 13 6 14 3 4 
6 9 9 2 8 1. 4 
Q 
3 
10 
7 
.s 
1 
S 
5 
7 
5 
9 
12 
9 
2 
10 
11 
2 5 ", 2 3 9 14 5 7 
6 I1 
Raw score correct ...... J 60 ,'-. 
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Section 10 - investigations 
Bloodtests 
Biochemistry 
result 
Sodium 
Potassium 
Urea 
'I Creatinine 
t: 
JCOSB 
HbAlc 
3H 
Digoxiri, 
Cholesterol 
Haematology 
Haemoglobin 
s. . 
"=r Haematocrit 
UBC 
Platelets 
I 
STUDY NUMBER' 
day month year 
Date°-öf investigaton 
ýý ý'ý `" 
_ 
iL 
LTT 
"r 
I 
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.. 
is AF in case? Yes I Confirms SR in controls? Yes 1 
No 2 No 2 
AF STUDY ECG CODING FORM (MINNESOTA CODE) STUDY NO. 
___ 
_ 
ECG DATE 
_I 
I_ CODING DATE-/-/ 
1. O& OS PATTERNS fr 
Anterolateral site (I, aVL, V6) I"-_ 
Posterior (inferior) site (II, III, *aVF) 1-- 
Anterior site (V 1- V5) 1-- 
2. FRONTAL PLANE ORS AXIS 2- 
3. HIGH AMPLITUDE R WAVES 3- 
4. S-T JUNCTION (J) & SEGMENT DEPRESSION 
Anterolateral site 4- 
Posterior site 4- 
Anterior site 4- 
5. T -WAVE ITEMS 
Anterolateral site 5- 
Posterior site 5- 
Anterior site 5- 
6. A-V CONDUCTION DEFECT 6- 
7. VENTRICULAR CONDUCTION DEFECT 7- 
8. ARRHYTHMIAS 0= normal, 1= abnormal 
Arrhythmia code (8-3-1 = AF) 8-- 
9-2 ST SEGMENT ELEVATION 0= no, 1 =yes 
Anterolateral site 
Posterior site 
Anterior site 
9. WSCELLANEOUS CODES 9 
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1 
Private and confidential 
y NosýýTýt 
s 
sGNDýý 
G. A. F. E. 
(cognition and atrial fibrillation evaluafion -a 
study of memory problems in older people) 
(Patient visit 1 a: 
physical examination 
datawform (section 11) 
i 
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I,: 
STUDY NUMBER 
status in study: 
j led from study 
fed in study 
lion 11.1 - personal details 
kdY 
id number (check. against other records) 
to of birth(check against other records) 
day month year 
iasic information 
Height m or feet inches 
Weight Kg or stone -pounds 
º8M, 
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cardiovascular examination 
} 11.4Pulse rate 
rhythm regular I 
irregular 2 
11.5BIood pressure systolic mmHg diastolic mmHg 
11.6Pedal pulses present right Yes I left Yes 
No 2 No 2 
11.70edema Yes 1 
1- No 2 
11.8Raised JVP Yes 1 
No 2 
11.9Added heart sounds Ygs I 
I No 
2 
. l. 1OHeart murmur, systolic 
Yes I 
r No 2 
11.11 Heart murmur, diastolic Yes 1 
No 2 
11.12Carotid, bruit. Left Yes 1 
No 2 
11.13Carotid bruit, right Yes 1 
No 2 
11.148asal crepitations Yes I 
No 2 
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Appendix 13: Data cleaning 
Data cleaning procedures undertaken (for both baseline and follow-up databases). 
For the database containing the information from general practitioner notes: - 
i) Checking for duplicates, including whether or not the same patient had been 
entered more than once, and whether more than one control had been identified 
for a given case and vice versa. 
ii) Checking that date of birth for all patients corresponded to the inclusion criterion 
that they should be aged 60 years or over, and that the date of birth was appropriate 
(for example not bom in . 1828). 
iii) Checking that a typically male/female forename corresponded to the sex assigned 
to the patient. 
iv) Checking that cases had a control, that controls had a case and that controls did not 
have a control. 
v) Checking that the date of echocardiogram was appropriate. 
vi) Checking that the data of diagnosis of atrial fibrillation was appropriate and 
corresponded to the criterion of diagnosis of AF within the last five years. 
vii) Checking that all cases had the section `source of identification' completed. For 
those where this was not complete, the remainder of their record was checked to 
verify that they were true cases. 
viii) Checking that those who had ever taken aspirin had an appropriate dose of aspirin 
recorded, and that all of those for whom a dose of aspirin was recorded had the 
box `has ever taken aspirin' completed. 
ix) Checking that the duration of time taking aspirin and warfarin was sensible, where 
this was completed. 
A. 83 
x) Checking that those who had the section `contra-indications to aspirin' or 
`contraindications to warfarin' completed had the section `has ever taken aspirin / 
warfarin' completed. 
xi) Checking that those for whom contraindications to warfarin were listed had the 
answer `yes' to the question `are there contraindications to aspirin', and the same 
process for warfarin. Also check that those who had `yes' to the question `are there 
contraindications to aspirin' had contraindications listed, and the same process for 
warfarin. 
xii) Check that those who were on warfarin had a record of the date warfarin treatment 
commenced. 
For the database containing the information from the patient interviews and examinations: 
i) Consistency checks were made with a proportion of interview and examination 
forms, against the data already entered onto the database, to ensure that there were 
no repeated sections of missing or inaccurate data. This process was applied to 
both baseline and follow-up interviews. 
ii) The patient categories of `control', `case on aspirin', `case on warfarin', `case on 
neither', which had been based upon the data from GP notes, were compared with 
the actual prescriptions and replies to questions about warfarin and aspirin noted at 
interview, to ensure that all patients had been categorised appropriately. In addition 
the numbers in total and in each category were compared. 
iii) Checking for duplicates (names and study ID numbers). 
iv) Checking that date of birth for all patients corresponded to the inclusion criterion 
that they should be aged 60 years or over, and that the date of birth was sensible. 
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v) Checking that a typically male/female forename corresponded to the sex assigned 
to the patient. 
vi) Checking the distribution of cognitive function test scores to identify outlying 
values which may be errors. 
vii) Checking the clinical findings of `regular' or `irregular' heart rate on examination 
and atrial fibrillation or sinus rhythm on ECG against `case' or `control' status. 
viii) Checking that cognitive function test results were sensible (e. g. time taken for an 
individual component was reasonable). Checking that all values were below the 
maximum score or above the minimum where maximum/minimum scores existed 
(e. g. maximum MMSE, minimum MMSE, maximum telephone task 1 and 3 
score, maximum logical memory immediate and delayed, maximum Rey figure 
immediate and delayed, maximum map search test, maximum PASAT 2-second 
and 4-second, maximum NART, maximum digit-span). 
ix) Checking the distribution of some variables such as blood test results, to identify 
whether or not these are near-normal, and to identify outliers which may represent 
errors in recording /data-entry. 
x) Checking that no patients were taking both aspirin and warfarin at interview. 
xi) Comparison of the patient information from GP notes with the information from 
interviews was made to identify missing patients. 
xü) Checking of the whole database for missing data was made at regular intervals. 
Any identifiable reasons for such missing data was documented, and where 
possible missing data was sought and the database amended. Examples of missing 
data that was identified include blood tests, which were for the most part missing 
due to patient's decline to have test, and family history. 
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xiii) Examples of checks run on this databases: cases were sorted in ascending order of 
NART number of errors, and this column was inserted next to the NART score 
column. Two observers then scrolled down the two columns and it was easy to 
identify any pairs which did not match (since there was often 5 or 6 of each pairing, 
it was easy to see where pairings did not match). 
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Appendix 14: Table of characteristics of CAFE 
individual general practices 
Practice ID number List size Number of Number Number Method of Level of 
full-time of part- of anticoagulant Computerisation 
partners time practice monitoring of records 
partners nurses 
5500 2 1 1 Secondary care Partial - 1 medication 
7500 3 0 1 Secondary care Partial - 
2 medication 
6400 3 1 2 Secondary care Ahmst fully - 
medicationand 
3 most 
consultations 
8600 5 0 2 Shared care Fully- paperless 
(GP and 
secondarycare) 
4 with plans for 
pharmacist led 
clinics 
13563 6 0 1.5 Pharmacist led Partial - 
5 medication 
9700 4 0 2 Mostly Partial - 
6 secondary care medication 
3600 2 0 1 Some patients Partial - 
in primary care, medication 
7 some in 
secondary care 
5000 2 0 1 Pharmacist-led Partial - 
8 clinic medication 
14500 7 0 2 Some patients Partial - 
have GP/ medication 
district nurse, 
9 some 
secondary care/ 
district nurse 
9316 4 0 2 Secondary care Partial - 
10 medication 
5100 2 1 2 Pharmacist led Partial - 11 medication 
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Practice ID number List size Number of Number Number Method of Level of 
full-time of part- of anticoagulant Computerisation 
partners time practice monitoring of records 
partners nurses 
n/a n/a n/a n/a n/a Partially- 
12 medication and 
some notes 
2400 1 0 1 Secondary care Partial- 
13 medication and 
disease registers 
6500 1 3 2 PCG's Partial - 
14 pbarnxist-led medication 
clinic 
7500 4 0 2 Secondary care Partial- 
15 medication and 
disease registers 
10024 3 0 2 Secondary care Partial - 
16 medication 
6238 3 1 1 Some patients Partial - 
in primary care, medication 
some in 
secondary care 
17 
5900 3 0 1 Secondary care Partial - 
medication, 
health checks, 
some medical 
history 
18 
4000 1 1 2 Secondary care Partial - 
medication 
19 
12300 5 0 2 Some patients Partial - 
in primary care, medication 
some in 
secondary care 
20 
4500 2 0 1 Some patients Partial - 
in primary care, medication 
most in 
secondary care 
21 
6200 3 0 1 Pbammacist-led Partial- 
clinics medication 
22 
4700 2 0 1 Secondary care Almost fully- 
medication and 
some 
consultations 
23 
9100 4 1 1 Pharmacist led Fully 
24 clinics in 
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Practice ID number List size Number of Number Number Method of Level of 
full-time of part- of anticoagulant Computerisation 
partners time practice monitoring of records 
partners nurses 
secondary care 
2200 1 0 1 Some patients Partial - 
in primary care, medication 
some in 
secondary care 
25 
1800 1 0 1 Secondary care None - only 
adnvn 
26 
3100 1 0 1 Pharmacist-led Partial - 
clinic in medication 
PAY care 
27 
1700 1 0 0.5 Some patients Partial- 
in primary care, medication 
some in 
secondary care 
28 
6681 3 0 1 Primary care Partial - 
medication 
29 
6,500 3 2 1 Pharmacist- Almost fully- 
led (secondary medication and 
care) most 
consultations 
30 
6,500 3 2 1 Pharmacist- Almost fully - 
led medication and 
most 
consultations 
31 
6,500 3 1 2 Some Partial 
secondary care, 
some GP 
32 
9,800 3 1 1 Secondary care Partial 
33 
11,400 6 1 Secondary care Partial- 
medication 
34 
3533 2 0 1 Secondary care Partial - 
medication and 
consultation 
35 
headings 
3 800 1 1 1 Primary care Almost fu ly - 
medication and 
consultations 
36 
4000 2 0 1 Primary care Almost fully- 
medication and 
37 some 
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-A 
P' Practice ID number List size Number of Number Number Method of Level of 
full-time of part- of anticoagulant Computerisation 
partners time practice monitoring of records 
partners nurses 
consultations 
12500 5 1 2.5 Secondary care Partial- 
medication 
38 
2800 1 0 1 Pharmacist-led Partial - 
mdication and 
patient 
summaries 
39 
n/a n/a n/a n/a n/a n/a 
40 
n/a n/a n/a n/a n/a n/a 
41 
n/a n/a n/a n/a n/a n/a 
42 
n/a n/a n/a n/a n/a n/a 
43 
n/a n/a n/a n/a n/a n/a 
44 
Abbreviations: 
GP = General practitioner 
N/A= information not available 
PCG = Primary Care Group (at time of recruitment - now Primary Care Trust) 
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Appendix 15: List of conference presentations and 
publications 
I) Publications 
Full Publications 
" Park HL*, O'Connell JE, Thomson RG. A Systematic Review of Cognitive 
Decline in the General Elderly Population. International Journal of 
Geriatric Psychiatry 18(12): 1121-34,2003 
Letters 
" Park HL*. Gray CS. O'Connell JE. Thomson RG. In re atrial fibrillation. 
[letter; comment. ]. Journal of the American Geriatrics Society. 49(1): 99-100, 
2001 Jan. 
II) Abstracts and Conferences 
International 
" Park HL*. O'Connell JE, Hildreth AJ, Thomson RG. Cognitive decline in the 
`normal' elderly population -a systematic review. Abstracts from the Second 
International Congress on Vascular Dementia. Salzburg, January 2002. 
(Poster presentation) 
" O'Connell JE*, Park HL, Hildreth AJ, Gray CS, Thomson RG. Silent cerebral 
infarction and cognitive impairment in atrial fibrillation. Abstract from the 
Fourth World Stroke Congress. Melbourne 2000. (Poster presentation) 
UK 
Park HL*, Gray CS, Hildreth AJ, Thomson RG, O'Connell JE. Does atrial 
fibrillation cause cognitive decline? Follow-up results of the Cognition in 
Atrial Fibrillation Evaluation (CAFE). British Geriatrics Society Autumn 
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